DNAP vom Pennystock zum Bluechip! - 500 Beiträge pro Seite (Seite 2)

[JS222]

Von FREITAG

DNAP
DNAPRINT GENOMICS INC
0.048
0.000 0.00%


Daily Commentary
WAIT

Our system recommends WAIT as of today. Previous SELL recommendation was made on 6/19/2002 (23) days ago, when the stock price was 0.058. Since then the stock fell -17.24% .

Today the stock closed unchanged with an unchanged high and an unchanged low. The volume is normal. The security price is trending down.



Candlestick Analysis


Today’s Candlestick Patterns:
Inverted Hammer


Today a Inverted Hammer formed. The bulls drove the price higher but could not hold on to the gains. By the close the bears had prevailed and the price ended close to where it started. Be careful, resurgence in the bullish camp shows that the current downtrend could be due for a reversal!

JS222/200

[ge4teilter]

We believe our share price will ultimately reflect this quality, in addition to the quality of our business decisions. Keep in mind, however, that our aim is to build a company for the long term

Hau rein, Tony! Ich zähl´ auf Euch!



g4

[JS222]

DNAP - DNAPrint Genomics Inc (OTCBB : DNAP)

--------------------------------------------------------------------------------
VOLUME(+): DNAP Volume 22% > 20-adsv, Stock +4.17%



MONDAY , JULY 15, 2002 10:56 AM

This is the 1st VOLUME alert for DNAP in the past 7 calendar days.

Trading for DNAPrint Genomics Inc (OTCBB: DNAP) has been heavier than usual in today`s session. By 10:55 ET, the stock had already traded 1,383,300 shares via 40 trades. The cumulative volume is 22.21% above than its 20-day average of 1,131,900. Normally the stock experiences around 68 individual trades per session.

So far, today`s volume surge has caused a net rise in DNAP`s stock price. At the time of this alert, the stock was trading at $0.050, up $0.002 (+4.17%).

One year ago, the Company`s shares closed at $0.060. The price has declined more than 16 percent since then.

Over the last 10 trading session DNAP has traded in a range between $0.045 and $0.063 and is currently trading 62.12% below its 52-week high of $0.132 set on October 23, 2001 and 47.06% above its 52-week low of $0.034 from August 17, 2001.

In the previous 3 sessions, DNAP trading has displayed a mixed trend. Closing results have been as follows:

July 12, 2002 --- closed at $0.048 even for the day on 1,111,600 shares
July 11, 2002 --- closed at $0.048 down $0.001 (-2.04%) on 935,900 shares
July 10, 2002 --- closed at $0.049 up $0.002 (+4.26%) on 1,021,400 shares

The Company last released news on July 10, 2002:

"DNAPrint Inks Research and Product Development Alliance With Penn State University"

DNAPRINT GENOMICS INC
DNAPrint Genomics, Inc., a development-stage company, intends to be a national provider of analytical tools and knowledge-based solutions for personalized medicine, using DNA-related products and procedures. The Company is developing genetic analytics and information resource products for next-generation personalized medicine. The Company`s products will provide practitioners of genomic research and personalized medicine with a system for trait dissection and patient classification.


JS200

[cariocca]

DNAP wird der...



in den nächsten Jahren.

Roger

[ge4teilter]

Moin

[cariocca]

Moin, geteilter.

Was ist jetzt mit den nächsten Sommerferien in der Toscana?
Vorgesehen sind wieder 3 Wochen voller Dolce Vita.
Ich werde Anfang August buchen. Wär doch toll wenn Du mit Familie kommen könntest!


Roger

[ge4teilter]

cariocca > BM



g4

[cariocca]

Gefourteilter...

POST!

Prost

Roger

[JS222]

Von GESTERN

DNAP
DNAPRINT GENOMICS INC
0.048
-0.002 -4.00%


Daily Commentary
WAIT

Our system recommends WAIT as of today. Previous SELL recommendation was made on 6/19/2002 (27) days ago, when the stock price was 0.058. Since then the stock fell -17.24% .

Today the stock closed lower, at its low (sign of weakness) with an unchanged high and an unchanged low. The volume is extremely low. The security price is trending down.



Candlestick Analysis


Today’s Candlestick Patterns:
Short Black Candlestick


Today a Short Black Candlestick formed. There was a limited price change that may represent consolidation


JS200

[ge4teilter]

Jetzt muß ich mich aber doch wundern, liebe Gemeinde!
Seit 1 geschlagenen Woche kriegt hier keiner mehr ein Posting hin? Was ist los????

Während ich ernsthaft überlege, mein Engagement zu verdoppeln, haltet Ihr Euch vornehm zurück, statt mir Mut zuzusprechen!

Sowas!

g4

[cariocca]

MU(H)T für G4...



Roger (wartet bis 0.035 mit weiteren Käufen)

[ge4teilter]

0,035

Glaubst Du wirklich, Roger, daß wir da nochmal hinkommen???

[cariocca]

Ja...Gevierteilter. (spüre es im Urin)
Bin übrigens z.Z. 55% im Minus mit unserer heissgeliebten DNAP.

Gooooooo DNAP!

Roger

[robby.r]

jetzt oder nie

Bin drin 0,037
und warte noch auf einen Abstauber

[hvs1]

Halle DNAP-Freunde,

ich habe mir noch einmal 75K zu 0,04 ins Depot
gelegt.Wollte eigentlich 100K haben,sind aber nur 75K
daraus geworden.
Vielleicht lege ich aber nächste Woche noch einmal nach.
Ich glaube,daß das der Tiefstand war.
Gruß an die DNAP-Fangemeinde.
hvs1

[BBPushi]

Ist Morchel in Urlaub?

[ge4teilter]

Scheint so. Ist ruhig geworden hier. Habt Ihr alle verkauft?

[hvs1]

ge4teilter,

ich hatte zwar geglaubt,daß der Tiefpunkt erreicht ist,
aber in der nächsten Woche kaufe ich eventuell noch einmal
nach.
Ich muß mit meiner Bank noch die ausl. Spesenabrechnung
klären.
Die haben mir für 75 k zu 0,4 1.497,90 EUR in Rechnung ge-
stellt.
Der Umsatz war 3.004,81 EUR Abwicklungskosten 17,69 EUR
und Provision 30,05 EUR
Für ausl. Spesen habe ich sonst auch nur 30,- bis 40,- EUR
bezahlt.
Bevor das nicht geklärt ist kaufe ich natürlich nicht nach.

Gruß hvs1

[cariocca]

G4...

Alles noch im Depot. Keine Panik, vor ziemlich genau einem Jahr waren wir auch auf diesen Kursen anzutreffen.


Roger

[JS222]

@Cariocca

Ich habe meine 200.000 noch und du ???????

Gruss

JS200

[hvs1]

Hallo Roger,

Glückwunsch zu Deinen 522.500 Stck.

Gruß hvs1

[hvs1]

Hallo Roger,

das gehört hier zwar nicht rein,aber kannst Du mir Info´s
zu Fonix geben.

Gruß hvs1

[morchel]

ebenfalls noch voll dabei!

morchel

[cariocca]

hvs1...

FONX...leider nicht. Aber schau doch mal auf morchel`s Seite nach.

http://www.zockstocks.com

JS200...522.500 sinds jetzt schon geworden. zu ca. 0.085

Und jetzt: Ab in den Garten (die Schweizer feiern heute den Nationalfeiertag)



Roger

[hvs1]

DNAPÉRS

Fand den Spruch stark!

Buy when there is blood on the street.

hvs1

[ge4teilter]

Na, da waren meine leisen Befürchtungen doch anscheinend völlig unbegründet!

Habe in meine rgrenzenlosen Freude nochmal einen Auftrag über 30000 zu 0,035 platziert. Mal sehen .....

g4

[hvs1]

G4

habe noch einmal 50k zu 0,035 eingegeben.

hvs1

[CR0K0]

Hallo DNAP`er,

es war einmal hier die Rede von einem DNAP-Listing in D...

Wer weiss etwas genaues ?

Croko

[ge4teilter]

hvs1 .... und beide haben wir nix abbekommen! Waren wir wieder zu gierig - 0,036 hätten´s doch auch getan!

[cariocca]

G4 und hvs1...

Ihr werdet eure Stücke schon noch bekommen...

Meinem Gefühl folgend (nicht sehr verlässlich, sagt meine Frau) spühre ich den Hauch eines 0.03 - 0.033 in der nächsten Woche...


Schönes Wochenende

Roger

[cariocca]

Habt ihr das gesehen und gehört?! Negative Zinsrate in USA möglich!!


Wall Street: Abschlussbericht, Markus Koch (2.August 2002)

http://www.n-tv.de/701211.html

Klickt auf Schlussbericht von Markus.


Roger

[hvs1]

G4,Roger,

ich habe meine 50K erst einmal rausgenommen.
Warte die nächste Woche ab.Vielleicht ist Dein Bauchgefühl
ja richtig.
Könnte sein,daß ich dann auch 100K nachlege.z.Zt. sind
475K in meinem Depot.Möchte auf 750K aufstocken.Geld ist
noch ein wenig da.
Gruß und schönen Sonntag.
hvs1

[BBPushi]

Habe lange nichts positives über DNAP gehört.
Woher nimmt ihr eure Euphorie.
Habe selbst 100.000.
Kann aber mit der aktuellen Kursentwicklung nicht viel anfangen. Gibt es verwertbare Nachrichten oder worauf stützt ihr eure Hoffnungen.
Warum sollte man jetzt kaufen?

[robby.r]

dat is nicht gut

11:13:55 0.044 2000 OTCBB at Ask
11:13:55 0.040 2000 OTCBB


dat riecht nach abgang

[smiling]

Hallo Freunde!

Wollte nur sagen:

Still Long, Still Strong!

Der Kurs ist zwar in der Zwischenzeit so ziemlich zusammengeprügelt worden, bin jetzt ca. 60% im Minus mit meinen DNAP shares hab aber noch immer die selbe Zuversicht wie zu Beginn.

Ich verfolge das Börsengeschehen überhaupt nur mehr am Rande, da ich meinen Traumberuf gefunden habe, ich arbeite als Rangemaster und Clubmaker auf einem Golfplatz und kann Bälle schlagen und trainieren ohne Ende, nächstes Jahr beginne ich die Ausbildung zum Golfpro.

Hab in der Zwischenzeit noch 10.000 Dnap dazugekauft bei 0.046 und alle anderen behalten...

Zur Aufmunterung und für alle die etwas unsicher sind hab ich hier im RB was gefunden, ist zwar schon vom letzten Jahr aber ziemlich ausführlich:

http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=…

Alles Gute Euch Allen

[cariocca]

smiling...Toll!

Du kennst ja sicher die alte Golf-Regel:

Ohne Gras kein Spass.



Gruss

Roger

[hvs1]

Hallo,

sind schon alle weg?
Hab ich schon wieder den Ausstieg verpasst?

Gruß hvs1

War nur Spaß!

[hvs1]

DNAPérs

By when there is Blood on the Street!

hvs1

[hvs1]

DNAPérs

By when there is Blood on the Street!

hvs1

[hvs1]

DNAPérs

Habe heute noch zwei Aufträge drin.
25k zu 0,04 und 50k zu 0,04
mal sehen,was kommt.

Gruß hvs1

[hvs1]

Hallooo,

ich glaube Ihr könnt nicht mehr posten,weil Ihr mit dem
Nachkaufen so beschäftigt seid.

hvs1

Meine Frau hält mich zwar für verrückt,weil ich angeblich
unser Geld verschleuder,indem ich noch mehr DNAP nachkaufe.
Mein Ziel bleiben 750k

[hvs1]

DNAPérs,

wenn Ihr keine Lust habt zu posten,dann fahre ich jetzt
auch nach Hause.
Mal sehen,ob Ihr heute abend noch aufwacht.

hvs1

[cariocca]

hvs1...Ich bin doch da!

Besucht doch mal wieder meine Page...

http://community.webshots.com/user/sambista


Danke

Roger

[hvs1]

Hallo Roger,

meine 75k zu o,o4 sind zu o,039 durchgegangen.
Damit sind 550k im Depot

Gruß hvs1

[hvs1]

Hallo smiling,

ich wünsche Dir alles Gute und Erfolg in der Ausbildung
zum Golfpro.
Die Zeit DNAP nachzukaufen ist sehr gut,vielleicht als
vorgezogenes Weihnachtsgeschenk.

Gruß hvs1

[hvs1]

Hallo Leute,

bei DNAP gibt es zur Zeit keine News.
Das sollte Euch aber am Nachkaufen nicht hindern.Also
ran,viel billiger können sie ja nicht mehr werden.

hvs1

[hvs1]

Hallo Roger,

was ist mit Stockholder im RB los?

hvs1

[cariocca]

hvs1...

Der Ärmste wird wieder einmal von allen Seiten zerpflückt! Tja, er ist halt einer der ganz treuen DNAP-Optimisten und scheut sich glücklicherweise auch nicht, in seiner meiner Meinung nach sehr glaubhaften Art, die Flagge der Zuversicht (auch in schlechteren Zeiten) hoch zu halten.

Chapeau, Monsieur stockholder101, kann ich da nur sagen.

Leider ist mein Autodidaktisches Englisch so mies, dass ich meine Meinung zum Thema "du bist ein Pusher / Basher" einfach nicht richtig formulieren kann...Französisch / italienisch ging`s besser...aber die meisten Amis kennen ja nur eine Sprache, und mit Verlaub: EINGEBILDET und PATRIARCHAISCH sind sie (auch eine ganze Menge von ihnen) allemal.

Roger

[hvs1]

Roger,

ruhig Blut.
Hast Du schon Shares verkauft?Im moment geht ja wohl alles
nach unten.
DNAP hält sich noch gut.
Am 15ten
sind,glaube ich,ZAHLEN dran,mal sehen was kommt.
Ich warte jetzt mal 2 Tage ab.Eigentlich müsste man noch
einmal zuschlagen.

hvs1

[cariocca]

Nun bin ich fast seid 2 Jahren in DNAP investiert und werde garantiert keine einzige Aktie verkaufen, bis der Kurs die 0.1 Dollar erreicht hat.

Ein bisschen Gewinn möchte ich schon haben. Bei 0.085 wäre ich glatt. Hab halt auch noch Teile zu 0.36 gekauft! Nun wird nur noch der Durchschnittspreis kosmetisch angepasst.

Auch ich muss für`s Geld arbeiten und mein Einkommen ernährt so nebenbei noch 5 Personen. Tja schlechte Zeiten am Aktienmarkt...für alle.

Roger

[hvs1]

Roger,

Kopf hoch.Es wird auch wieder besser.
Hast Du was mit den schrecklichen Wassermassen zu tun?

hvs1

[cariocca]

Nein, keine Wasserschäden in Zürich und Umgebung. Einzig meine Tomaten im Garten leiden an Überfeuchtung.

BTW: Ich lasse den Kopf eigentlich nie hängen (positive Feng-Shui-Energien wirken Wunder!)...und schon gar nicht wegen Aktienpreisen.

Mein jetziger Arbeitgeber hat heute einen Quartalsgewinn von 1.33 Mrd. sFr. erwirtschaftet. Leider sind diese Aktien in einem gesperrten Depot, sonst wäre ich doch glatt in Versuchung geraten....

Roger

(noch 35 Minuten bis zur Telebörse (schau ich jeden Tag)

[otcbhappytrader]

Ich hätte DNAP in den letzten 12 Monaten dreimal mit guten
Gewinn verkaufen können. Jetzt bin auch ich im Minus und das
finde ich nicht so lustig. Ich weiss nicht ob ich 10 Jahre warten soll bis der letzte Insider verkauft hat oder irgendwann doch mal was verwertbares kommt. Es gibt auch Firmen wie CPRD, die ein Hammerprodukt haben und kurz vor der Zulassung sind. Es muss halt nicht immer Biotchnologie sein...Schaut Euch das mal an.

[robby.r]

CPRD
wie Optionsschein ohne verfall datum

[otcbhappytrader]

Genau, ich wünschte ich hätte weniger DNAP und mehr CPRD. Falls der Kurs von CPRD noch mal runtergeht, bringe ich es fertig und switche einfach um. Es ist schon ärgerlich das man hier in Deutschland wegen der Spekulationssteuer seine
Aktienanlagen viel zu lange hält. In diesen Zeiten kann man aber meist nur mit kurzfristigen Trades Geld machen. Im übrigen gibt es viele gefallene Biotech Engel. Wenn eine
Myriad, Medarex, Sequenom, etc. schon auf dem Boden liegt, warum sollte ein neuer Anleger dann eigentlich DNAP kaufen
anstatt eine bekanntere? Stimmt hier noch das Chance:Risiko
Ratio? Hier tun viele so, als wären sie mit DNAP in 5 Jahren
Millionär. Ich sehe die Firma auch nicht negativ, sonst hätte ich die Aktie nicht. Aber es gibt halt noch interessantere wie eben CPRD...

[cariocca]

otcbhappytrader...

Mach doch einfach einen CPRD-Thread auf und vergiss die phänomenalen Börsenzeiten von 2000 - 2001 für die nächsten 5-10 Jahre.

DNAP ist ein ganz klares Langzeit-Investment.

Wenn Du in dieser unsicheren Zeit schnell Geld verdienen willst musst Du meiner Meinung nach einen guten Freund Namens Zufall oder Glück haben.

Roger

[cariocca]

Übrigens: Ich glaube fest daran, in 5 Jahren DNAP-Millionär zu sein...

Roger

[wsperber]

Hallo cari,

gute Antwort an otchappytrader.

Aber ich finde wir sind wirklich alle sehr geduldig.

Irgendwelche News oder ein wirklich guter Vierteljahresbericht
würden dich hoffentlich auch nicht stören.

Gruß

entspannt aus dem Urlaub

Wolfgang

[robby.r]

Ich glaube fest daran, in 5 Jahren DNAP-Millionär zu sein...

stückzahl ???

[JS222]

08/14/2002 (19:03 ET) New 10QSB just released for DNAP - Edgar
07/25/2002 (10:36 ET) VOLUME(-): DNAP Volume 12% > 20-adsv, Stock -9.76% - Knobias
07/22/2002 (12:11 ET) VOLUME(-): DNAP Volume 30% > 20-adsv, Stock -10.64% - Knobias


JS200

[morchel]

...da verkauf ich früher meinen Spider, bevor ich nur ein Stück DNAP hergebe!

Als Investor der ersten Stunde bin ich das dem Mr. Frudrakis wohl schuldig!

Der liebe Mann mit dem Bart kann uns alle reich machen!
Schneller wie wir alle glauben!

morchel

[cariocca]

Na...nicht wirklich toll...

http://www.pinksheets.com/quote/filings.jsp?url=%2Fredirect.…

Mal sehen wo`s heute Abend hinführt.

Danke wsperber...
morchel...hab auch ein Auto verkauft um DNAP`s nachzukaufen. Gebracht hat`s leider bis zum heutigen Tag nicht viel.


Roger (betend)

[otcbhappytrader]

Danke für Eure Antworten,
ich war auch lange Zeit überrascht wie gut sich DNAP gehalten hat. Im amerikanischen Board scheint aber die Stimmung merklich zu kippen. Gerne würde ich auch von Morchel und Roger wissen warum DNAP mich zum Millionär machen kann ? Der Grund das ich 99500 Stück seit ca. 14 Mon.
halte, ist eigentlich der Enthusiasmus vieler Aktionäre und die Hoffnung möglicherweise in ein interessantes neues Geschäftsfeld zu investieren. Warum aber verkaufen die Insider ? Warum gibt es seit 12 Monaten keinen einzigen Kauf? Ich glaube ohne Umsätze und konkete Geschäfte in Aussicht wird es auf Dauer eng. Und Biotechfirmen bekommen heute nicht mehr so einfach Geld für Ihre Ideen. DNAP braucht aber bald Geld.

[cariocca]

otcbhappytrader...

- Der Hauptfaktor im DNAP-Segment ist der Faktor "ZEIT".
Keine Firma kann es sich zur heutigen Zeit noch leisten,
"halbfertige" Produkte anzubieten.

- Wir sind einfach zu ungeduldig (inkl. meiner Wenigkeit)

- Tony ist ein genialer Wissenschaftler...aber ein schlechter Mediator.


...robby.r...

~500`000 Stk


Roger

[otcbhappytrader]

Danke für die Antwort, meinen PT-Cruiser werde ich aber nicht verkaufen um noch mehr in DNAP zu stecken. Interessant wäre auch einmal von Morchel zu hören, wem er mehr Potential zutraut CPRD oder DNAP ? Auf DNAP bin gestossen über OTCBB.com most active boards, reiner Zufall.
Auf CPRD über wie ich glaube Morchels Seite. Falls sich cprd
so entwickelt wie ich vermute und hoffe, ist ein Champagner für Morchel mindestens drin. :-)

[robby.r]

500`000 Stk

könnte klappen , viel Glück

[ge4teilter]

Moin Gemeinde!

Morchel, Du hast ´nen Spider? Was für einen denn - Alfa oder Fiat?

So oder so solltest Du ihn nicht wegen ein paar Aktien verkaufen!

g4

[robby.r]

52 Week Low

[otcbhappytrader]

Mist, ich hab´s kommen sehen und nicht rechtzeitig genug verkauft. Jetzt brauche ich wohl auch nicht mehr umswitchen.
Das Problem ist wohl hauptsächlich das man Erlöse von GMED
erwartet hat, statt dessen noch höhere Kosten entstanden sind und die im amerik. Board die Rolle von Craig Hall zwielichtig gesehen wird. Andererseits ist das doch eine ganz normale Entwicklung für eine Biotechfirma, ich sehe da keinen Unterschied zu Firmen wie Medarex und anderen - Forschung kostet eben. Auf eine baldige Stabilisierung, noch lieber dicke Erholung hoffend...

[otcbhappytrader]

Yep, Investoren schlagen wieder als käufer zu. Gutes Zeichen! Bin wieder einigermaßen beruhigt. Meine Frau sitzt mir schon im Nacken und ist sauer das ich DNAP bisher nicht verkauft habe, wenn der Kurs hoch war

[otcbhappytrader]

Konnte mich nicht überwinden meine DNAP zu verkaufen...jetzt wo ich sie bis in die steuerfreie Zone über 14 Monate geschleppt habe. Über dieses unqualifizierte
Geschwätze und die unsoliden Basher im amerikanischen Board
war ich so ungehalten, das ich da selbst mal in Erscheinung
getreten bin und auch ein wenig zur Beruhigung beitragen konnte.

[Neoe]

Über den Aktienpreis würde ich mich nicht aufregen. Eine drastische Verwässerung ist zumindest unter der derzeit authorisierten Aktienzahl nicht mehr möglich und ein Absinken des Kurses ist auch alles andere als überraschend.

Schaut euch LAMP , IQPR etc. an. Normalerweise erwartet jeder , daß es jetzt zu einem signifikanten Anstieg kommt , doch die Praxis ist eher die, im Vorfeld großer Veränderungen den Aktienpreis zu überheizen und wenn sich die entscheidenden Dinge anbahnen , kam/kommt es bereits zu einem Rückgang des Preises , was dann keiner versteht und man als MarketMaker-Feiertag bezeichnen könnte.
Jedenfalls war das die einzig logische Erklärung , die ich bisher gefunden habe , denn DNAP hat in meinen Augen bisher nichts falsch gemacht.Kleine Warnung: NPCT wird das auch noch passieren; nur für die ,die es interessiert.

otcbbhappytrader@:
Deine Frau wird dich eines Tages mächtig dafür belohnen , daß du nicht verkauft hast. In 12-18 Monaten wird die Situation sowohl fundamental als auch von der Phantasie her in Richtung NASDAQ deuten. Zwar nicht ohne reverse split , so dreist bin ich nun auch wieder nicht , aber die NASDAQ
wird kommen.

[hvs1]

Neoe,

Toni hat gesagt,daß es keinen Reservesplit geben wird bevor
sie an die Nasdaq gehen.Hinterher schon.Ob das realistisch
ist kann er besser beurteilen als jeder andere.Wir können
doch nur ahnen,was der in der Pipeline hat.

hvs1

[ge4teilter]

hvs1,

da muß der gute Toni aber heftig was in der Pipeline haben, wenn er ohne RS einen Kurs von 4 $ hinkriegen will!!!

Mir soll´s natürlich recht sein, aber rechne doch mal 4$ x ca. 500000000 Aktien. Ich komme da auf eine MC von rund 2 Mrd. $. Is schon ´ne Menge für so´n kleinen Laden.

Abgesehen davon ist das unlogisch. Wenn er es ohne RS an die NASDAQ schafft, warum sollte er dann danach noch einen RS machen?

Schönen Tach noch Euch allen!

g4

[hvs1]

ge4teilter,

um den Kurs optisch wieder kleiner zu machen.(hi,hi)
Was der in der Pipeline hat,da sind 2 Milliarden doch ein
Witz.

Aber echt ge4teilter,der Toni mischt die gesamte Pharmain-
dustrie auf.Kann zwar noch 2 Jahre dauern,dann kommst aber
mächtig.Ich sammel bei diesen Kursen schon mal kräftig ein.
550k sind schon drin.
Ich hoffe Du machst es auch so.

Gruß hvs1

[ge4teilter]

hvs1,

um den Kurs optisch wieder kleiner zu machen.(hi,hi)

Das nennt man dann aber Forward Split

Wenn wir soweit mal kämen ........

g4

[cariocca]

g4...

Vergiss nicht unseren Traum...




Roger

[cariocca]

...Ich nehm den linken Turm...

Roger

[ge4teilter]

cari, wie könnte ich!

Bei meiner Anzahl shares kann ich mir wohl aber nur einen kleinen Eigentumsflügel im Schloss leisten

g4

[hvs1]

g4

das stimmt natürlich.

hvs1

[otcbhappytrader]

Was denn..als erfolgreiche Anleger habt Ihr immer noch kein Schloss ? ;-)

[JS222]

DNAP - DNAPrint Genomics Inc (OTCBB : DNAP)

--------------------------------------------------------------------------------
MOVER(-): DNAP Trading Lower In Session



MONDAY , AUGUST 19, 2002 11:01 AM

Shares of DNAPrint Genomics Inc (OTCBBNAP) are trading $0.00 or 5% lower in the session at this time, on volume that is on pace to reach its 20-day average daily share volume.

Dow Jones has reported the registration of 4,094,000 restricted shares to be sold by various shareholders.

The company has issued no news in the past 30-days, and last filed with the SEC on August 14, when a 10QSB was submitted to the commission.

The stock is trading lower than four of four moving averages, and at a level lower than consolidated technical downside price support at $0.037, as calculated by Knobias technical analysis.

JS200

[Traumfaenger]

DNAPrint Files Patent to Protect 2,425 SNPs Linked to Drug Response


SARASOTA, Fla., Aug 20, 2002 /PRNewswire-FirstCall via COMTEX/ -- DNAPrint
genomics, Inc. (OTC Bulletin Board: DNAP) announced today that it has filed a
patent application to protect 2,425 Single Nucleotide Polymorphisms (SNPs)
useful for predicting response to a large number of commonly prescribed drugs.

DNAPrint has previously compiled a candidate gene database of several thousand
validated drug metabolism and drug target gene SNPs -- collectively known as the
"PHENOME" SNP database. However, the new SNPs claimed in the present patent
application were identified from a different, more systematic screen of the
entire human genome. The sequence of each is useful for explaining variation in
drug response to differing extents, depending on the drug, and the Company`s
data suggests that most are likely linked to genes in the human genome
previously not known to be of pharmacological relevance. As such, DNAPrint
believes it is the first to claim markers of this type and elucidate the
potential of this new subset of the variable human genome as specifically
relevant for predicting drug response.

The new patent application could provide DNAPrint a tremendous advantage towards
developing pharmacogenomics classifiers that are specific, sensitive and
predictively powerful enough for routine clinical use. "Most of these SNPs have
been ignored by the genomics community. Though others may have unwittingly and
indirectly linked a very small fraction of these SNPs with variable drug
response, technical and conceptual considerations have evidently prevented them
from yet recognizing the underlying fundamentals of these associations," said
Tony Frudakis, Ph.D., DNAPrint`s CEO. "Such recognition would be required to
generate a competitive patent application." Indeed, a review of the journal and
patent literature reveals no reports describing the phenomena that the Company
believes cause the linkages.

The discovery that led to the patent application was unexpected, but part of a
deliberate and systematic genetic research strategy at DNAPrint. "That we could
identify linkages such as this en masse, within the confines of a relatively
small research budget, is indicative of the intelligence and objectivity of our
systematic study design and algorithmic approach," said Dr. Kondragunta
Venkateswarlu, Vice-President of DNAPrint genomics, Inc.

To maintain its competitive advantage, the company will refrain from presenting
details of the discovery until the findings are published by the US Patent and
Trademark Office.

DNAPrint genomics, Inc.

DNAPrint genomics, Inc. develops complex genetic analytics and information
resource products for an individualization of drug prescription and advancement
of forensic science. The company`s products provide practitioners of
genomics-based medicine and forensics with a comprehensive system for complex
trait dissection and patient/subject classification. This work has real-life
application to the germinating fields of Personalized Medicine and Qualitative
Forensics, and helps to lay the foundation for a brand-new area of medical
research called Phenomics. DNAPrint genomics Inc. was founded in 2000 by a group
of scientists with 57 total years of research and commercial experience in
high-level mathematical modeling, programming and molecular genetics. The
company is traded on the OTCBB and currently employs 14 people, 9 of whom are
Ph.D.s in Computer Science, Molecular Genetics, Statistics and/or Mathematics.
(www.dnaprint.com)

All statements in this press release that are not historical are forward-
looking statements within the meaning of Section 21E of the Securities Exchange
Act as amended. Such statements are subject to risks and uncertainties that
could cause actual results to differ materially from those projected, including,
but not limited to, uncertainties relating to technologies, product development,
manufacturing, market acceptance, cost and pricing of DNAPrint`s products,
dependence on collaborations and partners, regulatory approvals, competition,
intellectual property of others, and patent protection and litigation. DNAPrint
genomics, Inc. expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements contained
herein to reflect any change in DNAPrint`s expectations with regard thereto or
any change in events, conditions, or circumstances on which any such statements
are based.



Media and Press Contacts



Carrie Castillo

DNAPrint genomics, Inc.

Director, Marketing Communications

[phone]

[e-mail]



MAKE YOUR OPINION COUNT - Click Here

http://tbutton.prnewswire.com/prn/11690X42756848

SOURCE DNAPrint genomics, Inc.



CONTACT: Carrie Castillo, Director, Marketing Communications of DNAPrint

genomics, Inc., [phone], or [e-mail]



URL: http://www.dnaprint.com

http://www.prnewswire.com


Copyright (C) 2002 PR Newswire. All rights reserved.





KEYWORD: Florida

INDUSTRY KEYWORD: MTC

OTC

[otcbhappytrader]

Großartige Neuigkeiten...hoffentlich habt Ihr Eure shares nicht mit Minus verkauft. Um ehrlich zu sein war ich auch etwas nervös die letzten Tage. Die Patentanmeldung kam gerade richtig. Ich schätze das wird nicht die letzte gute
Meldung sein :-)

[JS222]

08/20/2002 (12:04 ET) MOVER(-): DNAP Lower; Files Patent For New SNPs - Knobias
08/20/2002 (11:49 ET) DNAPrint Files Patent to Protect 2,425 SNPs Linked to Drug Response - PR Newswire
08/19/2002 (11:01 ET) MOVER(-): DNAP Trading Lower In Session - Knobias
08/15/2002 (11:41 ET) VOLUME(-): DNAP Volume 24% > 20-adsv, Stock -15.38% - Knobias
08/14/2002 (19:03 ET) New 10QSB just released for DNAP - Edgar


JS200

[JS222]

DNAP - DNAPrint Genomics Inc (OTCBB : DNAP)

--------------------------------------------------------------------------------
MOVER(-): DNAP Lower; Files Patent For New SNPs



TUESDAY , AUGUST 20, 2002 12:04 PM

Shares of DNAPrint Genomics Inc (OTCBBNAP) are trading $0.003 or 7.9% higher in the session at this time, on volume that is not pace to reach its 20-day average daily share volume.

The company issued a press release today to announce that it has filed a patent application to protect 2,425 Single Nucleotide Polymorphisms (SNPs). According to the release these SNPs are useful for predicting response to a large number of commonly prescribed drugs.

The stock is trading lower than four of four moving averages, and at a level lower than consolidated technical downside price support at $0.037, as calculated by Knobias technical analysis.

JS200

[hvs1]

Hallo Roger,

was ist mit PPHM los?

Gruß hvs1

[cariocca]

hvs1...

Wenn ich das wüsste...aber alle warten seid Monaten auf Cotara Phase III Noch tut sich nichts!

Nur die Geduld ist derzeit hoch im Kurs.


Tschüss

Roger

[hvs1]

Hallo Roger,

habe gestern tatsächlich noch 10.000,- zu 0,036 erhalten.
Hatte ne Order von 60k zu 0,036 drin sind aber nur 10k aus-
geführt.Damit sind 560k im Depot.Werde heute noch 50k zu
0,038 eingeben.Denke das wird klappen.

Gruß hvs1

[otcbhappytrader]

Hi Roger,
für einen OTCB-Wert ist 560.000 Stück aber ein bischen viel,
oder ? Du scheinst ja sehr überzeugt zu sein.

[cariocca]

otc...

Roger = Cariocca

Ich bin bei 542`500 Shares zu ca. 0.082.

Ich besitze devinitiv ZU WENIG DNAP`s.


Roger

[otcbhappytrader]

Hi Roger,
ich bin auch im amerik. board der OTCBHAPPYTRADER. Habe 99500 Stück zu 0,O66 Eurocent, weil USD gefallen, vorher war mein Durchschnittskurs knapp über 0,06 cents.
muito sorte para o senhor :-)

[cariocca]

otc...

Uma mulher foi levada de urgência para um hospital, directamente para o Banco. Ao chegar lá, como ia numa
situação de pré-coma, entrou naquela famosa "quase morte". Nesse estado, encontrou-se com Deus:


- Que e isto? - perguntou ela ao Criador - Eu morri?


- Não, pelos meus cálculos só morrerás daqui a 43 anos, 8 meses,9 dias e 16 horas - respondeu o Criador.


Ao voltar a si, e sabendo quanto tempo ainda tinha de vida, resolveu, ali mesmo na clínica, fazer uma
lipo-aspiração, uma plástica de restauração dos seios, plástica no rosto, no nariz, na barriga, tirou todos os
excessos, ficando linda, jovial e teve alta uma semana depois.

No dia seguinte ao atravessar um rua, veio um veículo em alta velocidade e atropelou-a, matando-a na hora. Ao
encontrar-se de novo com Deus, ela perguntou:


- Então, Senhor, eu acreditei em Ti e achei que tinha mais 43 anos de vida, porque morri? Logo depois daquela
despesa toda com cirurgias plásticas!?


E Deus, aproximando-se dela e olhando-a directamente nos olhos, respondeu:


- LAMENTO, MAS JURO QUE NÃO TE RECONHECI!

[cariocca]

He-heeee!...

A língua alemã é relativamente fácil. Todos aqueles que conhecem as línguas derivadas do latim e estão habituados a conjugar alguns verbos podem aprende-la rapidamente. Isso dizem os professores de alemão logo na primeira lição.

Para ilustrar como é simples , vamos estudar um exemplo em alemão.

Primeiro, pegamos um livro em alemão, neste caso, um magnifico volume, com capa dura, publicado em Dortmund, e que trata dos usos e costumes dos índios australianos Hotentotes (em alemão, Hottentotten).

Conta o livro que os cangurus (Beutelratten) são capturados e colocados em jaulas (Kotter), cobertas com uma tela (Lattengitter) para protege-las das intempéries. Estas jaulas, em alemão, chamam-se jaulas cobertas com tela (Lattengitterkotter) e quando possuem em seu interior um canguru, chamamos ao conjunto de "jaula coberta de tela com canguru" (Lattengitterkotterbeutelratten).

Um dia os Hotentotes prenderam um assassino (Attentater), acusado de haver matado a uma mãe (Mutter) hotentote (Hottentottermutter), mãe de um garoto surdo e mudo (Stottertrottel). Esta mulher, em alemão, chama-se (Hottentottenstottertrottelmutter) e a seu assassino chamamos, facilmente, (Hottentottenstottertrottelmutterattentater).

No livro, os índios o capturaram e , sem ter onde colocá-lo, puseram-no numa jaula de canguru (Beutelrattenlattengitterkotter).

Mas, incidentalmente, o preso escapou. Após iniciarem uma busca, rapidamente vem um guerreiro Hotentote gritando:

- Capturamos um assassino (Attentater)

- Qual? pergunta o chefe indígena

- O Lattengitterkotterbeutelratterattentater, comenta o guerreiro.

- Como? O assassino que estava na jaula de cangurus coberta de tela? - pergunta o chefe dos Hotentotes.

- Sim - responde a duras penas o indígena - O Hottentottenstottertrottelmutteratentater. (assassino da mãe do garoto surdo e mudo).

- Ah, demônios - diz o chefe - você poderia ter dito desde o inicio que havia capturado o Hottentotterstottertrottel-mutterlattengitterkotterbeutelrattenattentater.

Assim, através deste exemplo, podemos ver que o alemão é facílimo e simplifica muito as coisas. Basta um pouco de interesse.

Boa noite

Roger

[hvs1]

Hallo Roger,

nun sind es 610k.
Morgen leg ich noch einmal 40k nach.Dann fehlen nur noch 100k zum Ziel von 750k.
Du hast wirklich zu wenig,aber Du wirst noch eimal nachlegen,hab ich im Gefühl.

Gruß hvs1

[cariocca]

Martin...

Was war denn genau los mit Kollege "edahsdvk" im RB?


Gute Nacht

Roger

[hvs1]

Hallo Martin,

würde auch gerne hören,worum es konkret ging.

hvs1

[hvs1]

Martin,

edahsdvk hat Dich also mißverstanden.

hvs1

[otcbhappytrader]

Ola´o Roger,
muito obrigado. Voce fala mais melhor portugues do que eu. Eu vou viver com 60 anos no Brasil. Talvez com ajuda de DNAP!? :-)
Muitos cumprimentos
UDO OU OTCHAPPYTRADER

[Sven Christian]

Wann geht es endlich wieder nach oben mit DNAP ?

[cariocca]

otcbhappytrader...

Hast mich erwischt! LOL! Aber, vor 20 Jahren besuchte ich für 6 Monate einen Brasilianisch-Sprachkurs in Zürich. Gebracht hat`s nicht viel. Die Texte sind, wie Du gemerkt hast, aus dem WEB geklaut...

Ich bin ein absoluter Brasil-Fan (hatte eine Band welche im Escola de Samba-Stil musizierte) "Augustos Explosao de Samba" Ich spielte Cuica, Congas und Agogo...


Schönes Wochenende

Roger

[hvs1]

Sven Christian,

nutze die Zeit um noch günstig einzusteigen oder nachzulegen.

hvs1

[jumanii]

hallo zusammen,

mal ne frage was soll aus DNAP werden? hab noch nie solch insider
verkäufe gesehen, bekommt man ja angst!

mfg

[cariocca]

he-heeeee!

Ich hatte beim Film "Jumanii" auch Angst...Keep Cool!

Roger

[hvs1]

Jumanii,

ich kaufe die Dinger alle auf.
Nun sind es schon 650k.

hvs1

[hvs1]

Hallo Leute,

wo seid ihr.
Habe mal in den alten Beiträgen zu DNAP gestöbert,als Noe
noch die Shareholderliste führte.
Macdiri führte diese seinerzeit mit 1.090.000,- an.
Macdiri bist Du noch dabei.

hvs1

[cariocca]

Im RB wird fleissig über meinen, mit Copernic gefundenen Bericht diskutiert...

***DNAP-Article in The Straits Time***...

http://straitstimes.asia1.com.sg/cybernews/story/0,1870,1382…


Roger

[hvs1]

Roger,

es ist ja auch immer wieder erstaunlich was DU über DNAP
so alles auftreibst.
Im RB gehen sie ja soweit unsere DNAP infrage zu stellen.
Sie meinen es ist eine andere Firma.So´n Quatsch.

hvs1

[hvs1]

DNAPérs

wer bisher noch nicht mitbekommen hat,was für eine Perle wir im Depot haben,der müßte doch allmählich aufwachen.
Und das ist doch nur eine Sache von vielen,an der die DNAP
arbeitet.
Selbstverständlich gehen wir nach wie vor ein Risiko ein,
wenn wir die Aktie kaufen aber no Risk no Fun.

hvs1

[hvs1]

DNAPérs,

es wird Zeit,daß Ihr aus Euren Löchern wieder herauskommt.
Macdiri,SMCP Hunter,Neoe,smiling und.. und.. und
Sonst schaut Euch die alten Beiträge an,dort wurde auch gepostet,obwohl es keine News gab.
Was ist mit der Liste Neoe,können wir die nicht fortführen.
Laß bitte die Zweifel raus,ob jemand die Anzahl der Aktien
hat oder nicht.Ich habe 650k zu o,o89

Gruß hvs1

[hvs1]

Hallo DNAPèrs,

die Resonanz ist ja überwältigend!
Sind wir pleite und ich habe das wieder einmal verpasst.
Man,ich glaube es ist zum Posten zu heiß oder?

hvs1

[hvs1]

Hallo morchel,

entschuldige,Dich als Entdecker der Aktie habe ich total
vergessen.
Durch Dich habe ich die ersten Informationen über DNAP er-
halten.
Wäre gut,wenn Du mal wieder etwas über DNAP posten würdest.


Gruß hvs1

[cariocca]

hvs1...

Es ist Wochenende und vielleicht gibts ja ein paar ältere Semester unter uns welche noch gewisse Familienpflichten zu erfüllen haben...



Roger

[hvs1]

Roger,

auf Dich ist Verlaß,das weiß ich.
Meine Frau hatte heute Frauentag bei uns zu Hause,da bin
ich ins Büro und hatte nicht nur Lust auf Arbeit.Übrigens
bin ich auch nicht mehr so ganz jung,Baujahr 1947,keine Kinder.Daher viel Zeit für mich.
Dein T-shirt ist super,gefällt mir sehr.

Gruß hvs1

[macdiri]

Hallo Leute ! Klar bin ich noch hier.War Sonntag auf dem Golfplatz. Finaltag der Zürcher Meisterschaft,habe eine 73 (1 über Par) gespielt mit einem Wasserball an der 18. Neues Handicap 4.5 ! Uebrigens habe ich noch alle 1090000 Aktien an Board und werde sie auch nicht so schnell verkaufen. Habe jedoch noch Putts auf den Dow und den Nasdaq gekauft,da ich überzogen bin das es nochmals kräftig runter geht. Ich wünsch Euch einen schönen Tag.Gruss MACDIRI

[ge4teilter]

Skandal! Skandal! Skandal!!!!

Ein FAKE, ein FAKE, ein FAKE!!!!



Der Cariocca hat doch tatsächlich ein gefaktes T-Shirt an!!!!





Ich kauf übrigens auch immer noch häppchenweise zu. Ist doch wohl logisch!

ge4teilter

[cariocca]

DIE SENSATION!

Der genveränderte Ge4teilte beim Hauskauf in der TOSCANA!



Hääää-hääääää!


Roger

[hvs1]

Gottseidank

kommt wieder etwas Leben in die Bude.

hvs1

[ge4teilter]

@cariocca: Ich muß Dich da etwas korrigieren. Erst das 356 B-Cabriolet, und dann das Häuschen in der Toskana!

@hvs1: Wart ab was hier für Leben reinkommt, wenn es erstmal losgeht! Schließlich haben wir auch noch unser Millionärstreffen in Planung. Werde den Thread bei Gelegenheit mal wieder hervorkramen!

g4

[hvs1]

Neuer Zwischstand DNAP(in Vertretung für Neoe)

macdiri 1.090.000,-
hvs1 650.000,-
cariocca 542.500,-
smCphunter 333.000,-
snoopy 250.000,-
js200 150.000,-
ge4teilter 85.000,-
Tho 123 80.000,-
sclabo 80.000,-
bh franky 55.000,-
Blackjack 50.000,-
Gerd N 29.500,-
doppelkopf 20.000,-
marterpfahl 20.000,-
Wallgrekk 17.500,-
MZipperling 15.000,-
Neoe 10.000,-

Bitte gebt eure Anzahl an Aktien auf

Gruß hvs1

[hvs1]

DNAPérs

morchel
wsperber
N.Y
Babyelch
automania
Agrippina
NetBunny
smiling
MeierM

wo bleiben eure Angaben.Wir wollen den Thread in Schwung
halten.
Roger,wäre gut,wenn Du die Liste weiterführen würdest,wenn
Neoe nicht mehr will oder kann.

Gruß hvs1

[JS222]

Neuer Zwischstand DNAP(in Vertretung für Neoe)

macdiri 1.090.000,-
hvs1 650.000,-
cariocca 542.500,-
smCphunter 333.000,-
snoopy 250.000,-
js200 200.000,- !!!!!!!!!!!!!!!!!!!!!!!!
ge4teilter 85.000,-
Tho 123 80.000,-
sclabo 80.000,-
bh franky 55.000,-
Blackjack 50.000,-
Gerd N 29.500,-
doppelkopf 20.000,-
marterpfahl 20.000,-
Wallgrekk 17.500,-
MZipperling 15.000,-
Neoe 10.000,-

Kleine Richtigstellung

Gruß JS200

[proFEiT]

Guten Tag Allerseits

ich lese hier zu diesem Wert ausnahmslos optimistische Meinungen was es sonst so nirgendwo gibt, wenn ich mich recht erinnere.

Meine erste Frage lautet deshalb, da ich des Englischen nicht sehr mächtig bin, folgendermassen;

Was hat diese Firma, was andere nicht haben?
Woran wird geforscht oder was wird produziert?
Wird Geld verbrannt oder bald verdient?
Noch was Interessantes?


Was ich bis jetzt weiss ist, dass es viel Geduld braucht...

proFEiT ein künftiger Shareholder???

im Angesicht einer oder mehrerer ausführlichen Antworten im Vorraus dankend,


proFEiT

[doppelkopf]

sorry, ich war lange nicht mehr dabei. meine 20000 stk. hab ich schon länger verkauft zu 0,06 mit kleinem verlust.

[otcbhappytrader]

habe immer noch 99500 Stück.

[Blackjack2000]

Hallo Leute!

Hab mich lange Zeit nicht mehr gemeldet,bei mir sind es inzwischen 75000 Stück und es werden garantiert noch mehr!

Viele Grüsse
Blackjack

[Tho123]

Hallo miteinander!

Auch ich war in den letzten Wochen stiller Beobachter.

Habe immer noch meine 80000 Shares.

Das ganze ist zur Zeit etwas richtungslos, deswegen auch

schwer einschätzbar.

Ich warte zur Zeit einfach mal ab. Vielleicht kommt die

Initialzündung für unseren Wert zu einem Zeitpunkt,zu dem

wir es nicht erwarten.

Ich denke,wir sind alle ein bißchen unsicher über die

weitere Entwicklung von DNAP trotz unserer

grundsätzlichen Begeisterung für diesen Wert.

Aber, wer nichts wagt, der gewinnt auch nichts!! Oder??

Gruß Tho123

[proFEiT]

Bevor meine Fragen untergehen...


Guten Tag Allerseits

ich lese hier zu diesem Wert ausnahmslos optimistische Meinungen was es sonst so nirgendwo gibt, wenn ich mich recht erinnere.

Meine erste Frage lautet deshalb, da ich des Englishen nicht sehr mächtig bin, folgendermassen;

Was hat diese Firma, was andere nicht haben?
Woran wird geforscht oder was wird produziert?
Wird Geld verbrannt oder bald verdient?
Noch was Interessantes?


Was ich bis jetzt weiss ist, dass es viel Geduld braucht...

proFEiT ein künftiger Shareholder???

im Angesicht einer oder mehrerer ausführlicher Antworten im Vorraus dankend,


proFEiT

[hvs1]

ProFEit

herzlich willkommen im DNAP-Thread,der von morchel eröffnet
worden ist.
Es ist das Beste,wenn Du Dich durch den Thread wühlst.z.Bsp.
der Betrag Nr. 5.812.753 von SmCpHunter ist schon sehr informativ.Ein wenig Geduld ist sicherlich angebracht aber
die Vielfälltigkeit in der DNAP forscht und bereits Patente
besitzt läßt uns auf großes hoffen.Das 10Q war zwar nicht
so doll aber wiederum auch nicht so negativ.Es ist eine junge Firma ca. 2,5 Jahre alt die in der Genomic noch für
aufsehen sorgen wird,da bin ich mir sicher.
Also pack es an und Du wirst ein DNAP-Fan.

Gruß hvs1

[cariocca]

proFEiT...


Was hat diese Firma, was andere nicht haben?

http://www.dnaprint.com

Woran wird geforscht oder was wird produziert?

http://www.dnaprint.com

Wird Geld verbrannt oder bald verdient?

Ja (Forschen kostet Geld) /Ja (wir hoffen)

Noch was Interessantes?

Ja (die Entwicklungsmöglichkeiten in diesem Segment sind nahezu unbegrenzt)

Roger

[cariocca]

Artikel von "Straw5" aus dem RB:

A good article on the state of the art of DNA applied to forensics: wishlist, limitations, etc. DNAP was specifically mentioned in the article.

(It is about a month old; but if it was previously posted I missed it)

Full article here:

http://archive.newscientist.com/secure/article/article.jsp?r…

This is an excerpt where DNAP is discussed:

But biotech firm DNAPrint Genomics of Sarasota, Florida, is having a crack at both problems, and has made most progress so far with eye colour. Its starting point was basic research in mice and the fruit fly Drosophila that identified several genes involved in eye colour. Geneticists then looked for similar sequences in the human genome, and identified 10 candidate genes for eye colour.

DNAPrint has now taken that information and turned it into a test. The firm took DNA samples from 500 volunteers and recorded their eye colour. Then it applied a technique called SNP mapping to find correlations between the two.

SNP stands for "single nucleotide polymorphism" - a single "letter" change in the genetic code. These variations account for most of the genetic differences between individuals. DNAPrint sequenced the 10 candidate genes from each volunteer then sifted through the sequences looking for SNPs. It found 50 in total. Then it set computers to work out how the SNPs correlated with eye colour.

Of the 10 genes, DNAPrint found that only four really matter. Chief executive Tony Frudakis says that by looking at these four genes, it can classify someone into one of three eye-colour groups - dark (black and brown), light (blue and grey), or hazel - with 97 per cent certainty. Exactly what the four genes do, and how they combine to determine eye colour remains a mystery, but that`s not a problem for DNAPrint: to make a commercial test it doesn`t need to know how it works, just that it does.

The next challenge is hair colour. DNAPrint is applying exactly the same technique to this problem, identifying candidate genes and looking for SNPs. Frudakis says they have made some headway and can tentatively classify people as blonde, red, auburn, brown, or black-haired from their DNA alone.

Kannte den noch nicht.

Roger

[cariocca]

DER
LINK
FUNZT
NICH!

Tja, so is dat Leben.

Roger

[bhfranky]

Hy,
endlich mal wieder bewegung in dem Thread.
Hab auf 67.500 erhöht.

Go DNAP

bhfranky

[hvs1]

Sauber DNAPèrs

so macht es doch wieder Spaß!
Wäre auch schön wenn morchel,SmCpHunter,Smiling etc.wieder
mal reinschauen.

Gruß hvs1

[cariocca]

Ein Ossi bewirbt sich bei "Wetten, daß..." mit der Wette, einen Wessi mit einem Kaffeelöffel innerhalb von 5 Minuten erschlagen zu können. "Und was machen Sie, wenn Sie es nicht schaffen?", fragt Thomas Gottschalk. "Dann nehme ich einen Spaten..."

[cariocca]

Wie nennt man das Geschlechtsteil einer Nonne?

-Christstollen-


Gute Nacht

Roger

[hvs1]

Roger,

was ist los?
Hast Du etwas getrunken?
So,so Christstollen.

[cariocca]

hvs1...
...nur Kaffee...

BTW: In der Schweiz lacht man über solche Witze...




Roger

[cariocca]

Übrigens:

DNAP = Christstollen

Kompaktes Gebilde mit vielen guten Dingen drin. Das muss man doch einkach probiert haben!

Roger

[ge4teilter]

Moin!

Bei mir sind´s inzwischen 120000 mit einem Mittel von ca. 0,18 $. Das soll aber noch nicht das Ende sein!

Schönen Tag Euch allen!

g4

[hvs1]

Roger,
auch bei uns lacht man über hintergründige Witze.

G4,
das hört sich doch gut an.

Ich wünsche euch einen schönen Dienstag.

Gruß hvs1

[cariocca]

.............................................................
DNAP - Shareholders, Germany / Swiss

macdiri------------1`090`000
hvs1------------------650`000
cariocca-------------542`500
smCphunter-------333`000
snoopy--------------250`000
js200-----------------200`000
ge4teilter------------120`000
otcbhappytrader----99`500
Tho 123---------------80`000
sclabo-----------------80`000
bh franky--------------67`500
Blackjack-------------75`000
Gerd N-----------------29`500
marterpfahl-----------20`000
Wallgrekk-------------17`500
MZipperling----------15`000
Neoe-------------------10`000

Liste bei Roger (Cariocca)
....................................................

[cariocca]

DNAP - SHAREHOLDERS

http://community.webshots.com/user/sambista

Roger
.

[marterpfahl]

Nur zur Korrektur:
Mittlerweile 40000 Anteile in meinem Depot.

mfg, Geduld bewahren !

marterpfahl

[hvs1]

Roger,

den mit dem Rezept und den mit den 57 Einschußlöchern
fand ich am Stärksten.

Gruß hvs1

[meisterspieler]

danke roger für die erheiterung in schweren zeiten

hab` auch einen kleinen fiesen parat:

was macht eine frau mit einem leeren blatt papier in der hand? - sie liest sich ihre rechte durch...

aber spaß beiseite. ich halte über 400000 shares, weiß aber nicht was ich machen soll, wenn wir die 3.5 nach unten durchbrechen. und ich spreche nicht nur von einem tagestief...

naja, ich hoffe, es geht wieder aufwärts technisch gesehen sind wir ja in einem fallenden keil, was eigentlich ein recht bullishes zeichen ist...

long and strong - der meister

[JS222]

DNAP - DNAPrint Genomics Inc (OTCBB : DNAP)

--------------------------------------------------------------------------------
VOLUME(-): DNAP Volume 47% > 20-adsv, Stock -2.78%



TUESDAY , AUGUST 27, 2002 12:46 PM

This is the 1st VOLUME alert for DNAP in the past 7 calendar days.

Trading for DNAPrint Genomics Inc (OTCBB: DNAP) has been heavier than usual in today`s session. By 12:45 ET, the stock had already traded 1,647,000 shares via 68 trades. The cumulative volume is 47.49% above than its 20-day average of 1,116,715. Normally the stock experiences around 51 individual trades per session.

So far, today`s volume surge has caused a net decline in DNAP`s stock price. At the time of this alert, the stock was trading at $0.035, down $-0.001 (-2.78%).

One year ago, the Company`s shares closed at $0.040. The price has declined more than 12 percent since then.

Over the last 10 trading session DNAP has traded in a range between $0.031 and $0.040 and is currently trading 73.48% below its 52-week high of $0.132 set on October 23, 2001 and 12.90% above its 52-week low of $0.031 from August 15, 2002.

In the previous 3 sessions, DNAP trading has displayed a mixed trend. Closing results have been as follows:

August 26, 2002 --- closed at $0.036 down $0.001 (-2.70%) on 1,018,300 shares
August 23, 2002 --- closed at $0.037 down $0.001 (-2.63%) on 966,600 shares
August 22, 2002 --- closed at $0.038 up $0.002 (+5.56%) on 1,619,300 shares

The Company last released news on August 20, 2002:

"DNAPrint Files Patent to Protect 2,425 SNPs Linked to Drug Response"

DNAPRINT GENOMICS INC
DNAPrint Genomics, Inc., a development-stage company, intends to be a national provider of analytical tools and knowledge-based solutions for personalized medicine, using DNA-related products and procedures. The Company is developing genetic analytics and information resource products for next-generation personalized medicine. The Company`s products will provide practitioners of genomic research and personalized medicine with a system for trait dissection and patient classification.

JS200

[hvs1]

Hallo DNAPèrs

There is Blood on the Street.
Morgen geht eine neue Order von mir rein o.o35/5ok

Gruß hvs1

[cariocca]

Wenn die 0.035 nicht hält...

...vermute ich die 0.03 bis Ende dieser Woche zu sehen.

meisterspieler...Meine Frau hat fast hyperventiliert! LOL!


Gute Nacht

Roger

[cariocca]

Yes...here!

Roger

[meisterspieler]

roger

hyperventiliert?

wegen dem witz oder weil dnap heute so unter druck war ...lol!

ich will dich nicht mit der charttechnik langweilen aber wir haben heute mit hohem volumen den "falling wedge" (wenn auch nur ein kleines bisschen...)durchbrochen. das könnte ein super zeichen sein. mal sehen

goodnight

[Sven Christian]

Wie sehen Eure Kursziele aus ?

[otcbhappytrader]

Die 0,035 USD scheinen zu halten...hopefully

[wsperber]

News

http://biz.yahoo.com/bw/020828/282244_1.html

[wsperber]

News

http://biz.yahoo.com/bw/020828/282244_1.html

[cariocca]

Hier im Klartext

NEWS OUT !!! DNAPrint Obtains a Supply Agreement on the LNA Technology From Exiqon

Business Wire - August 28, 2002 11:29
SARASOTA, Fla.--(BUSINESS WIRE)--Aug. 28, 2002--DNAPrint genomics, Inc. (OTCBBNAP) announced today that it has obtained a non-exclusive right of supply from the Danish company Exiqon A/S to incorporate Locked Nucleic Acid (LNA(TM)) technology into certain of its pharmacogenomics and forensics tests.

DNAPrint kits use small DNA probes to query specific single nucleotide polymorphisms (SNPs) within an individual`s genome. The probes contain molecular "addresses" that targets each particular SNP much like a street address targets a postal letter. Most kits made today contain natural DNA; however there are a number of technical advantages associated with using artificially modified DNA molecules instead. The supply agreement signed today enables DNAPrint to use a specially modified DNA called LNA(TM) in the construction of its test kits. Exiqon holds the patent for the LNA(TM) technology.

The use of LNA(TM) (Locked Nucleic Acid) is expected to provide superior technical performance and robustness for DNAprint kits and services. LNA(TM) is a novel class of DNA analogs that provide outstanding improvements in a number of key DNA hybridization properties. Of paramount importance for diagnostic use, the technology combines exquisite binding affinity towards complementary DNA, but with an unusual ability to discriminate between matching and mismatching target sequences. This quality makes LNA(TM) ideal for SNP (Single Nucleotide Polymorphism) detection, particularly within the context of gene families. The term "Locked Nucleic Acids" was coined by Exiqon to emphasize that the usual conformational freedom of the furanose ring in standard nucleosides is restricted in LNA(TM) due to a methylene linker connecting the 2`-O position to the 4`-C position. This restriction accounts for the enhanced specificity.

Terms of the open-ended supply agreement were not disclosed.

About DNAPrint genomics, Inc.:

DNAPrint genomics Inc. was founded by a team of scientists with research and commercial experience in high-level mathematical and statistical modeling, programming and molecular genetics. Our quest is to become the leader in the development of complex pharmacogenomics classifiers for a personalization of drug prescription. The Company is traded on the NASDAQ OTC Bulletin Board under the ticker symbol: DNAP. For more information about the Company, please visit http://www.dnaprint.com.

About Exiqon A/S:

Exiqon A/S is a privately held Scandinavian biotech company offering technologies and services for the development of simple and accurate molecular assays in the pharmaco- and functional genomics and proteomics fields. The Company provides a variety of technologies for genetic testing, gene expression analysis, sample preparation and biomolecular immobilization and assay. For more information about the Company, please visit http://www.exiqon.com.

All statements in this press release that are not historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint`s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.


CONTACT: DNAPrint genomics, Inc., Sarasota
Investor Contact:
Carrie Castillo, 941/366-3400
[e-mail]

[ge4teilter]

Moin zusammen!

Cariocca, setze er mich in seiner Liste bitte auf 150` rauf. Meinereiner hat gestern noch einen kleinen Happen zu 0,034 erstehen können.

Schöntachnoch

g4

[cariocca]

DNAP - Shareholders, Germany / Swiss

macdiri------------1`090`000
hvs1------------------650`000
cariocca-------------542`500
meisterspieler-------400`000
smCphunter---------333`000
snoopy--------------250`000
js200-----------------200`000
ge4teilter------------150`000
otcbhappytrader-----99`500
Tho 123---------------80`000
sclabo-----------------80`000
bh franky--------------67`500
Blackjack--------------75`000
marterpfahl-----------40`000
Gerd N-----------------29`500
Wallgrekk--------------17`500
MZipperling-----------15`000
Neoe-------------------10`000

Liste bei Roger (Cariocca)

[JS222]

Von Gestern

DNAPRINT GENOMICS INC
0.034
+0.001 +3.03%


Daily Commentary
WAIT

Our system recommends WAIT as of today. Previous SELL recommendation was made on 6/19/2002 (71) days ago, when the stock price was 0.058. Since then the stock fell -41.38% .

Today the stock closed higher with a lower high and a lower low. The volume is normal. The security price is trending down.

Candlestick Analysis


Today’s Candlestick Patterns:
White Candlestick


Today a White Candlestick formed. Buyers were in control but the buying pressure was not very strong.


JS200

[Wallgrekk]

Hi Roger & all,

meine Teile habe ich doch schon längst
zu 0.072 geschmissen....!!

Erwäge aber derzeit einen
Neu-Einstieg, bin jedoch nicht
so auf dem Laufenden...

[js200]

Von Gestern

DNAP
DNAPRINT GENOMICS INC
0.031
-0.001 -3.13%

Daily Commentary
WAIT

Our system recommends WAIT as of today. Previous SELL recommendation was made on 6/19/2002 (76) days ago, when the stock price was 0.058. Since then the stock fell -46.55% .

Today the stock closed lower, at its low (sign of weakness) with a lower high and an unchanged low. The volume is normal. The security price is trending down.

Candlestick Analysis

Today’s Candlestick Patterns:
Inverted Hammer

Today a Inverted Hammer formed. The bulls drove the price higher but could not hold on to the gains. By the close the bears had prevailed and the price ended close to where it started. Be careful, resurgence in the bullish camp shows that the current downtrend could be due for a reversal!

Stock Quote
Last 0.031
Previous Close 0.032
Change -0.001
% Change -3.13%
Volume 1,299,500
Stock Activity
Open 0.032
Day`s High 0.034
Day`s Low 0.031
52 Week High 0.120
52 Week Low 0.031


Stock Price History
3 Month % Change -55.71
6 Month % Change -50.00
12 Month % Change -38.00
Stock Statistics
50 Day Close MA 0.043
200 Day Close MA 0.056
65 Day Volume MA 1,191,248

JS200

[js200]

DNAP
DNAPRINT GENOMICS INC
0.032
+0.001 +3.23%


Daily Commentary
WAIT

Our system recommends WAIT as of today. Previous SELL recommendation was made on 6/19/2002 (77) days ago, when the stock price was 0.058. Since then the stock fell -44.83% .

Today the stock closed higher with an unchanged high and an unchanged low. The volume is normal. The security price is trending down.



Click here to get a full trend analysis of this stock Candlestick Analysis


Today’s Candlestick Patterns:
Spinning Top


Today a Spinning Top formed. Both the bulls and the bears were active during the session. Even though the session opened and closed with little change, prices moved significantly higher and lower in the mean time. Be careful, this indicates weakness among the bears and a potential change or interruption in the current trend!





Stock Quote
Last 0.032
Previous Close 0.031
Change +0.001
% Change +3.23%
Volume 1,130,800
Stock Activity
Open 0.033
Day`s High 0.034
Day`s Low 0.031
52 Week High 0.120
52 Week Low 0.031


Stock Price History
3 Month % Change -52.24
6 Month % Change -48.39
12 Month % Change -36.00
Stock Statistics
50 Day Close MA 0.042
200 Day Close MA 0.056
65 Day Volume MA 1,182,842

JS200

[js200]

?????????SEHR HOHE UMSÄTZE AM ANFANG, KOMMT DA WAS ????????

10:02:37 AM Trade (at Bid) 0.032 100000 OTC BB
10:00:44 AM Trade (at Bid) 0.032 100000 OTC BB
10:00:39 AM Trade (at Ask) 0.033 26700 OTC BB
10:00:27 AM Ask 0.033 5000 OTC BB
10:00:27 AM Bid 0.032 5000 OTC BB
9:40:42 AM Trade (at Bid) 0.031 35000 OTC BB
9:38:37 AM Trade 0.032 100000 OTC BB
9:38:36 AM Ask 0.033 5000 OTC BB
9:38:36 AM Bid 0.031 5000 OTC BB
9:36:10 AM Trade 0.0325 216800 OTC BB
9:35:30 AM Trade (at Bid) 0.032 200000 OTC BB

JS200

[js200]

11:20:20 AM Trade (at Bid) 0.031 20000 OTC BB
11:19:58 AM Trade (at Bid) 0.031 160000 OTC BB
11:19:27 AM Trade (at Bid) 0.031 10000 OTC BB
11:17:42 AM Trade 0.032 45000 OTC BB
11:17:25 AM Ask 0.033 5000 OTC BB
11:17:25 AM Bid 0.031 5000 OTC BB
11:16:56 AM Trade (at Bid) 0.032 40000 OTC BB

JS200

[*Burna*]

was beteuted den im OTC wenn hinter dem kürzel ein E kommt wenn ein Q kommt heist das sie pleite sind aber was bedeutet E ???? DANKE

[js200]

DNAP - DNAPrint Genomics Inc (OTCBB : DNAP)

--------------------------------------------------------------------------------
VOLUME(-): DNAP Volume 22% > 20-adsv, Stock -3.13%



THURSDAY , SEPTEMBER 05, 2002 11:36 AM

This is the 1st VOLUME alert for DNAP in the past 7 calendar days.

Trading for DNAPrint Genomics Inc (OTCBB: DNAP) has been heavier than usual in today`s session. By 11:35 ET, the stock had already traded 1,423,300 shares via 30 trades. The cumulative volume is 22.06% above than its 20-day average of 1,166,020. Normally the stock experiences around 53 individual trades per session.

So far, today`s volume surge has caused a net decline in DNAP`s stock price. At the time of this alert, the stock was trading at $0.031, down $-0.001 (-3.13%).

One year ago, the Company`s shares closed at $0.040. The price has declined more than 22 percent since then.

Over the last 10 trading session DNAP has traded in a range between $0.031 and $0.038 and is currently trading 76.52% below its 52-week high of $0.132 set on October 23, 2001 and 0.00% above its 52-week low of $0.031 from September 04, 2002.

In the previous 3 sessions, DNAP trading has displayed a mixed trend. Closing results have been as follows:

September 04, 2002 --- closed at $0.032 up $0.001 (+3.23%) on 1,130,800 shares
September 03, 2002 --- closed at $0.031 down $0.001 (-3.12%) on 1,299,500 shares
August 30, 2002 --- closed at $0.032 down $0.002 (-5.88%) on 601,400 shares

The Company last released news on August 28, 2002:

"DNAPrint Obtains a Supply Agreement on the LNA Technology From Exiqon"

DNAPRINT GENOMICS INC
DNAPrint Genomics, Inc., a development-stage company, intends to be a national provider of analytical tools and knowledge-based solutions for personalized medicine, using DNA-related products and procedures. The Company is developing genetic analytics and information resource products for next-generation personalized medicine. The Company`s products will provide practitioners of genomic research and personalized medicine with a system for trait dissection and patient classification.


JS200

[CR0K0]

Hallo DNAP`ers,

packe momentan wieder ein paar Euros zusammen für Rückkauf Anfang Oktober

(Zwangs-)Verkauf war zu $.064...

Über den Kursrückgang seit Februar 02 kann ich mich nicht wirklich freuen - hätte ich so niemals erwartet - $.04 war doch immer der Boden...

Habe mich(ausgenommen dem Kursverlauf)seit Februar nicht mehr um DNAP gekümmert...

Was ist mit den "Insiderverkäufern" ???

cu Croko - go DNAP

[js200]

DNAP - DNAPrint Genomics Inc (OTCBB : DNAP)

--------------------------------------------------------------------------------
52W LOW: New 52-Wk Low for DNAP @ $0.030 dn1.61%



FRIDAY , SEPTEMBER 06, 2002 03:16 PM

This is the 1st 52 WEEK LOW alert for DNAP in the past 7 calendar days.

The share price for DNAPrint Genomics Inc (OTCBB: DNAP) reached a new 52-week low today, trading at $0.030, down $-0.001 (-1.61%) from its previous close of $0.031.

The Company`s previous 52-week low of $0.031 was set yesterday on September 05, 2002.

One year ago, the Company`s shares closed at $0.040. The price has declined more than 23 percent since then.

At the time of this alert, the stock had traded 887,500 shares via 43 trades, 28.35% below it`s 20day average of 1,238,690 shares.

This new 52-week low currently puts the stock:

15.28% below its 20day Moving Average of $0.036
27.23% below its 50day Moving Average of $0.042
40.53% below its 100day Moving Average of $0.051

The Company last released news on August 28, 2002:

"DNAPrint Obtains a Supply Agreement on the LNA Technology From Exiqon"

DNAPRINT GENOMICS INC
DNAPrint Genomics, Inc., a development-stage company, intends to be a national provider of analytical tools and knowledge-based solutions for personalized medicine, using DNA-related products and procedures. The Company is developing genetic analytics and information resource products for next-generation personalized medicine. The Company`s products will provide practitioners of genomic research and personalized medicine with a system for trait dissection and patient classification.


JS200

[js200]

DNAP
DNAPRINT GENOMICS INC
0.031
0.000 0.00%


Daily Commentary
WAIT

Our system recommends WAIT as of today. Previous SELL recommendation was made on 6/19/2002 (79) days ago, when the stock price was 0.058. Since then the stock fell -46.55% .

Today the stock closed unchanged with an unchanged high and a lower low. The volume is normal. The security price is trending down.



Click here to get a full trend analysis of this stock Candlestick Analysis


Today’s Candlestick Patterns:
Long-Legged Doji


Today a Long-Legged Doji formed. The prices traded well above and below the session’s opening level, but closed virtually even with the open. Be careful, this is a sign of a great amount of volatility and indecision; the current trend may be about to stall!





Stock Quote
Last 0.031
Previous Close 0.031
Change 0.000
% Change 0.00%
Volume 985,200
Stock Activity
Open 0.031
Day`s High 0.033
Day`s Low 0.030
52 Week High 0.120
52 Week Low 0.031


Stock Price History
3 Month % Change -51.56
6 Month % Change -56.34
12 Month % Change -22.50
Stock Statistics
50 Day Close MA 0.041
200 Day Close MA 0.055
65 Day Volume MA 1,198,485

JS200

[wsperber]

Schaut mal,

was stockholder101 aus dem Raging-Bull-Board mit
der Erwähnung von DNAP in deutscher Sprache entdeckt hat:

http://warpsix.dva.de/sixcms/detail.php?id=129238

[otcbhappytrader]

Hi, ich bin am Freitag zu 0,031 Euro mit Riesenverlust aus-
gestiegen. Ich halte sogar ein Abrutschen in den Bereich 0,009 nicht mehr ausgeschlossen. Ich kann als Investor kein
Geld verdienen, wenn Altinvestoren, insb. Finanzierungsgesellschaften Aktien in Riesenmengen und zu jedem Preis raushauen. Eventuell kaufe ich noch einmal wenn
der Kurs noch billiger wird und es sieht leider so aus als
würde es hier kein halten mehr geben. Schade lange Zeit war dieser Penny-stock einer der stabilsten Aktien in meinem Depot und ich hatte mehrfach die Möglichkeit mit sehr guten
Gewinn auszusteigen.

[ge4teilter]

Ach Du Kacke!

DNAP Quote
10:27 AM ET
(delayed 15 min.)

0.0260
-0.0050 (-16.13 %)
Volume: 1,035,000

[otcbhappytrader]

Quao vadis DNAP ?

[otcbhappytrader]

Ich glaub´s selber nicht : 0,022- Da habe ich wohl wenigstens noch ein bischen glück gehabt

[ge4teilter]

Egal. Ich kauf nach!

[otcbhappytrader]

Es gibt auch noch ein Morgen, würde Bodenbildung abwarten.

[cariocca]

Auf eine Bodenbildung warten wir seid nun seid 2 Jahren. Meiner Meinung nach verkauft zur Zeit eine Einzelperson, und ein paar Lemminge folgen...

Mögen sie bald ersoffen sein.

Roger

[cariocca]

Auf eine Bodenbildung warten wir seid nun seid 2 Jahren. Meiner Meinung nach verkauft zur Zeit eine Einzelperson, und ein paar Lemminge folgen...

Mögen sie bald ersoffen sein.

Roger

[cariocca]

Hier ein bisschen GRÜN:

http://www.chalberweid.ch/

Meine NEUE Page des Familiengarten-Vereins...

Roger

[js200]

DNAP - DNAPrint Genomics Inc (OTCBB : DNAP)

--------------------------------------------------------------------------------
MOVER(-): DNAP Trading Lower



MONDAY , SEPTEMBER 09, 2002 01:38 PM

DNAPrint Genomics Inc (OTCBB: DNAP) is trading sharply lower at this time in the session, down about $0.005 or 16.13%, on volume that is approximately 174% greater than its 20-day average.

Recent News:

8/28/02: Announced that it obtained a non-exclusive right of supply from the Danish company Exiqon A/S to incorporate Locked Nucleic Acid technology into certain of its pharmacogenomics and forensics tests.

8/30/2002: Jennifer Miller sold 200,000 shares; 8/26/02: Willie Flangan sold 100,000 shares; and 8/26/02: Tampa Bay Financial, Inc. sold 2,000,000 shares.

Recent SEC Filings:

10QSB on 8/14/02, for the second quarter ended 6/30/02, including the following highlights:

For the three months ended 6/30/02; 6/30/01
Revenues: $42,693; $11,702
Net Loss: $(1,070,517); $(591,836)


Knobias Technical Analysis:

Trading lower than four of four moving averages
Consolidated support price: $0.03

JS200

[js200]

9:25:15 AM Ask 0.027 5000 OTC BB
9:25:15 AM Bid 0.026 5000 OTC BB
9:25:13 AM Ask 0.027 5000 OTC BB
9:25:13 AM Bid 0.025 5000 OTC BB
9:25:06 AM Ask 0.027 5000 OTC BB
9:25:06 AM Bid 0.0251 5000 OTC BB

most recent back next
9:26:32 AM EDT - Tuesday, September 10, 2002 - data is real-time


JS200

[wsperber]

Hallo cari,

auf deiner DNAP-WEB-Seite hast du zweimal einen Link
auf den zweiten Newsletter. Wäre vielleicht besser
auch den ersten Newsletter mit einzubeziehen.

Sonst aber Klasse (auch der Rest der WEB-Page)

Gruß

Wolfgang

[CR0K0]

Hallo Roger,habe bei mir auch ein wenig DNAP verbaut.

Stammt vom ge4teilten glaube ich ?

Bin leider bisher noch immer ohne shares

http://www.spatializer.org/wf00007.htm

cu Croko

[cariocca]

Danke, Wolfgang...

Kannst Du mir vielleicht mit dem 1.Newsletter weiterhelfen?
Kann ihn in im Moment nicht finden...

Ich habe die Links übrigens aus dem RB von "investor2047" geklaut. Aber das weist Du sicherlich.


Merci bien

Roger

[cariocca]

Croko...

Du schaffst es bestimmt in die Gilde der DNAPsters zurück zu kommen.

Der Link ist sicherlich nicht von G4...

...da war doch mal ein SPAZ-Fan im Bord?!


Grüsse nach Kölle

Roger

[CR0K0]

@Roger,comeback ist spätestens Ende November - die Spazen sind schon zuhause im Nest...

Croko

[proFEiT]

Hallo zusammen,

mir kommt da gerade in den Sinn, das DNAP ein Übernahmekandidat für ... wäre.

Sollte DNAP "fusionsfähig sein", was hier bestimmt bestätigt werden kann, werde ich meine Idee hier einbringen

MfG pF

[wsperber]

Hallo cariocca,

hab im Moment auch keinen Link vom 1 Newsletter.
Tut mir leid

Gruß

Wolfgang

[wsperber]

Hallo cari,

hab doch noch einen Link gefunden:

http://ragingbull.lycos.com/mboard/boards.cgi?board=DNAP&rea…

[ge4teilter]

Moin Roger,

doch, Croko hat Recht, diese Übersetzung hatte ich damals verbrochen.

g4

[cariocca]

Vielen Dank, Wolfgang...

...werde den Link heute Abend einfügen.

G4...aber die Spaz-Seite ist nicht aus Deinem Fundus, oder?


Roger

[proFEiT]

Was haltet ihr von der Überlegung, die Geschäftsfelder von DNAP und der Par-se Tech. zusammenzulegen?


Es gibt Dinge die immer wieder passieren, und weitreichende Konsequenzen nach sich ziehen können. Dazu gehört;

Du musst aus irgendeinem Zwang deinen Arzt wechseln...und sei es nur kurzzeitig und dein "neuer Arzt" hat keinerlei Unterlagen über dich!
Er weiss nicht, welche Beschwerden du noch nebenbei hast, welche Medikamente du nicht verträgst, auf welche Medikamenten-Cocktails du evt. allergisch reagierst usw.
Auch beim Gang zur Apotheke gibt es das gleiche Problem, dass der Apotheker dir ein Medikament verschreibt welches Nebenwirkungen mit anderen von dir eingenommenen Medikamente hat und haben könnte...
Da wäre es sehr hilfreich eine Option und Garantie zu habe, dass solches nicht passiert:

Hier kommt Par-Se Technologies aus der e-Health - Branche ins Spiel.
Par-se hat eine Software entwickelt die deine bekannten gesundheitlichen Daten abspeichert und für den Arzt, die Apotheke, das Krankenhaus und der Krankenkasse etc. sichtbar macht.

Par-Se ist in der Vorreiter-Nation "USA" Marktführer. Ca. 8% der dort ansässigen Arztpraxen benutzen diese Software schon - Tendenz steigend.
Der Wert wird an der Nasdaq gehandelt. Helmut hält das Unternehmen auch für interessant...

[js200]

DNAPRINT GENOMICS INC - OTC BB: DNAP

Consolidated Real-time Market Quote*
Last Change (%) After Hours Chg (%)** Bid Ask Trade Time
-- -- -- -- -- --

--------------------------------------------------------------------------------
Exchange QuoteLast Change (%) Bid (size) Ask (size) Trade Time
0.03 0.003 (11.11) 0.029 (50) 0.031 (50) 11:39
Day Volume Last Size Open High Low
698,700 100,000 0.029 0.032 0.028
Latest Ticks # of Trades Avg Trade Size 52 Wk High 52 Wk Low
+++- 33 21,173 N/A N/A
Prev Close VWAP Avg Day Vol
0.027 0.0295 N/A


JS200

[wsperber]

News

http://biz.yahoo.com/bw/020919/192053_1.html

DNAPrint Launches ANCESTRYbyDNA 2.0 - World`s First Recreational Genomics Testing Service
Business Wire - September 19, 2002 07:58
SARASOTA, Fla.--(BUSINESS WIRE)--Sept. 19, 2002--DNAPrint genomics, Inc. (OTCBBNAP) today announced that it has
launched what it believes to be the world`s first recreational genomics testing service. The service is the first to provide the everyday
consumer the opportunity for introspection from his or her own genome sequence, and as such, it is expected to become a trailblazer in
the newly forming consumer genomics marketplace.

ANCESTRYbyDNA 2.0 will scan the genome for customers in order to determine their BioGeographical Ancestry (BGA) or ancestral
proportions. The test is powered by DNAPrint`s ANCESTRY panel of proprietary Single Nucleotide Polymorphisms (SNPs), and reveals
the proportional extent to which a customer is of European, Native American, African, East Asian, South/Middle Asian and/or Pacific
Islander genetic heritage. Making such determinations by eye is unreliable, and from family records tedious and inexact, but recent human
genome research by DNAPrint`s scientists and Dr. Mark Shriver of The Pennsylvania State University (PSU) have shown that biological
ancestry proportions are clearly written in the DNA and extractable with certain mathematical algorithms. Some of the underlying
science supporting the test has been published over the last three years by both labs (Parra et al.1; Pfaff et al. 2; Parra et al., 3 and
Frudakis et al. 4).

Until today, two types of genetic tests have been available for the study of human heredity. Both the Y-chromosome and mitochondrial
tests are simple tests best suited for revealing that relation exists between two specific individuals, such as daughter and grandmother.
In contrast, ANCESTRYbyDNA 2.0 is a significantly more complex test that queries hundreds of Single Nucleotide Polymorphisms
(SNPs) spread throughout the human genome. Using proprietary algorithms and database resources, this sequence information is
summarized for each customer by plotting their heredity along "A Multi-Dimensional Continuum of Ancestry"(TM), thereby allowing for a
calculation of ancestral proportions (such as 90% European, 10% African or some other ratio, as the case may be). In a recently filmed
BBC interview, Dr. Shriver relates that he is ostensibly of European ancestry, yet he was surprised to learn from the test that his
ancestral proportions are in fact 63% European, 27% African and 10% Native American. Pilot studies on populations have shown that
the test produces results that are in general agreement with what is known from the anthropological history of the world`s various
peoples. For example, Africans and Europeans test as of relatively pure ancestry, but the African-American individuals tested are from
70-97% African and 3-30% European ancestry (some with substantial Native American ancestry) and the different Hispanic
populations range from of 50-70% European, 30-40% Native American and 0-20% African ancestry, depending on the geographical
region. Until the development of the ANCESTRY test earlier this year, the estimation of ancestral proportions from DNA had not been
possible.

In addition to serving individuals curious about their ancestry, the testing service has practical implications for certain types of
customers. In early August, a customer used an earlier version of the service to help focus a bone marrow donor search for a leukemic
child. The child harbored an unusual HLA profile, which made it difficult to match her with a bone marrow donor. In this case, the family
was apparently of European heritage, but the unusual HLA profile suggested the family was of mixed heritage. The test confirmed this to
be the case, and the knowledge gained is expected to allow the family members to focus their search towards the appropriate admixed
group. Another early customer in Utah used the test to demonstrate that he was of Native American heritage in an effort to validate his
entitlement to participate in business ventures reserved for Native Americans. Other early customers have included university
researchers who desired to qualify ancestral proportions for study samples, and the test would be appropriate for the adopted or for
genealogists who desire to learn about ambiguous regions of their family tree.

DNAPrint scientists are collaborating with Dr. Shriver to develop more advanced versions of ANCESTRYbyDNA that may be useful for
discerning regional heritage proportions in individuals. For example, ANCESTRYbyDNA 3.0 is expected to be capable in the near future
of determining whether an individual is of Irish/British, Middle European (French, German), Scandinavian, Mediterranean (Italian, Greek,
Spanish) or Eastern European heritage as well as of Western/Central versus East African heritage or of Japanese, Chinese or Korean
heritage. For more information about the ANCESTRYbyDNA 2.0 service please visit http://www.ancestrybydna.com.

About DNAPrint genomics, Inc.:

DNAPrint genomics, Inc. was founded by a team of scientists with research and commercial experience in high-level mathematical and
statistical modeling, programming and molecular genetics. Our quest is to become the leader in the development of complex
pharmacogenomics and forensics classifiers for a personalization of drug prescription and enhancement of our criminal justice system.
DNAPrint is the only company in the world building an eigengenotype database for routine complex/quantitative genetics analysis from
population level genomics data. The Company is traded on the NASDAQ OTC Bulletin Board under the ticker symbol: DNAP. For more
information about the company, please visit http://www.dnaprint.com.

[wsperber]

Und mit anderen Worten und Preisen für den Test

http://www.heraldtribune.com/apps/pbcs.dll/artikkel?SearchID…


SARASOTA -- In an effort to stimulate cash flow, DNAPrint Genomics Inc. today begins
selling to the public a service it touts as the first recreational genetic testing of its kind.

The research and development company says that ANCESTRYbyDNA 2.0 can tell a person`s
racial mix by determining the sequence of his genetic data. It hopes to gain a following from
genealogy enthusiasts exploring ambiguous parts of their family trees.

DNAPrint planned to primarily target the forensics market. But it needs to start making money
soon -- the company has lost $5.46 million since late 1998 because it`s been spending its
capital on research.


"When the economy was doing well, we could put money
into research," said Tony Frudakis, DNAPrint`s chief
executive officer.

"Things have really changed. We are forced now to realize
the economic potential of the work we have already done,
rather than invest all of our resources into discovery."

The service, which initially will cost $150 but will rise in price
to $290, includes a test kit containing a plastic serrated
instrument for scraping saliva. The user then sends the
sample to the company for analysis.

Frudakis said this testing can prove within a few percentage
points to what extent a person is of European, Native
American, African, Asian or Pacific Islander heritage. He
hopes sales will fuel development of an upgraded ANCESTRY version that will further
distinguish whether an individual is of Southern, Western or Northern European, Western,
Central or East African, Japanese or Chinese descent.

An ANCESTRY pilot program helped one consumer narrow a bone marrow search for a
leukemic child; it also enabled a Utah man to prove he qualified for a business venture
exclusive to Native Americans.

Frudakis said he`s unable to gauge sales potential because there`s no similar product on the
market.

Human genetic testing basically comes in two forms: Y-chromosome and mitochondrial tests
are used to determine relationships between two people, such as mother and daughter.

Mark Shriver, an assistant professor of anthropology and genetics at Pennsylvania State
University, has collaborated with Frudakis on several genetic testing products, including
ANCESTRY.

"I don`t think anybody else has even used the phrase `recreational genomics,`" he said. "I see
(research and development) extending into physical features and personality traits. There`s
going to be a blurry line between medical information and recreational information."

DNAPrint still plans to target the forensic industry for other tests in development, including
those that determine eye, skin and hair color from DNA samples left at crime scenes. The
company also continues to research how genetic information can predict how individuals will
react to certain prescription drugs.

"We`re not jumping tracks and losing focus," Frudakis said of ANCESTRY. "We`re developing
products for the consumer genomics marketplace."

[wsperber]

Es gint auch schon eine extrA WEB-Seite

http://www.ancestrybydna.com/

Die Jungs im RB-Board sind wirklich fix, dies alles zu finden.

[wsperber]

Es gint auch schon eine extrA WEB-Seite

heißt übersetzt:

Es gibt auch schon eine Extra-Web-Seite

[ge4teilter]

Jau, es tut sich was!

[JS222]

Wird aber auch Zeit

JS200

[Traumfaenger]

09:53:35 0.029 20000 OTCBB
09:53:32 0.029 34000 OTCBB
09:52:25 0.031 1400 OTCBB at Ask
09:39:11 0.031 300 OTCBB at Ask
09:37:07 0.031 10000 OTCBB at Ask
09:35:28 0.030 10000 OTCBB
09:34:56 0.031 2000 OTCBB at Ask
09:34:51 0.031 1000 OTCBB at Ask
09:30:31 0.030 400 OTCBB at Bid
09:30:26 0.032 5000 OTCBB at Ask

[Traumfaenger]

10:03:12 0.029 10000 OTCBB at Ask
10:02:51 0.029 4900 OTCBB at Ask
10:02:28 0.029 5000 OTCBB at Ask
10:02:18 0.029 4000 OTCBB at Ask
10:02:18 0.028 100000 OTCBB
10:01:23 0.029 130000 OTCBB at Ask
10:01:23 0.030 170000 OTCBB at Ask
10:00:31 0.029 4900 OTCBB
10:00:30 0.030 4900 OTCBB at Ask
10:00:19 0.029 50000 OTCBB

[Traumfaenger]

10:34:51 0.030 5000 OTCBB at Ask
10:32:57 0.029 25000 OTCBB
10:32:21 0.030 25000 OTCBB at Ask
10:26:00 0.030 7800 OTCBB
10:25:07 0.029 5000 OTCBB
10:25:06 0.030 5000 OTCBB
10:23:53 0.029 31000 OTCBB
10:23:53 0.030 31000 OTCBB
10:22:13 0.030 50000 OTCBB
10:21:37 0.030 5000 OTCBB

[JS222]

DNAPRINT GENOMICS INC - OTC BB: DNAP

Consolidated Real-time Market Quote*
Last Change (%) After Hours Chg (%)** Bid Ask Trade Time
-- -- -- -- -- --

--------------------------------------------------------------------------------
Exchange QuoteLast Change (%) Bid (size) Ask (size) Trade Time
0.029 0.001 (3.57) 0.027 (50) 0.029 (50) 12:14
Day Volume Last Size Open High Low
1,407,200 5,000 0.032 0.032 0.028
Latest Ticks # of Trades Avg Trade Size 52 Wk High 52 Wk Low
-+-+ 55 25,585 N/A N/A


JS200

[cariocca]

Für mich ist es spätestens ab JETZT, sonnenklar...

DER MARKT HÄLT UNS UNTEN!

Tolle News!


Roger

[hvs1]

Roger,
es wird schon werden.

Gruß hvs1

[N.Y.]

Wollte auch mal Hallo sagen, ich verfolge DNAP noch immer von der Seitenlinie. Die Story ist nach wie vor interessant, wird wohl aber noch Jahre dauern bis diese richtig zum tragen kommen, ob DNAP überleben wird, hängt von den weiteren Entwicklungen und vor allem von ersten Umsätzen und weiteren Geldgebern ab, die neueste NR gibt Anlaß zur Hoffnung. Ich sehe aber bei der momentanen Marktkapitalisierung weiteres Rückschlagspotenzial von 50 % – 60 %, in der heutigen Zeit wird leider kein Geld mehr für Fantasie bezahlt. Sollten die Umsätze erheblich anziehen oder der Kurs sich nochmals halbieren oder die Beteiligung eines Major Players bekannt gegeben werden, bin ich auch dabei.

Hier ist ein interessanter Artikel aus der Zeit:

http://www.zeit.de/2002/39/Wissen/200239_m-rassenmedizin.htm…


Allen viel Glück und ein schönes Wochenende

N.Y.

[cariocca]

Guten Morgen, DNAPsters...

Hier findet ihr die neuesten Bilder der Chicago-Konferenz.

http://community.webshots.com/user/sambista


Danke an Tamulonis und ifida0001 aus dem Raging-Bull.

Roger
.

[Traumfaenger]

Last: 0.026
High: 0.029
Low: 0.025
Open: 0.029
Change: -0.002
Volume: 847,500


Bid: 0.023
Ask: 0.026
Bid/Ask Size: 5,000 / 5,000


52 Wk High: 0.132
52 Wk Low: 0.023
%Change: -7.2%


Market Cap: N/A
Price/Sales: N/A
EPS: $0.00
P/E Ratio: N/A


Quotes provided by S&P Comstock
09/23/02 - 10:00 a.m. Eastern -- No Quote Delay.

Last 10 trades


Time Price Volume Exchange Info


10:00:25 0.026 2500 OTCBB at Ask
09:57:20 0.025 47000 OTCBB
09:54:38 0.026 5000 OTCBB at Ask
09:50:18 0.026 5000 OTCBB
09:50:18 0.025 45300 OTCBB
09:48:59 0.025 50000 OTCBB
09:48:58 0.026 2500 OTCBB
09:48:49 0.027 100000 OTCBB at Ask
09:48:49 0.026 150000 OTCBB
09:47:35 0.026 10000 OTCBB

[Blackjack2000]

NEWS!!!!




DNAPrint Presents Statin Classifier At Chicago DMC Meeting
Business Wire - September 23, 2002 11:02
SARASOTA, Fla.--(BUSINESS WIRE)--Sept. 23, 2002--DNAPrint genomics, Inc. (OTCBBNAP) announced on Friday successful results from its ongoing research into the genetic basis for variable Statin response. The results were presented to an audience of health care professionals at the 7th Annual Disease Management Congress in Chicago, IL.

CEO Dr. Tony Frudakis described Company research that has resulted in the identification of certain gene variants associated with and predictive for Statin response. Statins are a class of drugs used to treat lipid disorders and reduce the risk of cardiovascular disease. Largely due to patient genetics, about 25% of patients fail to respond positively to any given Statin, but those that fail to respond to one often respond to another. The findings are the result of a two-year study that focused on 575 patients and seven different clinical measures of response. Using proprietary screening methods, Company scientists were able to identify an unexpectedly large number of variants linked to response. Those associated with response to standard doses of Artorvastatin (sold under the trade name Lipitor by Pfizer, NYSE:PFE) were generally different from those associated with response to standard doses of Simvistatin (sold under the trade name Zocor by Merck, NYSE:MRK), and those predictive for efficacy (how well the drug does its job) were different from those predictive of adverse events such as early stage hepatocellular toxicity (liver stress) or myalgia (muscle pain). The research condensed mathematical encodings for these variants, which the Company calls "eigengenotypes", into a complex genetics classifier capable of explaining almost all of the observed variability in response. Details on how the "eigengenotypes" were measured and computed, or from what genes they are derived were not presented.

The results were described as the fabric for a new genomics test, called STATNOME(TM), which the Company intends to market to the managed health care industry. By allowing physicians to match patients with the Statin most appropriate for their genetic constitution, STATNOME(TM) could enable a dramatic enhancement the therapeutic benefit of this class of drugs. The Company hopes that STATNOME(TM) will reduce the need for frequent follow up visits to the doctors office, obviate an entire menu of clinical tests for monitoring Statin response and reduce the waste that comes from giving medicines to people who are genetically incapable of responding to them. In so doing, the new test could help managed care providers save thousands of dollars per patient, while at the same time, treat their patients more effectively.

Until the tests are manufactured and distributed, Dr. Frudakis explained that the Company plans to exclusively provide STATNOME(TM) classification services for early clinical adopters and progressive patients. The commencement of this service would be announced at a later date. He also outlined Company plans to begin offering services based on the OVANOME(TM) test, which was introduced by the Company last year as the world`s first genomics-based test for flagging patients who are incompatible with paclataxel and carboplatin combination chemotherapy (which is the current FDA approved first-line therapy for ovarian cancer; paclitaxel is sold under the trade name Taxol and carboplatin is sold under the trade name Paraplatin, both are manufactured by Bristol-Myers Squibb, NYSE:BMY). The commencement of STATNOME(TM) and OVANOME(TM) services would make DNAPrint the only laboratory in the world using internally-developed, wholly owned and drug-specific classifiers for the individualization of drug treatment. The tests would be among the very first genomics-based tests ever applied before routine drug use, or for any other clinical practice.

The STATNOME(TM) test could have significant implications for the safety and effectiveness of Artorvastatin and Simvistatin, which combine to serve a $12 billion annual market projected to grow to $20 billion by 2003. Though generally well tolerated, adverse events associated with the use of Statins have recently begun to receive widespread attention. Recently Bayer (NYSE:BAY) was forced to pull their Statin "Baycol" from the market due to a fatal response linked to muscle damage and myalgia. Though myalgia is reversible, like hepatocellular toxicity, it is part of a continuum of pathology that leads physicians to switch treatments. By flagging the genetically incompatible before treatment, the Company hopes that STATNOME(TM) will help minimize the negative impact of this widely used class of drugs and change the "trial and error" mentality of today`s drug prescription process. In addition, STATNOME(TM) could help expand the market for Statins, many of which are already considered "blockbuster" drugs. For example, Statins are usually given to patients that have a lipid condition that can lead to cardiovascular disease, but there are an estimated 30 million healthy people in the US who are at risk of developing this condition for whom Statins would serve as an effective prophylactic. Mainly due to side effects, and the cost of monitoring these side effects, the cost/impact and risk/reward values for a healthy person at risk of developing a lipid disorder is less desirable than that for the already afflicted. As a result, Statins are still not used in the healthy population. By accurately flagging those who would develop an adverse reaction to them before the drug is given, STATNOME(TM) could someday help Statins overcome this barrier for more widespread use.

About DNAPrint genomics, Inc.:

DNAPrint genomics Inc. was founded by a team of scientists with research and commercial experience in high-level mathematical and statistical modeling, programming and molecular genetics. Our quest is to become the leader in the development of complex pharmacogenomics and forensics classifiers for a personalization of drug prescription and enhancement of our criminal justice system. DNAPrint is the only company in the world building an eigengenotype database for routine complex/quantitative genetics analysis from population level genomics data. The Company is traded on the NASDAQ OTC Bulletin Board under the ticker symbol: DNAP. For more information about the company, please visit http://www.dnaprint.com.

All statements in this press release that are not historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint`s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.


CONTACT: DNAPrint genomics, Inc., Sarasota
Investor Contact:
Carrie Castillo, 941/366-3400
[e-mail]

[js200]

Was das HEUTE der SELLOFF ????????

DNAPRINT GENOMICS INC - OTC BB: DNAP

Consolidated Real-time Market Quote*
Last Change (%) After Hours Chg (%)** Bid Ask Trade Time
-- -- -- -- -- --

--------------------------------------------------------------------------------
Exchange QuoteLast Change (%) Bid (size) Ask (size) Trade Time
0.029 0.001 (3.57) 0.027 (50) 0.029 (50) 15:11
Day Volume Last Size Open High Low
2,601,500 53,600 0.029 0.029 0.024
Latest Ticks # of Trades Avg Trade Size 52 Wk High 52 Wk Low
-+-+ 110 23,650 N/A N/A
Prev Close VWAP Avg Day Vol
0.028 0.0269 N/A


JS200

[js200]

09/23/2002 (13:36 ET) VOLUME(+): DNAP Volume 41% > 20-adsv, Stock +3.57% - Knobias
09/23/2002 (11:02 ET) DNAPrint Presents Statin Classifier At Chicago DMC Meeting - Business Wire
09/23/2002 (10:38 ET) MOVER(-): DNAP Lower; Launched Genomcs Testing Service - Knobias
09/19/2002 (07:58 ET) DNAPrint Launches ANCESTRYbyDNA 2.0 - World`s First Recreational Genomics Testing Service - Business Wire
09/18/2002 (15:56 ET) VOLUME(-): DNAP Volume 100% > 20-adsv, Stock -6.67% - Knobias


JS200

[js200]

DNAP - DNAPrint Genomics Inc (OTCBB : DNAP)

--------------------------------------------------------------------------------
MOVER(-): DNAP Lower; Launched Genomcs Testing Service



MONDAY , SEPTEMBER 23, 2002 10:38 AM

DNAPrint Genomics Inc (OTCBB: DNAP) shares are trading $0.002 or 7.1% lower in the session at this time, on volume that is on pace to exceed its 20-day average daily share volume.

Recent company news:

09/19/02: DNAPrint genomics, Inc. (OTCBBNAP) today announced that it has launched what it believes to be the world`s first recreational genomics testing service. The service is the first to provide the everyday consumer the opportunity for introspection from his or her own genome sequence, and as such, it is expected to become a trailblazer in the newly forming consumer genomics marketplace.

08/28/02: DNAPrint genomics, Inc. (OTCBBNAP) announced today that it has obtained a non-exclusive right of supply from the Danish company Exiqon A/S to incorporate Locked Nucleic Acid (LNA(TM)) technology into certain of its pharmacogenomics and forensics tests.

Recent company filings:

10QSB filed on 08/14/02 included the following:

Three months ended: 06/30/02; 06/30/01
Total Revenues: $42,693; $11,702
Net Income: $(1,070,517); $(591,836)

10QSB: filed on 05/15/02 to report financial results for the quarter ended March 31, 2002.

Technical analysis:

Below 4 of 4 moving averages
Near-term support price: $0.027
Near-term resistance price: $0.034

JS200

[js200]

DNAP - DNAPrint Genomics Inc (OTCBB : DNAP)

--------------------------------------------------------------------------------
VOLUME(+): DNAP Volume 41% > 20-adsv, Stock +3.57%



MONDAY , SEPTEMBER 23, 2002 01:36 PM

This is the 2nd VOLUME alert for DNAP in the past 7 calendar days.

Trading for DNAPrint Genomics Inc (OTCBB: DNAP) has been heavier than usual in today`s session. By 13:35 ET, the stock had already traded 2,147,700 shares via 85 trades. The cumulative volume is 40.97% above than its 20-day average of 1,523,550. Normally the stock experiences around 62 individual trades per session.

So far, today`s volume surge has caused a net rise in DNAP`s stock price. At the time of this alert, the stock was trading at $0.029, up $0.001 (+3.57%).

One year ago, the Company`s shares closed at $0.040. The price has declined more than 27 percent since then.

Over the last 10 trading session DNAP has traded in a range between $0.023 and $0.034 and is currently trading 78.03% below its 52-week high of $0.132 set on October 23, 2001 and 26.09% above its 52-week low of $0.023 from September 09, 2002.

In the previous 3 sessions, DNAP trading has displayed a mixed trend. Closing results have been as follows:

September 20, 2002 --- closed at $0.028 even for the day on 2,499,400 shares
September 19, 2002 --- closed at $0.028 even for the day on 1,655,700 shares
September 18, 2002 --- closed at $0.028 down $0.002 (-6.67%) on 2,785,500 shares

The Company last released news on September 23, 2002 (today):

"DNAPrint Presents Statin Classifier At Chicago DMC Meeting"

DNAPRINT GENOMICS INC
DNAPrint Genomics, Inc., a development-stage company, intends to be a national provider of analytical tools and knowledge-based solutions for personalized medicine, using DNA-related products and procedures. The Company is developing genetic analytics and information resource products for next-generation personalized medicine. The Company`s products will provide practitioners of genomic research and personalized medicine with a system for trait dissection and patient classification.


JS200

[js200]

DNAPRINT GENOMICS INC - OTC BB: DNAP

Consolidated Real-time Market Quote*
Last Change (%) After Hours Chg (%)** Bid Ask Trade Time
-- -- -- -- -- --

--------------------------------------------------------------------------------
Exchange QuoteLast Change (%) Bid (size) Ask (size) Trade Time
0.028 0 (0.00) 0.028 (50) 0.029 (50) 15:59
Day Volume Last Size Open High Low
3,060,000 65,000 0.029 0.029 0.024
Latest Ticks # of Trades Avg Trade Size 52 Wk High 52 Wk Low
-++- 124 24,677 N/A N/A
Prev Close VWAP Avg Day Vol
0.028 0.0271 N/A

JS200

[js200]

By: j3ric0 $$$$$
23 Sep 2002, 03:51 PM EDT Msg. 203650 of 203652

OTCHighway.com - Stock Report For September 23, 2002
Update on DnaPrint Genomics

Company name: DnaPrint Genomics
Stock symbol: [OTC:BB DNAP]
Current price: $0.029
1-year target: $0.65
Suggested Action: Strong Buy

-------------------------------------------
Latest Press Releases:
-------------------------------------------
DNAPrint Presents Statin Classifier At Chicago DMC Meeting
DNAPrint Launches ANCESTRYbyDNA 2.0 - World`s First Recreational Genomics Testing Service


-------------------------------------------
Our Input/Summary:
-------------------------------------------
Dnaprint Genomics has seen a dramatic decline in PPS over the past couple of months. This is simply due to the lack of expertise in marketing their pipeline of products.

Currently Dnaprint has Statinome, Retinome, and Ovanome on the go. All three products have tremendous potential, and will be a matter of time before the market demands them. Revenues should be around the corner, and the PPS should jump rather quickly. A price of 2.9 cents is definitely not reflective of Dnaprint`s success and should be looked upon as a great buying opportunity.

Otchighway suggests a strong buy for Dnaprint Genomics. The foundation has been laid out, and it should be a only a matter of months before the ball starts rolling.

Please refer to our disclaimer before making any assessments.

Click Here to unsubscribe from Otchighway`s newsletter.


JS200

[js200]

DNAP
DNAPRINT GENOMICS INC
0.028
0.000 0.00%


Daily Commentary
WAIT

Our system recommends WAIT as of today. Previous SELL recommendation was made on 6/19/2002 (96) days ago, when the stock price was 0.058. Since then the stock fell -51.72% .

Today the stock closed unchanged with a lower high and a lower low. The volume is extremely high. The security price is trending down.

Candlestick Analysis

Today’s Candlestick Patterns:
Short Black Candlestick

Today a Short Black Candlestick formed. There was a limited price change that may represent consolidation

Stock Quote
Last 0.028
Previous Close 0.028
Change 0.000
% Change 0.00%
Volume 3,109,900
Stock Activity
Open 0.029
Day`s High 0.029
Day`s Low 0.024
52 Week High 0.120
52 Week Low 0.026

Stock Price History
3 Month % Change -50.88
6 Month % Change -56.92
12 Month % Change -30.00
Stock Statistics
50 Day Close MA 0.036
200 Day Close MA 0.054
65 Day Volume MA 1,318,277

JS200

[Traumfaenger]

09:38:16 0.029 10000 OTCBB
09:37:49 0.030 5000 OTCBB at Ask
09:32:36 0.029 50000 OTCBB at Bid
09:31:57 0.029 9000 OTCBB at Bid
09:31:57 0.030 9000 OTCBB at Ask
09:31:49 0.029 2500 OTCBB at Bid
09:31:49 0.030 2500 OTCBB at Ask
09:31:47 0.029 2500 OTCBB at Bid
09:31:47 0.030 2500 OTCBB at Ask
09:31:24 0.029 68500 OTCBB at Bid

[Traumfaenger]

12:04:06 0.027 56000 OTCBB at Bid
12:04:06 0.028 56000 OTCBB at Ask
12:03:28 0.027 50000 OTCBB at Bid
12:00:34 0.027 5000 OTCBB at Bid
11:48:22 0.028 39700 OTCBB
11:48:22 0.028 21500 OTCBB
11:48:21 0.027 61100 OTCBB at Bid
11:43:06 0.029 7500 OTCBB at Ask
11:42:57 0.028 10000 OTCBB at Bid
11:40:50 0.028 15000 OTCBB at Bid

[wsperber]

Hallo Mitinvestierte,

es gibt ein Diskussionsforum über ANCESTRYbyDNA.

http://boards.ancestry.com/mbexec/message/an/topics.software…

2 Beiträge sind darin bis jetzt enthalten. Sollte man
vielleicht beobachten, ob das mehr wird. Vielleicht
hat ja auch einer von euch Lust, einen Beitrag zu schreiben.

Gruß

Wolfgang

[Traumfaenger]

09:56:55 0.027 71500 OTCBB
09:48:59 0.026 95000 OTCBB at Bid
09:48:53 0.026 5000 OTCBB at Bid
09:48:24 0.027 100000 OTCBB
09:38:59 0.027 100000 OTCBB
09:38:50 0.026 100000 OTCBB
09:37:49 0.026 25000 OTCBB at Bid
09:34:53 0.027 5000 OTCBB
09:34:50 0.027 5000 OTCBB
09:31:47 0.027 4000 OTCBB at Ask

[wsperber]

traurig, traurig

dieser Kursverlauf.

Gibt es eigentlich noch Aktien, die keine
Pennystocks sind?

[js200]

09/25/2002 (11:26 ET) VOLUME(-): DNAP Volume 19% > 20-adsv, Stock -19.23% - Knobias
09/25/2002 (11:21 ET) 52W LOW: New 52-Wk Low for DNAP @ $0.021 dn19.23% - Knobias
09/25/2002 (11:00 ET) MOVER(-): DNAP Trading Lower - Knobias
09/23/2002 (13:36 ET) VOLUME(+): DNAP Volume 41% > 20-adsv, Stock +3.57% - Knobias
09/23/2002 (11:02 ET) DNAPrint Presents Statin Classifier At Chicago DMC Meeting - Business Wire

JS200

[Traumfaenger]

13:57:14 0.024 2500 OTCBB at Ask
13:56:31 0.024 2500 OTCBB at Ask
13:55:03 0.024 70000 OTCBB at Ask
13:54:56 0.024 45000 OTCBB at Ask
13:53:56 0.024 5000 OTCBB at Ask
13:53:42 0.024 2500 OTCBB at Ask
13:52:33 0.024 5000 OTCBB at Ask
13:41:36 0.024 15000 OTCBB at Ask
13:26:01 0.023 10000 OTCBB at Bid
13:26:36 0.023 5000 OTCBB at Bid


Recent News:

Today: According to Dow Jones News, Anderson IMC Group LLC sold 2,250,000 restricted shares on 9/18/02.

9/18/02: According to Dow Jones News, Mervin R. Bernard registered to sell 617,000 restricted shares on 9/25/02.

9/23/02: Announced successful results from its ongoing research into the genetic basis for variable Statin response. The results were presented to an audience of health care professionals at the 7th Annual Disease Management Congress in Chicago, IL.

9/19/02: Announced that it launched what it believes to be the world`s first recreational genomics testing service. The service is the first to provide the everyday consumer the opportunity for introspection from his or her own genome sequence.

[ge4teilter]

Na, da bin ich ja froh, daß ich vorgestern nicht zu 0.027 reingekommen bin

(Und ich hatte mich erst noch geärgert!)

[cariocca]

Wissen 39/2002

Andere Rasse, andere Pille

--------------------------------------------------------------------------------

Mediziner und Genforscher beleben die Rassendiskussion neu: Sie fordern, Medikamente je
nach Hautfarbe zu verordnen. Damit wollen sie genetischen Unterschieden gerecht werden

von Hubertus Breuer

Wenn Sally Satel in ihrem Arztkittel ins Behandlungszimmer stürmt, bringt sie stets ihre Rassenvorurteile mit.
Verschreibt die Psychiaterin in ihrer Washingtoner Drogenklinik etwa das Antidepressivum Prozac, setzt sie bei
Afroamerikanern eine niedrigere Dosis als bei weißen Junkies an. Der Grund: "Schwarze verarbeiten den
Stimmungsaufheller langsamer als Weiße und Asiaten." Bei 40 Prozent aller Schwarzen komme es zu
unerwünschten Nebenwirkungen - deshalb beginnt Satel mit einem kleinen Quantum.

Auch andere Mediziner wollen Schluss machen mit der politisch korrekten Gleichbehandlung von Weiß und
Schwarz: Kürzlich berichtete das New England Journal of Medicine, dass das Herzmedikament Enalapril bei
Patienten schwarzer und weißer Hautfarbe unterschiedlich anschlägt. Schwarze zeigten sich für den heilenden
Wirkstoff weniger empfänglich. Zudem mussten sie wegen Herzschwäche öfter ins Krankenhaus. Das könnte
auf einen unterschiedlichen Lebensstil hinweisen, meinen die Autoren vorsichtig - es könne aber auch an
Arzneimittel abbauenden Enzymen und anderen Wirkstoffrezeptoren liegen, die bei beiden Gruppen
verschieden sind. Weil Schwarze oft an Stickstoffmangel leiden, der den Blutdruck erhöht, vermuteten sie, wirke
Enalapril wohl nicht richtig.

Solche Studien entfachen in den Vereinigten Staaten eine Debatte neu, die längst als überwunden galt. Plötzlich
steht der verpönte Begriff "Rasse" wieder auf der Agenda. Doch dieses Mal sind es nicht Soziologen oder
Anthropologen, die sich über die Unterschiedlichkeit menschlicher Ethnien streiten, sondern Mediziner und
Genforscher. Sie verlangen, das Charakteristikum "Rasse" in der Medizin stärker zu berücksichtigen, um
Patienten unterschiedlicher Herkunft besser gerecht zu werden.

Solche Forderungen sind brisant in einem Land, das sich stets bemüht, seine Bürger "farbenneutral" zu
betrachten. Auf Versuche, ethnische Gruppen wissenschaftlich einzuordnen, reagiert die amerikanische
Öffentlichkeit allergisch. Das hat zuletzt der Skandal um das Buch The Bell Curve im Jahr 1994 gezeigt. Darin
behaupten der Psychologe Richard Herrnstein und der Soziologe Charles Murray, auf der Intelligenzskala der
Menschheit stünden Asiaten und Juden obenan, Schwarze dagegen am Ende - und zwar nicht nur aus
soziologischen Gründen. Deren Abstieg sei auch genetisch bedingt. Am Ende erwies sich die diskriminierende
Behauptung als unhaltbar.

Doch seit etwa einem Jahr wird der umstrittene Begriff "Rasse" enttabuisiert. Nicht nur Ärzte wie Sally Satel
fordern, Rasse als probates Diagnosekriterium anzuerkennen. Im vergangenen März genehmigte selbst die
amerikanische Gesundheitsbehörde erstmals in ihrer Geschichte eine klinische Studie, die sich allein auf
Schwarze richtet - für den Test eines Blutdruckmittels, das die Stickstoffwerte im Blut erhöht. Bürgerrechtler
gaben ihren Segen.

Adams Söhne, Evas Töchter

Rückendeckung können sich die rassebewussten Mediziner bei Genetikern holen. Denn ihre Erkenntnisse
geben der Idee, unterschiedlicher menschlicher "Familien" durchaus Auftrieb - wenn auch anders, als sich dies
mancher Rassist in seinem Schwarzweißdenken gedacht hatte.

Der Humangenetiker Luca Cavalli-Sforza machte sich bereits Anfang der neunziger Jahre daran, das
Rassengemisch genetisch zu sortieren. 1993 setzte er das Human Genome Diversity Project in Gang, um
einen Weltatlas der Genvielfalt zu erstellen und den Stammbaum des Menschen zu rekonstruieren. Die
Methode hatte Erfolg. Genarchäologen um Cavalli-Sforza und andere Forscher entdeckten, dass der Homo
sapiens in verschiedenen Erdteilen unterschiedliche Mutationen des Erbguts entwickelt hatte, nachdem er aus
Afrika ausgewandert war. Über die Welt verstreut, fanden die Forscher auf diese Weise 10 männliche und 18
weibliche Stammhalter der Menschheit, gewissermaßen Adams Söhne und Evas Töchter.

Die genetischen Unterschiede zwischen diesen Ureltern der verschiedenen Ethnien sind allerdings minimal.
99,9 Prozent ihrer Gene teilen alle Menschen miteinander, egal, ob sie aus Asien, Afrika oder Europa stammen.
Nur das restliche Zehntelprozent der Erbinformation ist variabel. "Die Differenzen zwischen Rassen", sagt
Cavalli-Sforza, "sind oberflächlicher Natur. Sie repräsentieren Anpassungen an die jeweiligen klimatischen
Bedingungen." Die dunkle Haut der Schwarzen etwa ist auf das Pigment Melanin zurückzuführen, das vor
starker Sonnenstrahlung schützt.

Andere allerdings interpretieren Cavalli-Sforzas Befund genau umgekehrt: Jenes Zehntelprozent sei von größter
Bedeutung, betonen sie. Denn vom Schimpansen unterscheiden den Menschen auch nur 1,3 Prozent
Erbsubstanz - dennoch gehören beide völlig anderen Gattungen an. Ein Zehntelprozent unseres Erbguts, das
immerhin drei Millionen Genbuchstaben entspricht, mag da markante Unterschiede zwischen ethnischen
Gruppen verkörpern. Auch die Psychiaterin Sally Satel warnt davor, diese Differenz zu ignorieren. "Es geht um
mehr als um Hautpigmente. Hinter solchen Merkmalen verbirgt sich die genetische Evolutionsgeschichte" - und
just darauf beziehe sich der Begriff Rasse.

Satel behauptet damit allerdings keineswegs, es gebe einen tiefen Graben, der Weiße von Schwarzen trenne.
Im Lotteriespiel der Genverteilung kann ein Asiate gelegentlich einem Europäer durchaus näher stehen als
seinem einheimischen Nachbarn. Der Psychiaterin und ihren Mitstreitern geht es vielmehr um das
durchschnittliche Genprofil der Rassen. Aus statistischer Sicht verteilen sich die Erbinformationen auf eine
Weise, die australische Ureinwohner deutlich von Isländern unterscheidet. Und nur das sei für die Medizin
ausschlaggebend.

Ähnliche Überlegungen werden auch in Großbritannien angestellt. Dort hat der staatliche Forensic Science
Service (FSS) bereits ein DNS-Profil für die fünf größten Bevölkerungsgruppen auf den britischen Inseln
angelegt - komponiert aus genetischen Markern. Die Behörde geht damit der Polizei zur Hand. Aus dem
Speichel an einer Zigarettenkippe kann der forensische Dienst zum Beispiel mit hoher Wahrscheinlichkeit
ermitteln, ob sich hinter dem Raucher ein Mann indischer Abstammung verbirgt. Andrew Urquhart,
Chefgenetiker der Behörde, warnt allerdings davor, die genetischen Phantombilder als biologisches
Fundament der Rasse misszuverstehen. Denn die ausgewählten Merkmale des Erbguts gehören zur so
genannten Junk-DNA, zum Genmüll gewissermaßen. "Sie haben keinen Einfluss darauf, wie eine Person
aussieht oder ihr Stoffwechsel funktioniert", sagt Urquhart.

Der Großteil des menschlichen Erbguts besteht aus solchen scheinbar nutzlosen Buchstaben. Nur magere
fünf Prozent der Bausteine kontrollieren, wie ein Mensch aussieht und wie seine Körpermaschine läuft - also
das, was man den Phänotyp nennt. Doch auch in diesen relevanten, den kodierenden Genen wurde in den
vergangenen Jahren nach Entlarvendem gefahndet. Bereits 1995 hat das englische FSS-Team ein Gen für
rotes Haar entdeckt. Und die US-amerikanische Bio-Tech-Firma DNAPrint Genomics kann heute mithilfe einer
Genprobe die Augenfarbe recht gut ermitteln. Zu mehr als ein paar Mosaiksteinen im Gruppenporträt, das wir
uns intuitiv von Ethnien machen, reicht es bislang jedoch nicht.

Den Ärzten geht es weniger um das Aussehen. Sie interessieren Gene, die medizinisch relevant sind. Und
auch da zeigen sich Unterschiede zwischen ethnischen Gruppen. Hämochromatose, eine erbliche
Eisenspeicherkrankheit, ist bei Chinesen und Indern nahezu unbekannt, taucht aber bei 7,5 Prozent aller
Schweden auf. Die tödliche Tay-Sachs-Krankheit ist vor allem bei in Europa und Nordamerika lebenden Juden
verbreitet. Schwarze wiederum sind anfälliger für Sichelzellenanämie. Diese Erbkrankheit breitete sich im
südlichen Afrika aus, weil das dafür verantwortliche defekte Gen Schutz vor der Malaria bot. 20 bis 40 Prozent
Afrikaner leben mit dem Gendefekt.

"Lassen wir solche Unterschiede bewusst unter den Tisch fallen", erklärt der Genetiker Neil Risch von der
Stanford University im Fachjournal Genome Biology, "erweisen wir Minoritäten letztlich einen Bärendienst."
Risch sieht die ethnischen Besonderheiten als Bündel kleiner genetischer Mutationen, die sich in
geografischer Isolation über Jahrtausende hinweg vererbten. Nachdem er in den vergangenen Jahren eine
Reihe genetischer Marker untersuchte, schlägt Risch jetzt vor, den Homo sapiens in fünf große kontinentale
Gruppen von Gentypen aufzuteilen: Kaukasier, zu denen er Europäer, Inder und den Nahen Osten zählt;
Menschen aus Subsahara-Afrika; die Bewohner der pazifischen Inseln; Asiaten und die Ureinwohner Amerikas
- eine Kategorisierung, die unser an bloßen Äußerlichkeiten orientiertes Rassenverständnis durchaus
bestätigt.

Risch gibt an, dass 100 willkürlich selektierte beziehunsgweise 30 gezielt ausgewählte Stellen der
Erbgutsequenz ausreichten, die geografische Herkunft der meisten Personen zu ermitteln. Diese Einteilung
macht aber nur Aussagen über den Gentyp; wie sich der Bausatz tatsächlich auf das einzelne Individuum, also
den Phänotyp, auswirkt, bleibt unbeachtet - und damit werden genetische Mutationen, die womöglich eine Rolle
für die Verträglichkeit von Arzneien spielen, ignoriert.

Hautfarbe ist nicht alles

Dass die Arzneimittelverträglichkeit wenig mit dem Aussehen, wohl aber mit der Region verknüpft ist, entdeckte
kürzlich der Populationsgenetiker David Goldstein vom University College in London. An Probanden aus
verschiedenen Ländern fand er heraus, dass Genbereiche, die unsere Reaktion auf Präparate regeln, meist in
vier geografischen Gruppen gebündelt auftreten. Diese sind: das westliche Eurasien, Subsahara-Afrika, China
und Neuguinea. Das widerspricht nicht nur Rischs Kategorisierung, sondern ist auch für den bloßen
Augenschein irritierend: Denn nach Goldsteins Modell gehörten die Äthiopier als Nordafrikaner mit zu den
Eurasiern - in einen Topf mit Norwegern, Briten und Armeniern.

So bekommen letztlich wohl beide der sich zankenden Parteien ein wenig Recht. Befürworter des
Rassebegriffs werden auch in Zukunft darauf pochen, dass manche DNS-Schnipsel in geografischen
Bevölkerungsgruppen besonders oft vorkommen. Und die Gegner dürfen zu Recht darauf verweisen, dass sich
von Häufigkeitsverteilungen nie auf den Einzelnen schließen lässt.

Für die medizinische Behandlung bedeutet dies: Das simple Modell von Sally Satel, die Medikamentenvergabe
schlicht nach der Hautfarbe zu regulieren, taugt langfristig kaum. Wichtiger wären individuelle Gentests, die
schnell und billig das Erbgut der jeweiligen Patienten kartieren. Solche Tests werden immer wieder von der
Gen-Tech-Industrie versprochen: Zuletzt kündigte der Genomentzifferer Craig Venter bei der Eröffnung eines
neuen Sequenzierzentrums an, er wolle dafür sorgen, dass ein solcher individueller Gencheck künftig für nur
1000 Dollar zur Verfügung stehe. Heute kostet er noch Millionen. Auf der Basis solcher Analysen könnten Ärzte
dann zum individuellen Genprofil passende Medikamente verschreiben.

Doch ob es in der Praxis wirklich so weit kommen wird, ist fraglich. Derzeit jedenfalls haben die Pharmafirmen
nur ein äußerst geringes Interesse daran, Millionen in die Entwicklung von Medikamenten zu stecken, die am
Ende nur einigen wenigen Menschen zugute kommen. Medikamentenhersteller bieten heute oft nicht einmal
verschiedene Arzneien für Erwachsene und Kinder an, weil sie die Kosten für die aufwändigen Testreihen
scheuen. Der Traum vom individuellen Medikament wird sich, wenn überhaupt, nur für die Reichen erfüllen -
gleich, welcher Rasse sie angehören.

[url[http://www.zeit.de/2002/39/Wissen/print_200239_m-rassenmediz…[/url]

Roger

[Traumfaenger]

09:40:56 0.025 25000 OTCBB
09:36:47 0.026 50000 OTCBB
09:35:50 0.026 36000 OTCBB
09:35:58 0.025 25000 OTCBB at Bid
09:30:41 0.025 5000 OTCBB at Ask
09:30:36 0.024 5000 OTCBB at Bid
09:30:36 0.025 2000 OTCBB at Ask

[Traumfaenger]

10:37:46 0.026 5000 OTCBB at Ask
10:29:54 0.025 25000 OTCBB at Ask
10:29:54 0.026 25000 OTCBB at Ask
10:14:28 0.025 15000 OTCBB
10:07:59 0.025 5000 OTCBB
09:59:45 0.025 24000 OTCBB
09:58:32 0.025 5000 OTCBB
09:57:39 0.025 6000 OTCBB at Ask
09:42:20 0.025 55000 OTCBB at Ask
09:40:46 0.025 25000 OTCBB

[js200]

Tony Frudakis, Ph.D.
CEO and President



Using Analytics to Address Drug Inefficacy

What is the history of your company`s involvement in life sciences?
Frudakis: We`ve been in this industry about two and a half years, but we don`t market solutions to the life sciences community. Within the complex pharmacogenomics space, algorithms are king and we keep ours privately guarded.

We are not a pharmaceutical company – we are a source of intellectual property that will power the consumer genomics/personalized medicine market soon to be upon us. Our customer will be Pfizer`s customers, Lilly`s customers, and people like you and me who use pharmaceutical products to enhance the health and quality of their lives.

Our products are genomics-based classifiers for matching patients with drugs most appropriate for their genetic constitution. We intend that our products be sold and used as companions to the drugs of each drug customer. We hope to apply genomics for enhanced human health and to save the HMOs billions of dollars in waste — from return visits due to drug inefficacy, wasted prescription fulfillment, disease exacerbation due to inefficient treatment, and extraneous tests and treatments for adverse events.

What is your motivation and vision for the future development of the life sciences market?
Frudakis: Our motivation is to develop complex genomics-based classifiers for individualization of drug prescription. We develop these classifiers by drawing quantitative and complex associations between sets of genetic variants and continuously distributed drug reaction traits. This has never been done before because genomics-based study designs are only now possible, and nobody has yet developed the algorithms.

Our scientific motivation is to address these two problems. We do this by applying novel analytics and genomics-based approaches to "solve" drug inefficacy and adverse events. Specifically, we are building a database of multi-locus "eigengenotypes" for the world`s leading prescription drugs in order to identify and mathematically model genetic features for variable drug response.

What are the key organizational assets you have developed to serve this community?
Frudakis: Our key assets are the algorithms and programs (and patents) our mathematicians, statistical geneticists and computer scientists have developed. Most of our employees are analytical genomicists, and this gives us a distinct advantage in the race to the pharmacogenomics patent office.

What products and services does your company currently provide to the life sciences market?
Frudakis: We perform contract genotyping services and partner our expertise, but we don`t sell it. We feel that we are one of a few companies — if not the only one — with the mathematical expertise to use genomics-based study designs to develop pharmacogenomics classifiers with the sensitivity, specificity and predictive power necessary for use in the clinic.

What new products and services do you have in development?
Frudakis: Our forensics products are: Retinome, a complex genomics-based classifier for the inference of human eye color; Retinome HA, a complex genomics-based classifier for the inference of human hair color; and Verity, a SNP-based classifier for racial inference.

In addition, we have developed Statnome, a complex genetic classifier for variable Statin response, and Ovanome, a complex genetic classifier for variable paclitaxel (Taxol) response.

Which life sciences organizations have you partnered with or invested in, and why?
Frudakis: We have partnered with Orchid Biosciences to potentially co-commercialize and co-develop some of our classifiers due to their aggressiveness in the personalized drug prescription space. We have also partnered with GenoMed Inc. Others partners include the University of Miami and the New York University School of Medicine for their world-class oncology and transplant programs, respectively. www.dnaprint.com



Do you know a company at the forefront of Bio-IT? Click here to nominate that company for inclusion in our Champions of Bio-IT series.



JS200

[wsperber]

Hallo Leute,

heute ist übrigens ein Artikel mit dem Titel:


http://www.nytimes.com/2002/10/01/health/genetics/01RACE.htm…


For Sale: A DNA Test to Measure Racial Mix


in der New York Times enthalten. Man kann ihn unter oben
angegebener URL nachlesen. Man muss sich aber registrieren.
Deswegen hier exklusiv der Text:

October 1, 2002
By NICHOLAS WADE


A company in Sarasota, Fla., is offering a DNA test that it
says will measure customers` racial ancestry and their
ancestral proportions if they are of mixed race.

Claiming to be "the world`s first recreational genomics
testing service," the company, DNAPrint Genomics Inc., says
its test will be useful for people interested in their own
origins as well as for more practical purposes, like "to
validate your eligibility for race-based college admissions
or government entitlements."

A test costs $290, or $160 for an initial period, and is
conducted on DNA from cells swabbed from the inside of a
customer`s cheek.

Dr. Tony Frudakis, a molecular biologist who is the
company`s chief executive, said the test would help "belie
the myths on which racism is based" by showing that "in all
of us, especially in the U.S., there is a continuum of
ancestries."

But geneticists independent of the company expressed
reservations about the accuracy of any such test, noting
that there was still relatively little data about genetic
differences between ethnic groups.

"It`s possible in principle to estimate the extent of
admixture, but the number is not going to be very
accurate," said Dr. Stephen J. O`Brien, a population
geneticist at the National Cancer Institute, referring to
the proportion of different ancestry in people of mixed
race.

Dr. Frudakis said the test was based on a set of genetic
markers known as SNP`s, pronounced "snips," that were
mostly drawn from public databases. SNP`s are sites along
the human genome where alternative chemical letters of DNA,
the genetic material, are commonly found, with some people
having one letter, some another.

Working with Dr. Mark Shriver of Pennsylvania State
University, DNAPrint Genomics has developed SNP`s that are
diagnostic of a person`s continent of origin, Dr. Frudakis
said. These five geographical areas correspond to the major
human population groups or races, those of "Native
American, East Asian, South Asian, European, sub-Saharan
African, etc.," according to the company`s Web site.

The SNP`s were validated by testing them against a panel of
people from the five continental areas, and the accuracy of
the overall test has been checked by comparing results with
known pedigrees, Dr. Frudakis said.

All human populations have the same set of genes and much
the same set of variant forms of these genes, inherited
from the predecessor species. But small differences, mostly
a shift in the frequency of common genetic variations, have
built up over time in different populations around the
world. Study of these differences has come to the fore
largely as a byproduct of two other lines of inquiry made
possible by the Human Genome Project. One is the ability to
track ancient migrations out of Africa from the different
pattern of DNA changes that have accumulated among
populations in each continent breeding in substantial
isolation from one another.

The other line of inquiry, into the identity of variant
genes that cause disease, has run into the fact that
different ethnic groups appear to have somewhat different
patterns of genetic causation, leading biomedical
scientists to debate whether race should be taken into
account in studies of disease. But most researchers are
still reluctant to study race as such, and the DNAPrint
test seems to go further than anything in the published
scientific literature.

Dr. David B. Goldstein, a population geneticist at
University College London, said that it was misleading to
suppose that the human population fell into five neat
groups, as the DNAPrint researchers implied, and that the
true pattern would probably turn out to be much more
complicated. "This test really jumps the gun in reifying
groups that don`t have scientific support," he said.

But the test could in principle provide valid information
in assessing the relative degree of a person`s heritage
from two known populations, like West Africans and
Europeans, Dr. Goldstein said.

He and Dr. O`Brien expressed concern that tests like
DNAPrint`s might do more harm than good. If the promise of
the Human Genome Project is fulfilled and genetic
information starts to flow into the clinic, "People will
need a high level of confidence in what geneticists tell
them, so this kind of casual stuff is quite dangerous if it
makes people skeptical of genetic information," Dr.
Goldstein said.

But Dr. Shriver sees use of the test as beneficial. "The
ultimate outcome is that we are breaking down a dichotomous
classification," he said, meaning that instead of people
being considered either black or white, his test would show
a continuous spectrum of ancestry among African-Americans
and others.

The spectrum of mixed ancestry continues into the
European-American population, about 10 percent of whom have
some African ancestry, Dr. Shriver said. He had discovered
to his surprise that that included him. Probably through a
Mexican grandmother, he carries the Duffy null allele, he
said, a gene variant that protects against malaria and is
very common in sub-Saharan Africans but rare among others.

[js200]

company news

--------------------------------------------------------------------------------

DNAP - DNAPrint Genomics Inc (OTCBB : DNAP)

--------------------------------------------------------------------------------
New DNAPrint Testing Service Featured in the New York Times



TUESDAY , OCTOBER 01, 2002 11:38 AM

SARASOTA, Fla., Oct 1, 2002 (BUSINESS WIRE) -- DNAPrint genomics, Inc. (OTCBBNAP) (the "Company") announced that its newly introduced ANCESTRYbyDNA service was featured today in a New York Times article.

The article was published in today`s edition: "For Sale: A DNA Test to Measure Racial Mix," authored by Nicholas Wade. DNAP will add the article to its corporate website (http://www.dnaprint.com) later today. Details on the test`s utility and exceptional accuracy, as well as new validation data, can be found at http://www.ancestrybydna.com.



About ancestrybydna


ANCESTRYbyDNA 2.0 is a new genetic test for the determination of Biogeographical Ancestry (BGA) or ancestral proportions within individuals. Specifically, the test reveals the proportional extent to which a customer is of European, Native American, African, East Asian, South/Middle Asian and/or Pacific Islander genetic heritage. Being a pan-genome test, it is the first of its kind ever developed. Its development was made possible through innovative mathematics and recent advancements in our understanding of the human genome. Information on how to order the test can be found at http://www.ancestrybydna.com.


DNAPrint genomics, Inc.


DNAPrint genomics, Inc. develops complex genetic analytics and information resource products for an individualization of drug prescription and advancement of forensic science. The company`s products provide practitioners of genomics-based medicine and forensics with a comprehensive system for complex trait dissection and patient/subject classification. This work has real-life application to the germinating fields of Personalized Medicine and Qualitative Forensics, and helps to lay the foundation for a brand-new area of medical research called Phenomics. DNAPrint genomics Inc. was founded in 2000 by a group of scientists with 57 total years of research and commercial experience in high-level mathematical modeling, programming and molecular genetics. The company is traded on the OTCBB and currently employs 14 people, 9 of who are Ph.D.s in Computer Science, Molecular Genetics, Statistics and/or Mathematics. (http://www.dnaprint.com)

All statements in this press release that are not historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint`s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.


CONTACT: DNAPrint genomics, Inc., Sarasota
Carrie Castillo, 941/366-3400
[e-mail]

URL: http://www.businesswire.com
Today`s News On The Net - Business Wire`s full file on the Internet
with Hyperlinks to your home page.



Copyright (C) 2002 Business Wire. All rights reserved.


-0-


KEYWORD: FLORIDA
INDUSTRY KEYWORD: ADVERTISING/MARKETING
MEDICAL
EDUCATION
BIOTECHNOLOGY
SOURCE:
DNAPrint
genomics,
Inc.


STOCK SYMBOLS: [(dnap)]


JS200

[Traumfaenger]

14:30:50 0.023 25000 OTCBB
14:30:49 0.022 144900 OTCBB at Bid
14:10:52 0.024 4500 OTCBB at Ask
14:09:02 0.024 5000 OTCBB at Ask
14:03:46 0.023 3700 OTCBB at Ask
14:03:46 0.024 3700 OTCBB at Ask
13:47:44 0.024 13000 OTCBB at Ask
13:36:06 0.024 42000 OTCBB at Ask
13:35:49 0.024 5000 OTCBB at Ask
13:33:07 0.024 10500 OTCBB at Ask

[Traumfaenger]

12:30:54 0.021 25000 OTCBB at Ask
12:30:52 0.021 5000 OTCBB at Ask
12:30:39 0.020 5000 OTCBB at Bid
12:30:37 0.020 5000 OTCBB at Bid
12:27:34 0.020 5000 OTCBB at Bid
12:27:32 0.020 5000 OTCBB at Bid
11:51:51 0.022 5000 OTCBB at Ask
11:50:14 0.022 5000 OTCBB at Ask
11:47:15 0.020 13500 OTCBB at Bid
11:47:08 0.021 5000 OTCBB at Bid

[cariocca]

Oooohhh....

Da sehe ich ja meine fälschlicherweise abgeschossenen 25`000 Aktien. Hmmmmm...hatte noch ein altes Stop Loss im System.

Auf bessere Kurse hoffend..

Roger

[js200]

@ROGER

Was stimmt nicht bei DNAP, warum der Kursverfall die letzten 6 Monate ???????

JS200

[cariocca]

JS200...Keine Ahnung...

Aber wie schon erwähnt: Tony ist ein genialer Wissenschaftler aber anscheinend ein schlechter Verkäufer.

Die Meldungen ziehen nicht. Der Gesammtmarkt ist mies, wer also sollte sich in diesen Zeiten für eine Zusammenarbeit mit DNAP interessieren?

PS: YHOO (als Beispiel) ist mittlerweile auch um etwa 95% vom Top entfernt!

YHOO 255 -- 9
DNAP 0.47 -- 0.02

Roger

[wsperber]

Hallo js200,

das sind, meiner Meinung nach, schlicht und einfach Aktien
von Altaktionären,die noch aus der Vor-DNAP-Zeit stammen,
die den Kurs so weit drücken. Es hat halt
auch große Nachteile über einen pleitegegangenen
Aktienmantel an die Börse zu gehen. Ich erinnere mich
an Diskussionen im Raging-Bull-Board, die ungefähr
1 bis 2 Jahre zurückliegen, dort wurde auf diese Problematik
hingewiesen. Die meisten waren jedoch der Meinung, dass
DNAP so etwas auffangen könnte, da DNAP jetzt schon dick
im Geschäft sein sollte.

Wie es scheint muß sich DNAP erst gegen die Großindustrie
durchsetzen, da DNAPs Erfindungen den Verkauf ihrer
Produkte eher stört als hilft. Man lernt bei der mehrjährigen
Investition in DNAP einfach, dass es der Pharmaindustrie
mehr auf die Gewinne als auf die Gesundung der Bevölkerung
ankommt.

Hier hilft leider nur Geduld, die die meisten Menschen
nicht haben, deswegen gibt es bestimmt auch viele Verkäufe
von Leuten, die DNAP zwar als Langfristinvestment sehen,
aber längerfristig heisst halt auch nur ein halbes bis ein Jahr.

Das grosse Problem, was ich jetzt sehe, ist das DNAP
trotz ihrer guten Ideen Pleite gehen kann. Irgendwann
ist die Geduld jedes Anlegers überstrapaziert.
Den Versuch ANCESTRYbyDNA auf den Markt zu bringen, halte ich
zwar für gut, aber ich glaube auch, dass damit auf Dauer nicht soviel
Geld zu verdienen ist, wie nötig ist. Es wirkt für mich
leider auch etwas schlecht organisiert. Im RB-Board liest
man von Problemen das Produkt über die Web-Seite zu bestellen,
es gibt in der kurzen Lebenszeit von www.ancestrybydna.com
schon sehr viele Änderungen auf dieser Web-Präsenz und unter
Linux mit dem Netscape-Browser kann man im Moment gar nichts
mit der Seite anfangen. Das wirkt für mich etwas diletantisch.
Ich hoffe nur die wirklich wichtigen Ergebnisse wie
Statnome und Ovanome sind da nicht so mit der heißen Nadel
gestrickt.

Meine Geduld ist zwar im Moment auch angeknackst, gerade auch
wegen dieser vorschnellen Vermarktung von ANCESTRYbyDNA, was
für mich wirklich darauf hinweist, dass die Situation bei
DNAP langsam schwierig wird.

Noch habe ich aber Geduld

Gruß

Wolfgang

[js200]

10/03/2002 (12:31 ET) 52W LOW: New 52-Wk Low for DNAP @ $0.019 dn13.64% - Knobias
10/03/2002 (11:13 ET) MOVER(-): DNAP Trading Lower In Session - Knobias
10/01/2002 (11:38 ET) New DNAPrint Testing Service Featured in the New York Times - Business Wire
09/25/2002 (11:26 ET) VOLUME(-): DNAP Volume 19% > 20-adsv, Stock -19.23% - Knobias
09/25/2002 (11:21 ET) 52W LOW: New 52-Wk Low for DNAP @ $0.021 dn19.23% - Knobias


JS200

[otcbhappytrader]

Vor kurzem wurde man hier noch dämlich angegriffen, wenn man sagte das man seine DNAP verkauft hat-notfalls auch mit Verlust. Wie bei mir geschehen. Einem Traum hinterherzulaufen kann teuer werden. Hier wird zu jeden Preis verkauft und das im grossen Stil.

[ge4teilter]

Ich werde weiter kaufen, allerdings erst, wenn es eine signifikate Trendumkehr gibt. Ich glaube nach wie vor, daß der miese Kurs nix mit DNAP selbst zu tun hat. Schaut euch andere Biotechs an (ORCHID, MILLENIUM usw.) - denen geht´s auch nicht besser.

Und die ganzen DNAP-Aktien, die auf den Markt geschmissen werden: Ich wage mal die Behauptung, daß die Verkäufer es ganz schön nötig haben, sonst würden sie den "Pfennigskram" doch behalten!

Nur meine Meinung.

g4

[otcbhappytrader]

In der letzten Umfrage war ich so weit ich mich erinnere der drittgrößte Aktionär im deutschsprachigen Raum von DNAP.
Das mal zum Pfennigskram...die meisten von Euch besitzen so viele Aktien von DNAP wie bei mir ein durchschnittlicher
Restaurantbesuch kostet. Ich arbeite mit Stopp-Loss Marken
und verliere deshalb nicht 99,999 % oder 95 % wie man es in der Tat auch mit anderen Biotech- oder Tech Werten leicht schaffen kann. Wie ich schon vor einigen Wochen sagte, gehe ich davon aus das DNAP auf 0,009 USD fällt und falls sich dort ein Boden findet kaufe ich wieder ein. Es würde mich nicht wundern wenn ich mit meinem Pfennigskram dann der
größte DNAP-Anteilseigner im deutschsprachigen Raum bin.

[ge4teilter]

otchappytrader,

ich meinte nicht Dich damit, sondern die Millionen von Aktien, die von den vermeintlichen DNAP-Insidern "drüben" auf den Markt geschmissen werden!

g4

[cariocca]

DNAP-DD-Seite:

http://www.chalberweid.ch/

DNAP - Galerie:

http://community.webshots.com/user/sambista

Roger

[otcbhappytrader]

ge4teilter...alles klar...habe ich in den falschen Hals
bekommen ;-)

[Traumfaenger]

09:36:25 0.020 6500 OTCBB
09:34:50 0.019 5000 OTCBB
09:34:24 0.018 15000 OTCBB at Bid
09:32:17 0.018 22000 OTCBB at Bid
09:31:03 0.018 22000 OTCBB at Bid
09:31:54 0.018 100 OTCBB at Bid
09:31:28 0.018 2500 OTCBB at Bid
09:31:24 0.018 5000 OTCBB at Bid
09:31:18 0.018 5000 OTCBB at Bid
09:30:10 0.018 69100 OTCBB at Bid

[js200]

Hat DNAP den Boden gefunden ????????

JS200

[js200]

Von Gestern

DNAP
DNAPRINT GENOMICS INC
0.020
+0.001 +5.41%


Daily Commentary
WAIT

Our system recommends WAIT as of today. Previous SELL recommendation was made on 6/19/2002 (110) days ago, when the stock price was 0.058. Since then the stock fell -66.38% .

Today the stock closed higher with an unchanged high and a higher low. The volume is normal. The security price is trending down and is oversold.

Candlestick Analysis

Today’s Candlestick Patterns:
Spinning Top

Today a Spinning Top formed. Both the bulls and the bears were active during the session. Even though the session opened and closed with little change, prices moved significantly higher and lower in the mean time. Be careful, this indicates weakness among the bears and a potential change or interruption in the current trend!

Stock Quote
Last 0.020
Previous Close 0.019
Change +0.001
% Change +5.41%
Volume 1,647,400
Stock Activity
Open 0.019
Day`s High 0.020
Day`s Low 0.018
52 Week High 0.120
52 Week Low 0.019

Stock Price History
3 Month % Change -61.00
6 Month % Change -69.53
12 Month % Change -61.00
Stock Statistics
50 Day Close MA 0.032
200 Day Close MA 0.053
65 Day Volume MA 1,455,340

JS200

[Traumfaenger]

13:37:26 0.019 5000 OTCBB at Bid
13:37:22 0.019 100000 OTCBB at Bid
13:23:24 0.019 95000 OTCBB at Bid
13:23:02 0.019 21000 OTCBB at Bid
13:21:36 0.019 5000 OTCBB at Ask
13:10:18 0.019 8800 OTCBB at Ask
13:04:22 0.019 14000 OTCBB at Ask
13:04:22 0.019 14000 OTCBB at Ask
12:22:26 0.019 5000 OTCBB at Ask
12:22:26 0.019 5000 OTCBB at Ask

[Traumfaenger]

10:42:14 0.020 7400 OTCBB
10:42:14 0.021 7400 OTCBB at Ask
10:36:22 0.019 2500 OTCBB
10:36:01 0.019 5000 OTCBB
09:54:43 0.020 10000 OTCBB
09:54:42 0.019 10000 OTCBB
09:53:47 0.021 27600 OTCBB at Ask

[Traumfaenger]

10:55:37 0.020 150000 OTCBB at Ask
10:53:42 0.019 100000 OTCBB at Bid
10:51:06 0.019 100000 OTCBB at Bid
10:37:25 0.020 5000 OTCBB
10:20:24 0.020 10000 OTCBB
10:09:52 0.020 10000 OTCBB
09:46:57 0.019 2500 OTCBB
09:46:57 0.020 2500 OTCBB
09:46:34 0.019 2500 OTCBB
09:46:34 0.020 2500 OTCBB

[Traumfaenger]

12:22:56 0.019 100000 OTCBB at Ask
12:08:21 0.018 5300 OTCBB at Bid
12:06:09 0.019 25000 OTCBB
11:54:31 0.020 50000 OTCBB
11:54:30 0.019 5000 OTCBB
11:54:29 0.019 5000 OTCBB
11:54:27 0.019 5000 OTCBB
11:54:27 0.019 5000 OTCBB
11:54:27 0.019 5000 OTCBB
11:54:26 0.020 50000 OTCBB

[ge4teilter]

Und, gibt´s schon News bezgl. der Präsentation?

g4

[ge4teilter]

Hab´ mir gerade nochmal die letzten Einträge im RB-Board durchgelesen. Wie ist denn Eure Meinung zu der Tatsache, daß Carrie mit ony verwandt ist und er über sie ein paar Millionen shares verkauft zu haben scheint?

Für mich gibt es da zwei Betrachtungsweisen. Die Negative ist: Wenn er so überzeugt von sich und seiner Firma ist, warum verkauft er dann Millionen von Aktien zu einem Spottpreis?

Wenn man´s positiv sehen will: Er weiß, was kommt, und versucht mit allen Mittlen, dort hin zu kommen. Und von irgendwas muß er ja auch leben in der Zwischenzeit, denn für ein fürstliches Gehalt ist wohl nicht genug Kohle da.

Was meint Ihr?

g4

[ge4teilter]

Keiner schreibt mehr was Alle wech Ich bin der letzte

[fonx]

Hey ,steig doch bei uns Lampies mit ein,ist viel lustiger!Fonx

[hvs1]

Hallo G4,

so schnell wird man mich nicht los.
Ich habe immerhin 650.000,- Shares,die wollen behütet sein.
Zum Nachkaufen fehlt mir zur Zeit ein wenig Mut,da ich in
den vergangenen 2 Jahren ordentlich was auf die Mütze bekommen habe.Wird schon werden.Kommt Zeit,kommt "Rad".

Gruß an Dich und alle DNAPèrs
hvs1

[wsperber]

Hallo ge4teilter,

was soll man schreiben? Bis auf das Fallen des Kurses
passiert im Moment wohl nichts, was ein Aussenstehender
sehen und kommentieren könnte.

Abwarten und Teetrinken (eigentlich mag ich gar keinen Tee)

Gruß

Wolfgang

[js200]

Boden scheint gefunden zu sein!!!

9 Tage bei rund 0,02
Mehrere Indikatoren Positiv
Könnten schnelle 40-50% werden

Eine News und Hop

JS200

[JavierOxtoa]

noch so ein Rohrkrepierer

[js200]

@JAVIER OXTOA

Beim Nemax 95% Mise ist aber auch nicht von schlechten Eltern ??????

JS200

[JavierOxtoa]

was soll der Vergleich?

alles was morchel als long-toll-mega-globalplayer empfiehlt endet bei -90%.

was hat der nemax damit zu tun?

[Neono]

JavierOxtoa
Übertreibst Du es nicht etwas?


Neono

[morchel]

Tja, da kennt einer nicht die Geschichte von DNAP!

...aber egal, hauptsache was dahergebrabbelt!

morchel

[JavierOxtoa]

das ist die Geschichte




Eindrucksvoll

[js200]

Last Trade: 0.021 Change: 0.001 (+5.000%)
Previous Close: 0.020 Volume: 728,500
Bid: 0.020 Ask: 0.022
Today`s Open: 0.019 # of Trades: 45


JS200

[cariocca]

JavierOxtoa

Danke für deinen Chart. Gut, dass Du die "Light-Version" genommen hast.

Der ist besser:

http://quotes.nasdaq.com/quote.dll?page=charting&mode=basics…

Roger

[ge4teilter]

Ja, ich kann ihn auch gar nicht oft genug sehen. DNAP, Du meine teure Freundin!

[cariocca]

Tja, mein gevierteilter Freund...

Zum Thema Freundin:

Ich habe für meine Freundin eine teure Kette gekauft!"
"Mensch, eine gute Idee, meine läuft auch immer weg!"

...aber ALLES wird gut.


Gruss aus dem saukalten Adliswil (im Tessin war`s letzte Woche 19°)

Roger

[js200]

@CARIOCCA

A propo KETTEN

Was ist los wenn deine Frau im Wohnzimmer erscheint und dich anbrüllt ????

Ihre Kette ist zu lang

JS200

[js200]

DNAPRINT GENOMICS INC - OTC BB: DNAP

Consolidated Real-time Market Quote*
Last Change (%) After Hours Chg (%)** Bid Ask Trade Time
-- -- -- -- -- --

--------------------------------------------------------------------------------
Exchange QuoteLast Change (%) Bid (size) Ask (size) Trade Time
0.022 0.001 (4.76) 0.021 (50) 0.023 (50) 09:50
Day Volume Last Size Open High Low
336,200 200,000 0.024 0.024 0.021
Latest Ticks # of Trades Avg Trade Size 52 Wk High 52 Wk Low
+--+ 5 67,240 N/A 0.0156
Prev Close VWAP Avg Day Vol
0.021 0.0223 N/A


JS200

[cariocca]

js200 .... he-heeeee!

Roger

[fonx]

Einstiegskurse?Fonx

[js200]

War mehr drin heute, aber besser in kleinen Schritten und nichts überstürzen

3:56pm ET
0.022
0.00 (4.76%)
Day`s Range: 0.02 - 0.025
Day`s Volume: 1,749,800
Avg. Volume: 1,470,397


JS200

[js200]

Von Gestern

DNAP
DNAPRINT GENOMICS INC
0.022
+0.001 +4.76%


Daily Commentary
WAIT

Our system recommends WAIT as of today. Previous SELL recommendation was made on 6/19/2002 (121) days ago, when the stock price was 0.058. Since then the stock fell -62.07% .

Today the stock closed higher with a higher high and a higher low. The volume is normal. The security price is trending sideways.

Candlestick Analysis

Today’s Candlestick Patterns:
White Candlestick

Today a White Candlestick formed. Buyers were in control but the buying pressure was not very strong.

Stock Quote
Last 0.022
Previous Close 0.021
Change +0.001
% Change +4.76%
Volume 1,749,800
Stock Activity
Open 0.020
Day`s High 0.025
Day`s Low 0.020
52 Week High 0.120
52 Week Low 0.018

Stock Price History
3 Month % Change -54.17
6 Month % Change -62.71
12 Month % Change -63.33
Stock Statistics
50 Day Close MA 0.029
200 Day Close MA 0.051
65 Day Volume MA 1,501,335

JS200

[cariocca]

Besucht doch mal wieder meine

DNAP-DD-Seite

http://www.chalberweid.ch/DNAPrint/dnaprint.html



Roger

[zerro]

hi cariocca,
gibt es in der schweiz auch ein online-broker wie z.b. consors oder dab-bank?


gruss zerro

[Traumfaenger]

10:15:34 0.025 20000 OTCBB at Ask
10:15:17 0.024 20000 OTCBB at Bid
10:11:59 0.024 2000 OTCBB
10:11:59 0.025 2000 OTCBB
10:00:17 0.024 5000 OTCBB at Ask
10:00:17 0.025 5000 OTCBB at Ask
09:58:05 0.024 25000 OTCBB at Ask
09:58:05 0.025 25000 OTCBB at Ask
09:55:06 0.024 31000 OTCBB at Bid
09:55:06 0.025 31000 OTCBB at Ask

Volume: 1,000,000

[js200]

11:13am ET
0.025
0.00 (13.63%)
Day`s Range: 0.023 - 0.026
Day`s Volume: 1,303,000
Avg. Volume: 1,501,028


JS200

[cariocca]

zerro...

Ja, zb. Consors ist auch in der Schweiz tätig. Leider haben es die Consorianer seid 2 Jahren immer noch nicht geschafft, OTC-Werte handelbar zu machen.

Meine Trades laufen darum über UBS und ZKB

http://www.ubs.ch
http://www.zkb.ch
http://www.csgroup.ch


Roger

[cariocca]

zerro...

Ich vermute, Du möchtest die steuerlichen Abzüge in der BRD umgehen, gell?

Gut so!

In der Schweiz werden Börsengewinne nicht versteuert. (nur als Vermögen, wenn man sie dann überhaubt angibt)

Roger

[cariocca]

Sorry...

http://www.credit-suisse.ch/de/

Roger

[js200]

DNAP hällt sich wacker

JS200

[cariocca]

Hallo Wolfgang...

Vielen Dank für Deinen Eintrag im Gästebuch.



Roger

[cariocca]

Tja...

Soooo doooof können Schweizer aussehen!

Ha!

Roger

[js200]

@CARIOCCA

Du siehst aus als hättest du den Latz.

PS: Gibt es nicht diesen Monat noch eine Veranstaltung seitens DNAP ??????

JS200

[zerro]

@ cariocca,

vielen dank.

p.s. deine vermutung könnte stimmen!

gruss zerro

[js200]

3:58pm ET
0.024
0.00 (9.09%)
Day`s Range: 0.023 - 0.026
Day`s Volume: 2,160,700
Avg. Volume: 1,501,028


JS200

[cariocca]

Liebe DNAPsters

Seid ein paar Stunden versuche ich in den DNAP-Chat zu kommen. Leider ohne Erfolg. Mein Arbeitgeber stellt nur den Netscape 4.77 zur Verfügung. Ich vermute der Browser ist das Problem. Zu Hause habe ich`s noch nicht probiert (IE 6.0)

http://www.ancestrybydna.com/chatroom.html

Kommentare?


Roger

[ge4teilter]

http://www.ancestrybydna.com/chatroom.html

[ge4teilter]

Also, ich war drinne - auf Anhieb!

[js200]

Von Gestern

DNAP
DNAPRINT GENOMICS INC
0.024
+0.002 +9.09%


Daily Commentary
WAIT

Our system recommends WAIT as of today. Previous SELL recommendation was made on 6/19/2002 (124) days ago, when the stock price was 0.058. Since then the stock fell -58.62% .

Today the stock closed higher with a higher high and a higher low. The volume is high. The security price is trending sideways.

Candlestick Analysis

Today’s Candlestick Patterns:
Long-Legged Doji

Today a Long-Legged Doji formed. The prices traded well above and below the session’s opening level, but closed virtually even with the open. Be careful, this is a sign of a great amount of volatility and indecision; the current trend may be about to stall!

Stock Quote
Last 0.024
Previous Close 0.022
Change +0.002
% Change +9.09%
Volume 2,180,700
Stock Activity
Open 0.024
Day`s High 0.026
Day`s Low 0.023
52 Week High 0.120
52 Week Low 0.018

Stock Price History
3 Month % Change -45.45
6 Month % Change -58.62
12 Month % Change -78.18
Stock Statistics
50 Day Close MA 0.028
200 Day Close MA 0.051
65 Day Volume MA 1,528,049

JS200

[cariocca]

ICH SCHAFF`S NICHT!



Obwohl...es soll ja schlimmeres geben...im Leben...

Roger
.

[js200]

DNAP hat eine sehr schöne Untertassenformation vollbracht, wie gehts weiter???
Dieselbe ist auch bei SQNM zu sehen!!!!

JS200

[cariocca]

Eine nachfolgende astreine "Sektglas-Kurve" wär nischt schlescht.

Wir werden sehen...


Roger

[js200]

@CARIOCCA

bei 1Dollar schmeissen wir die SEKT PARTIE

JS200

[cariocca]

js200...

Prosecco - Party mit Wolfgang dem Ge4teilten und dem Rest der Aufrechten 7...

Natürlich in der Toscana...Oder?




Roger

[js200]

1:50pm ET
0.0291
0.01 (21.25%)
Day`s Range: 0.023 - 0.031
Day`s Volume: 2,253,800
Avg. Volume: 1,527,742


JS200

[js200]

3:41pm ET
0.03
0.01 (25.00%)
Day`s Range: 0.023 - 0.031
Day`s Volume: 2,991,200
Avg. Volume: 1,527,742


JS200

[js200]

TOLLE LEISTUNG

3:59pm ET
0.03
0.01 (25.00%)
Day`s Range: 0.023 - 0.031
Day`s Volume: 3,058,400
Avg. Volume: 1,527,742


JS200

[ge4teilter]

Mehr davon!

[js200]

Von GESTERN

DNAP
DNAPRINT GENOMICS INC
0.030
+0.006 +25.00%


Daily Commentary
WAIT

Our system recommends WAIT as of today. Previous SELL recommendation was made on 6/19/2002 (125) days ago, when the stock price was 0.058. Since then the stock fell -48.28% .

Today the stock closed higher, close to its high (sign of strength) with a higher high and an unchanged low. The volume is high. The security price is trending sideways.

Candlestick Analysis

Today’s Candlestick Patterns:
Long White Candlestick

Today a Long White Candlestick formed. Buyers were aggressive and the buying pressure was strong. Be careful, this may be a potential turning point!

Stock Quote
Last 0.030
Previous Close 0.024
Change +0.006
% Change +25.00%
Volume 3,058,400
Stock Activity
Open 0.025
Day`s High 0.031
Day`s Low 0.023
52 Week High 0.120
52 Week Low 0.018

Stock Price History
3 Month % Change -31.82
6 Month % Change -48.28
12 Month % Change -72.73
Stock Statistics
50 Day Close MA 0.028
200 Day Close MA 0.051
65 Day Volume MA 1,535,886

JS200

[cariocca]

Der DNAP - Chat ist zu finden unter:

http://www.chalberweid.ch/Chatroom/carioccas_dnapchat.htm

Roger

[morchel]

fängt sich wieder anscheinend!

morchel

[js200]

2:08pm ET
0.038
0.01 (22.58%)
Day`s Range: 0.031 - 0.038
Day`s Volume: 1,303,800
Avg. Volume: 1,541,106


JS200

[js200]

2:35pm ET
0.0399
0.01 (28.70%)
Day`s Range: 0.031 - 0.0399
Day`s Volume: 1,503,800
Avg. Volume: 1,541,106


JS200

[js200]

3:59pm ET
0.04
0.01 (29.03%)
Day`s Range: 0.031 - 0.04
Day`s Volume: 2,009,300
Avg. Volume: 1,541,106


JS200

[Neoe]

Nach diesem fulminanten Anstieg muss ich mich auch mal melden.....einfach so ,dass ihr wisst , dass ich (immer noch) mit euch leide und auf die Wende im Leben des Dnap-Halters warte.

[js200]

Von Gestern

DNAP
DNAPRINT GENOMICS INC
0.040
+0.009 +29.03%


Daily Commentary
HOLD

Our system recommends HOLD as of today. Previous BUY recommendation was made on 10/23/2002 (1) days ago, when the stock price was 0.031. Since then the stock gained 29.03% .

Today the stock closed higher, at its high (sign of strength) with a higher high and a higher low. The volume is high. The security price is trending up and is overbought.

Candlestick Analysis

Today’s Candlestick Patterns:
White Marubozu

Today a White Marubozu formed. Buyers have controlled the price action from the first trade to the last trade . Be careful, this may lead to excessive bullishness!

Stock Quote
Last 0.040
Previous Close 0.031
Change +0.009
% Change +29.03%
Volume 2,009,300
Stock Activity
Open 0.031
Day`s High 0.040
Day`s Low 0.031
52 Week High 0.120
52 Week Low 0.018

Stock Price History
3 Month % Change -2.44
6 Month % Change -28.57
12 Month % Change -60.00
Stock Statistics
50 Day Close MA 0.028
200 Day Close MA 0.051
65 Day Volume MA 1,555,223

JS200

[js200]

09:36am ET
0.041
0.00 (2.50%)
Day`s Range: 0.04 - 0.045
Day`s Volume: 383,400
Avg. Volume: 1,554,915

JS200

[js200]

09:39am ET
0.043
0.00 (7.50%)
Day`s Range: 0.04 - 0.045
Day`s Volume: 473,400
Avg. Volume: 1,554,915


JS200

[js200]

10:02am ET
0.045
0.01 (12.50%)
Day`s Range: 0.04 - 0.045
Day`s Volume: 982,400
Avg. Volume: 1,554,915


JS200

[js200]

WAS GEHT DA AB ???????

10:19am ET
0.049
0.01 (22.50%)
Day`s Range: 0.04 - 0.049
Day`s Volume: 1,525,100
Avg. Volume: 1,554,915

JS200

[Neoe]

all@:
Die Times and Sales auf Freerealtime sind jetzt leider auch 15 Minuten verzögert.
Wisst ihr eine (ebenfalls kostenlose) Alternative ?
Wäre euch sehr dankbar.

[js200]

Einfach DNAP# eingeben und du bekommst QUOTE REAL

JS200

[js200]

LIEGT HIER ein SECHSER im LOTTO begraben, innerhalb 2 Wochen 150% und zieht weiter Richtung Norden !!!!

10:36am ET
0.052
0.01 (30.00%)
Day`s Range: 0.04 - 0.053
Day`s Volume: 1,978,800
Avg. Volume: 1,554,915


JS200

[js200]

10:53am ET
0.05
0.01 (25.00%)
Day`s Range: 0.04 - 0.05
Day`s Volume: 3,126,200
Avg. Volume: 1,554,915

Doppelter Tagesumsatz innerhalb 1,5 Stunden = TOP

JS200

[wsperber]

Hallo js200,

wirklich toller Tip mit dnap#.
Wo hast du das erfahren? Wenn du mir jetzt auch
noch sagen kannst, wie ich die times&sales-Kurse
wieder umsonst "realtime" bekomme, dann spendiere
ich dir das Bier bei unserem "Treffen der Millionäre"
in der Toscana, das mir Roger noch schuldet.

Danke für den Tip

Wolfgang

[cariocca]

...Ich freue mich, Wolfgang.

Probiert doch bitte mal den neuen DNAP-Chat auf:

http://www.chalberweid.ch/DNAPrint/dnaprint.html


Funktionierts bei Euch?

Gruss
Roger
.

[JS222]

@WSPERBER

Probieres es mal bei lycos-finance, einfach auf freereal anmelden, ich habe mich vor 3 Wochen so angemeldet und hatte das Glück dabei zu sein.

Gruss

JS200 (im Ausland JS222)

[Neoe]

js200@:
Vielen Dank.

[JS222]

@NEOE

Hats geklappt ??????

JS200

[JS222]

Von FREITAG

DNAP
DNAPRINT GENOMICS INC
0.042
+0.002 +5.00%


Daily Commentary
HOLD

Our system recommends HOLD as of today. Previous BUY recommendation was made on 10/23/2002 (2) days ago, when the stock price was 0.031. Since then the stock gained 35.48% .

Today the stock closed higher with a higher high and a higher low. The volume is extremely high. The security price is trending up and is overbought.

Candlestick Analysis

Today’s Candlestick Patterns:
High Wave

Today a High Wave formed. Both the bulls and the bears were active during the session, and the volume was high. Even though the session opened and closed with little change, prices moved significantly higher and lower in the mean time. Be careful, this indicates that the market may be loosing its direction and a change in trend may be imminent!

Stock Quote
Last 0.042
Previous Close 0.040
Change +0.002
% Change +5.00%
Volume 5,775,500
Stock Activity
Open 0.041
Day`s High 0.053
Day`s Low 0.039
52 Week High 0.120
52 Week Low 0.018

Stock Price History
3 Month % Change 7.69
6 Month % Change -26.32
12 Month % Change -61.82
Stock Statistics
50 Day Close MA 0.028
200 Day Close MA 0.050
65 Day Volume MA 1,583,506

JS200

[cariocca]

JS222...

Vergiss diese Analyse. Ein Comuter-gesteuertes Programm welches anhand der aktuellen Zahlen einen Text generiert. Wie beim Lotto:

Alle Angaben ohne Gewähr!

Stockholder101 im RB vermutet auch ein Einbrechen des Kurses am Montag. Das macht er lustigerweise aber immer dann, wenn er wieder etwas Kleingeld in der Tasche hat.

Wir werden sehen.


Roger

[cariocca]

Das sind die wahren DNAP-Longs:

Out of curiosity, how many of us have been around since the beginning... (anytime in 2000)?

1)Glens0 (June)
2)Rhino_Jim (July)
3)Tamulonis (July)
4)Gcbr (July)
5)Stockholder101 (July)
6)Edahsdyk (July)
7)Theo (July)
8)Douglas Siu (July)
9)Steinburger (Aug.)
10)Ambier2001 (Aug.)
11)Golfball11 (Aug.)
12)Notamm (Aug.)
13)Geldmeister0 (Aug.)
14)Cgr (Aug.)
15)Gatorvestor (Sept.)
16)Brucefla (Sept.)
17)1USGrant (Sept.)
18)Jcryan19 (Sept.)
19)Cariocca (Sept.)
20)Chrisbaskett (Oct.)
21)Ddad (Oct.)
22)Meched (Oct.)
23)Joye1 (Nov.)
24) Rysiekny (Nov.)


Roger

[hvs1]

Hallo Roger,

mich kannst Du auch dazuschreiben!
August 2000

Gruß hvs1

[hvs1]

Roger,

die ersten 50k habe ich am 28.08.00 zu 0,16 gekauft.

Gruß hvs1

[Blackjack2000]

Hi Roger!

Mich kannst du auch auf diese Liste setzen,bin seit September 2000 dabei und habe seitdem keine einzige Aktie verkauft.
Ganz im Gegenteil,es werden immer mehr!

Grüsse an alle DNAP´ler!

Blackjack

[Tho123]

Hallo alle zusammen,

ich bin ebenfalls seit August 2000 dabei.Ich habe nicht
verkauft, obwohl das zwischenzeitlich mit Sicherheit besser gewesen wäre, bei den immensen Schwankungen, die immer wieder zu beobachten waren.

Gespannt bin ich darauf, was sich in den nächsten Wochen bis Jahresende auf der Nachrichtenseite tun wird.

Tschüß

[Neoe]

js200@:
Funktioniert wunderbar , aber mal was anderes...erwarte immer noch deine Antwort zu ENVC im anderen Board. Sieht ja doch nicht ganz so rosig aus.

[wsperber]

ich hab auch mal nachgeschaut,

erster Kauf 14.08.2000 20000 Stück zu 0,07.

@js200:

kannst du mir nochmal genauer erklären, wie man sich über
lycos-finance auf freereal anmeldet. ich wär dir
sehr dankbar.

@roger

dein neuer chat-room funktioniert bei mir. Leider nicht
mit netscape 4.8 unter Linux (noch immer mein Lieblingsbrowser),
der stürzt gnadenlos ab. mit dem konqueror oder netscape 7
funktioniert es aber gut unter linux.

gruß

wolfgang

[cariocca]

An Alle:

Die Liste wird im RB von Rhino_Jim geführt.

http://ragingbull.lycos.com/mboard/boards.cgi?board=DNAP&rea…

Meldet es bitte an ihn! Danke


Roger
.

[JS222]

Von GESTERN

DNAP
DNAPRINT GENOMICS INC
0.032
-0.010 -23.81%


Daily Commentary
HOLD

Our system recommends HOLD as of today. Previous BUY recommendation was made on 10/23/2002 (5) days ago, when the stock price was 0.031. Since then the stock gained 3.23% .

Today the stock closed lower, close to its low (sign of weakness) with a lower high and a lower low. The volume is high. The security price is trending up.

Candlestick Analysis

Today’s Candlestick Patterns:
Long Black Candlestick

Today a Long Black Candlestick formed. Sellers were aggressive and selling pressure was strong. Be careful, this may be a potential turning point!

Stock Quote
Last 0.032
Previous Close 0.042
Change -0.010
% Change -23.81%
Volume 3,149,300
Stock Activity
Open 0.042
Day`s High 0.042
Day`s Low 0.031
52 Week High 0.090
52 Week Low 0.018

Stock Price History
3 Month % Change -17.95
6 Month % Change -45.76
12 Month % Change -64.44
Stock Statistics
50 Day Close MA 0.028
200 Day Close MA 0.050
65 Day Volume MA 1,599,314

JS200

[ge4teilter]

NEWS!

DNAP NEWS:
DNAPrint Enters Into Development Site
Agreement With Nanogen to Develop DNA Chip
Based Tests
Tuesday October 29, 10:15 am ET

SARASOTA, Fla.--(BUSINESS WIRE)--Oct. 29, 2002--DNAPrint genomics, Inc.
(OTCBBNAP - News; "DNAPrint" or the "Company") announced today that it has
entered into a Development Site Agreement to develop DNA chip-based tests with San
Diego-based Nanogen, Inc. (Nasdaq:NGEN - News).

The Agreement calls for DNAPrint to develop NanoChip® versions of its proprietary
genomics tests. DNAPrint`s tests are complex because they involve the simultaneous
reading of large sets of genetic markers or positions per sample, and the NanoChip®
Molecular Biology Workstation platform is well suited for this type of test.

DNAPrint intends to first validate the performance of the tests on the NanoChip®
platform, and if successful, both companies would then co-market the new tests for
clinical and field application. Nanogen would receive a royalty on each
NanoChip®-based test sold. The Agreement provides DNAPrint with a non-exclusive
license to perform certain pharmacogenomics, recreational and forensics genomics
testing services on the NanoChip® platform. Other terms of the agreement were not
disclosed.

The Agreement is the second that DNAPrint has signed for helping it graduate tests
from its pipeline to market. Earlier this year, the Company signed an agreement with
Denmark-based Exiqon, enabling the Company to use Locked-Nucleic Acid (LNA)
technology in order to increase the specificity of synthetic DNA oligonucleotides used in
its tests.

About DNAPrint genomics, Inc.:

DNAPrint genomics Inc. is a personalized medicine company founded by a team of
scientists with research and commercial experience in high-level mathematical
modeling, programming and molecular genetics. The Company is traded on the
NASDAQ OTC Bulletin Board under the ticker symbol: DNAP. For more information
about the company, please visit http://www.dnaprint.com.

All statements in this press release that are not historical are forward-looking
statements within the meaning of Section 21E of the Securities Exchange Act as
amended. Such statements are subject to risks and uncertainties that could cause
actual results to differ materially from those projected, including, but not limited to,
uncertainties relating to technologies, product development, manufacturing, market
acceptance, cost and pricing of DNAPrint`s products, dependence on collaborations
and partners, regulatory approvals, competition, intellectual property of others, and
patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any
obligation or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change in DNAPrint`s
expectations with regard thereto or any change in events, conditions, or circumstances
on which any such statements are based.

[ge4teilter]

Nanogen ist ja nicht ganz unbekannt! Werde mir das Text jetzt mal GENAU durchlesen!

g4

[JS222]

DNAPRINT GENOMICS INC - OTC BB: DNAP

Consolidated Real-time Market Quote*
Last Change (%) After Hours Chg (%)** Bid Ask Trade Time
-- -- -- -- -- --

--------------------------------------------------------------------------------
Exchange QuoteLast Change (%) Bid (size) Ask (size) Trade Time
0.035 0.003 (9.38) 0.033 (50) 0.035 (50) 12:32
Day Volume Last Size Open High Low
1,761,400 5,000 0.034 0.037 0.031
Latest Ticks # of Trades Avg Trade Size 52 Wk High 52 Wk Low
++-+ 83 21,222 0.0938 0.0156
Prev Close VWAP Avg Day Vol
0.032 0.0329 N/A


JS200

[JS222]

DNAPRINT GENOMICS INC - OTC BB: DNAP

Consolidated Real-time Market Quote*
Last Change (%) After Hours Chg (%)** Bid Ask Trade Time
-- -- -- -- -- --

--------------------------------------------------------------------------------
Exchange QuoteLast Change (%) Bid (size) Ask (size) Trade Time
0.04 0.008 (25.00) 0.037 (50) 0.04 (50) 14:20
Day Volume Last Size Open High Low
2,521,300 600 0.034 0.04 0.031
Latest Ticks # of Trades Avg Trade Size 52 Wk High 52 Wk Low
-+++ 107 23,564 0.0938 0.0156
Prev Close VWAP Avg Day Vol
0.032 0.0336 N/A

JS200

[JS222]

DNAPRINT GENOMICS INC - OTC BB: DNAP

Consolidated Real-time Market Quote*
Last Change (%) After Hours Chg (%)** Bid Ask Trade Time
-- -- -- -- -- --

--------------------------------------------------------------------------------
Exchange QuoteLast Change (%) Bid (size) Ask (size) Trade Time
0.044 0.012 (37.50) 0.039 (50) 0.045 (50) 14:36
Day Volume Last Size Open High Low
2,905,400 10,000 0.034 0.045 0.031
Latest Ticks # of Trades Avg Trade Size 52 Wk High 52 Wk Low
-++- 119 24,415 0.0938 0.0156
Prev Close VWAP Avg Day Vol
0.032 0.0346 N/A


JS200

[JS222]

DNAPRINT GENOMICS INC - OTC BB: DNAP

Consolidated Real-time Market Quote*
Last Change (%) After Hours Chg (%)** Bid Ask Trade Time
-- -- -- -- -- --

--------------------------------------------------------------------------------
Exchange QuoteLast Change (%) Bid (size) Ask (size) Trade Time
0.045 0.013 (40.62) 0.04 (50) 0.045 (50) 14:38
Day Volume Last Size Open High Low
2,910,400 5,000 0.034 0.045 0.031
Latest Ticks # of Trades Avg Trade Size 52 Wk High 52 Wk Low
++-+ 120 24,253 0.0938 0.0156

[JS222]

DNAPRINT GENOMICS INC - OTC BB: DNAP

Consolidated Real-time Market Quote*
Last Change (%) After Hours Chg (%)** Bid Ask Trade Time
-- -- -- -- -- --

--------------------------------------------------------------------------------
Exchange QuoteLast Change (%) Bid (size) Ask (size) Trade Time
0.04 0.008 (25.00) 0.039 (50) 0.044 (50) 15:59
Day Volume Last Size Open High Low
3,580,200 59,000 0.034 0.045 0.031
Latest Ticks # of Trades Avg Trade Size 52 Wk High 52 Wk Low
-+-- 141 25,391 0.0938 0.0156
Prev Close VWAP Avg Day Vol
0.032 0.0359 N/A


JS200

[JS222]

Von Gestern

DNAP
DNAPRINT GENOMICS INC
0.040
+0.008 +25.00%


Daily Commentary
HOLD

Our system recommends HOLD as of today. Previous BUY recommendation was made on 10/23/2002 (6) days ago, when the stock price was 0.031. Since then the stock gained 29.03% .

Today the stock closed higher with a higher high and an unchanged low. The volume is extremely high. The security price is trending up.

Candlestick Analysis

Today’s Candlestick Patterns:
Long White Candlestick

Today a Long White Candlestick formed. Buyers were aggressive and buying pressure was strong. Be careful, this may lead to excessive bullishness!

Stock Quote
Last 0.040
Previous Close 0.032
Change +0.008
% Change +25.00%
Volume 3,580,200
Stock Activity
Open 0.034
Day`s High 0.045
Day`s Low 0.031
52 Week High 0.090
52 Week Low 0.018

Stock Price History
3 Month % Change 2.56
6 Month % Change -32.20
12 Month % Change -55.56
Stock Statistics
50 Day Close MA 0.028
200 Day Close MA 0.050
65 Day Volume MA 1,629,294

JS200

[JS222]

Von Gestern

DNAP
DNAPRINT GENOMICS INC
0.037
-0.003 -7.50%


Daily Commentary
HOLD

Our system recommends HOLD as of today. Previous BUY recommendation was made on 10/23/2002 (7) days ago, when the stock price was 0.031. Since then the stock gained 19.35% .

Today the stock closed lower with a lower high and a higher low (sign of decrease in volatility). The volume is normal. The security price is trending up.

Candlestick Analysis

Today’s Candlestick Patterns:
Black Candlestick

Today a Black Candlestick formed. Sellers were in control but the selling pressure was not very strong.

Stock Quote
Last 0.037
Previous Close 0.040
Change -0.003
% Change -7.50%
Volume 1,566,600
Stock Activity
Open 0.039
Day`s High 0.042
Day`s Low 0.034
52 Week High 0.080
52 Week Low 0.018

Stock Price History
3 Month % Change -2.63
6 Month % Change -37.29
12 Month % Change -53.75
Stock Statistics
50 Day Close MA 0.028
200 Day Close MA 0.050
65 Day Volume MA 1,637,128

JS200

[JS222]

Von Gestern

DNAP
DNAPRINT GENOMICS INC
0.034
-0.003 -8.11%


Daily Commentary
SELL

Our system recommends SELL as of today. Previous BUY recommendation was made on 10/23/2002 (8) days ago, when the stock price was 0.031. Since then the stock gained 9.68% .

Today the stock closed lower with a lower high and a lower low. The volume is normal. The security price is trending up.


Long-term trend is bullish, but the upward move seems to have stopped. Now, a short-term downtrend is starting. You may sell this stock now and wait for the next buy signal.

Candlestick Analysis

Today’s Candlestick Patterns:
Black Candlestick

Today a Black Candlestick formed. Sellers were in control but the selling pressure was not very strong.

Stock Quote
Last 0.034
Previous Close 0.037
Change -0.003
% Change -8.11%
Volume 1,444,800
Stock Activity
Open 0.036
Day`s High 0.036
Day`s Low 0.031
52 Week High 0.080
52 Week Low 0.018

Stock Price History
3 Month % Change -8.11
6 Month % Change -42.37
12 Month % Change -43.33
Stock Statistics
50 Day Close MA 0.028
200 Day Close MA 0.050
65 Day Volume MA 1,643,642

JS200

[js200]

Seh ich das richtig ????

DNAP mit einer Flaggenformation ????

Im BULLENTREND

JS200

[js200]

DNAPRINT GENOMICS INC - OTC BB: DNAP

Consolidated Real-time Market Quote*
Last Change (%) After Hours Chg (%)** Bid Ask Trade Time
-- -- -- -- -- --

--------------------------------------------------------------------------------
Exchange QuoteLast Change (%) Bid (size) Ask (size) Trade Time
0.034 0.001 (3.03) 0.032 (50) 0.034 (50) 14:15
Day Volume Last Size Open High Low
890,600 20,000 0.032 0.035 0.031
Latest Ticks # of Trades Avg Trade Size 52 Wk High 52 Wk Low
+-++ 48 18,554 N/A 0.0156
Prev Close VWAP Avg Day Vol
0.033 0.0327 N/A

JS200

[js200]

3:54pm ET
0.035
0.00 (6.06%)
Day`s Range: 0.031 - 0.035
Day`s Volume: 1,081,500
Avg. Volume: 1,561,058


JS200

[js200]

Von Gestern

DNAP
DNAPRINT GENOMICS INC
0.035
+0.002 +6.06%


Daily Commentary
WAIT

Our system recommends WAIT as of today. Previous SELL recommendation was made on 11/1/2002 (4) days ago, when the stock price was 0.035. Since then the stock gained 0.00% .

Today the stock closed higher, at its high (sign of strength) with a lower high and a lower low. The volume is low. The security price is trending sideways.

Click here to get a full trend analysis of this stock Candlestick Analysis

Today’s Candlestick Patterns:
Long White Candlestick

Today a Long White Candlestick formed. Buyers were aggressive and buying pressure was strong. Be careful, this may lead to excessive bullishness!

Stock Quote
Last 0.035
Previous Close 0.033
Change +0.002
% Change +6.06%
Volume 1,130,600
Stock Activity
Open 0.032
Day`s High 0.035
Day`s Low 0.031
52 Week High 0.080
52 Week Low 0.018

Stock Price History
3 Month % Change -12.50
6 Month % Change -39.66
12 Month % Change -41.67
Stock Statistics
50 Day Close MA 0.028
200 Day Close MA 0.050
65 Day Volume MA 1,642,182

JS200

[js200]

Von Gestern

DNAP
DNAPRINT GENOMICS INC
0.033
-0.002 -5.71%


Daily Commentary
WAIT

Our system recommends WAIT as of today. Previous SELL recommendation was made on 11/1/2002 (5) days ago, when the stock price was 0.035. Since then the stock fell -5.71% .

Today the stock closed lower with a higher high and a higher low. The volume is normal. The security price is trending sideways.

Candlestick Analysis

Today’s Candlestick Patterns:
Long Black Candlestick
Dark Cloud Cover Pattern

Today a Long Black Candlestick formed. Sellers were aggressive and selling pressure was strong. Be careful, this may be a potential turning point!

The last two candlesticks formed a Dark Cloud Cover Pattern. This is a bearish formation that marks a potential change in trend. However, a confirmation, in the form of a gap down or weak close following this pattern is needed.

Stock Quote
Last 0.033
Previous Close 0.035
Change -0.002
% Change -5.71%
Volume 1,496,000
Stock Activity
Open 0.037
Day`s High 0.037
Day`s Low 0.032
52 Week High 0.080
52 Week Low 0.018

Stock Price History
3 Month % Change -13.16
6 Month % Change -43.10
12 Month % Change -52.86
Stock Statistics
50 Day Close MA 0.028
200 Day Close MA 0.049
65 Day Volume MA 1,651,351

JS200

[cariocca]

Erbgut soll Phantombilder von Straftätern liefern
DNA-Analyse verrät Augen- und Haarfarbe
Birmingham - Nach einem grausigen Mord hat die Polizei nur eine einzige Spur: einen winzigen Spritzer Blut des Täters. Die Fahnder schicken die Probe zur DNA-Analyse und erhalten wenig später ein Phantombild des Verbrechers. Das klingt wie in einem Science-Fiction-Film, ist aber vielleicht in Zukunft möglich.

In Großbritannien ist der Forensische Wissenschaftsdienst (FSS) bereits dabei, ein so genanntes DNA-Photofit zu entwickeln - ein Phantombild des Täters auf der Basis seiner Gensequenz. Mit 96-prozentiger Sicherheit lässt sich bereits feststellen, ob der Täter rothaarig ist oder nicht. Dies ist relativ einfach, da die Wissenschaftler dazu nur ein einzelnes Gen betrachten müssen. Komplexer ist die Zuordnung der DNA zu einer bestimmten ethnischen Bevölkerungsgruppe. Diese kann bislang nur grob geschätzt werden durch den Vergleich von mehreren DNA-Sequenzen.

Die amerikanische Biotech-Firma "DNAPrint Genomics" bietet ein weiteres Puzzlestück für das Phantombild: Sie hat ein Nachweisverfahren entwickelt, mit dem sie die Augenfarbe anhand der DNA bestimmen kann - mit 99-prozentiger Sicherheit, wie sie auf ihren Internetseiten verkündet. An einem Test, der jede mögliche Haarfarbe auf Basis von DNA-Daten liefert, arbeitet das Unternehmen zurzeit. Auch andere äußere Merkmale könnte das Erbgut möglicherweise bald liefern, schätzen Wissenschaftler, etwa ob jemand ein Kinngrübchen hat oder ob die Ohrläppchen angewachsen sind.

In Deutschland verbietet die Strafprozessordnung Untersuchungen der DNA hinsichtlich des Aussehens eines Täters. Solange diese gesetzliche Grundlage besteht, sieht das Bundeskriminalamt (BKA) auch keine Veranlassung, auf diesem Gebiet zu forschen. "Wir werden uns auf dem Laufenden halten, wie es sich entwickelt," so ein Sprecher des BKA. "Unsere Wissenschaftler halten das Thema jedoch im Moment für mehr fiction als science." BSW


http://cgi.wn.com/?template=worldnews%2Fsearch.txt&action=se…

Roger

[wsperber]

Hallo cari,

Berichte über DNAP in deutsch hätte man sich vor einem Jahr kaum
träumen lassen, aber jetzt nach der "Zeit" auch in der "Welt" etwas
zu lesen, zeigt doch, dass es weitergeht.

Da du so gut wirbst für

http://www.chalberweid.ch/DNAPrint/dnaprint.html

klickt man ja ab und zu mal auf die Seite, was bestimmt auch
in deinem Interesse ist. Es fällt einem ja spontan immer was auf.
Ich würde ändern:

In der Zeile:

Just a few publications that reconize DNAPs potential:
ersetzten reconize -> recognize

und:

versuche ein anderes Bild von Dr. T zu finden. Ich finde es
nicht so vorteilhaft für unseren großen Hoffnungsträger.

Gruß

Wolfgang

Erwartet eigentlich jemand von den deutschen DNAPstern irgendwelche
deutliche Einnahmen im Quartalsbericht der Firma, der nächste Woche
Freitag rauskommen sollte?

[cariocca]

Danke, Wolfgang.

Die Seite ist angepasst. Leider habe ich nur noch ein Bild von Tony gefunden.



(aus der Chicago-Konferenz)

Roger

[js200]

Family Tree DNA to Market and Distribute ANCESTRYbyDNA
via COMTEX

November 7, 2002

SARASOTA, Fla., Nov 7, 2002 (BUSINESS WIRE) --

DNAPrint genomics, Inc. (DNAPrint or the `Company`)(OTCBBNAP) announced today that has signed an Agreement allowing Houston-based Genealogy by Genetics Ltd. (Family Tree DNA) to market and distribute its original ANCESTRYbyDNA 2.0 testing service.

Family Tree DNA will market ANCESTRYbyDNA 2.0 to its genealogy affiliates and to its large base of molecular genealogy customers, in part through its web site www.familytreedna.com. The Agreement, which is non-exclusive and open-ended, is expected to help DNAPrint accelerate the introduction of the test to the recreational genomics marketplace. Other specific terms of the agreement were not disclosed.

Family Tree DNA is recognized as the leading molecular genealogy testing company in the United States. Last year Family Tree DNA sold several thousands of Y-chromosome and mitochondrial tests to hobbyists throughout the US. DNAPrint has yet to advertise the testing service, but since introduction about a month ago the Company has already sold hundreds of tests. DNAPrint will continue to offer the testing service through its www.ancestrybydna.com website, and has recently acquired Phil Brooks as the Company`s first marketing director.

About ANCESTRYbyDNA.

ANCESTRYbyDNA is the world`s first recreational genomics test. Generally, the test provides a highly precise ancestral admixture analysis within individuals and in so doing provides an estimate of identity or affiliation with each of the world`s major continental populations. Specifically, the test measures an individual`s proportion of IndoEuropean, African, East Asian Pacific Islander and Native American ancestry. The testing service has been or will soon be featured in articles from the New York Times, Financial Times, the Sarasota-Bradenton Herald, US News and World Report and Popular Science Magazine. It has or will be featured on several different television and radio networks including WNYC, ABC, Fox, BBC, Germany`s ZDF and the Australian Broadcasting Corporation.

About Genealogy by Genetics Ltd.

Known to its customers as Family Tree DNA, Genealogy by Genetics Ltd. is a privately held company based in Houston, Texas. Family Tree DNA has pioneered the commercial use of DNA in the area of genealogy, helping connect branches of families when the paper trail was no longer available. Since its inception in 1999, Family Tree DNA has tested thousands of individuals and created a database of DNA markers that allow people to find common ancestry.

DNAPrint genomics, Inc.

DNAPrint genomics, Inc. is a personalized medicine company founded by a team of scientists with research and commercial experience in high-level mathematical modeling, programming and molecular genetics. The Company is traded on the NASDAQ OTC Bulletin Board under the ticker symbol: DNAP. For more information about the company, please visit http://www.dnaprint.com.

All statements in this press release that are not historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint`s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

DNAPrint genomics, Inc., Sarasota Carrie Castillo, 941/366-3400 [e-mail]

http://www.businesswire.com

Today`s News On The Net - Business Wire`s full file on the Internet with Hyperlinks to your home page.

Copyright (C) 2002 Business Wire. All rights reserved.

Print story

Current Quote

OBB: DNAP
Consumer Goods

Last: 0.031
Change: -0.002
Volume: 769,000
Day High: 0.034
Day Low: 0.031



First Alert News
Get real-time DNAP release alerts by entering your email address below.

JS200

[Neoe]

Ich sag nur "THE COMPANY HAS ALREADY SOLD HUNDREDS OF TESTS" und das ohne richtige Vermarktung. Ich glaub wir habens endlich geschafft.
Auf den Sendetermin im ZDF freue ich mich schon jetzt , da wird ein Kreuzchen im Kalender gemacht

[cariocca]

Ich glaube die Sendung lief schon...

Ein Tropfen Blut genügt

Wie Kriminalisten Phantombilder erstellen

Ganoven und Halunken aufgepasst: Verbrechen unerkannt zu begehen, wird von Tag zu Tag schwieriger. Immer raffinierter gestalten sich die Methoden der Polizei, Kriminalfällen auf den Grund zu gehen. Es reichen den Ermittlern wenige Tropfen Speichel, Samenflüssigkeit oder Blut, um äußere Erbgut-Merkmale herauszufinden.

31.10.2002







aspekte

Das Kulturmagazin im ZDF

nächste Sendung:
08.11.02 22:15 Uhr









Das Blut gibt Informationen über äußere Merkmale - z.B. über Haarfarbe oder Augenfarbe



Am besten gelingt der Polizei das Aufspüren rothaariger Menschen. Bereits vor einiger Zeit fanden britische Forscher heraus, dass die meisten Rothaarigen einen bestimmten Gendefekt tragen, der ihre Pigmentzellen schädigt. Mit 96-prozentiger Sicherheit kann man mit einer Erbgutanalyse feststellen, ob ein Täter rote Haare hat oder nicht.

Ermittlung der Haarfarbe
Doch diese Errungenschaft wird der Polizei nur in wenigen Fällen helfen. Denn der Täter kann bereits glatzköpfig oder ergraut sein oder sich auch einfach seine Haare gefärbt haben. Außerdem sind selbst unter den Briten nur sechs von hundert Menschen rothaarig. Blonde, braune oder schwarze Haare sind viel schwerer zu identifizieren. Die enorme Komplexität der Gene ist daran Schuld.


Augenfarbe und Geschlecht
Aber auch andere äußere Körpermerkmale können mit Hilfe von Erbgutanalysen bestimmt werden. So entdeckten amerikanische Forscher (mittlerweile weltweit führend auf diesem Gebiet), dass die Augenfarbe im Wesentlichen durch Variationen von vier Genen bestimmt wird. Dunkle Augen, helle Augen und solche mit hellbrauner Iris können bereits mit 97-prozentiger Sicherheit ermittelt werden. Genauso können sich im Erbgut Hinweise auf ein Kinngrübchen oder eine Glatze befinden. Mit einem Spritzer Blut können die Experten auch die Herkunft, das Geschlecht und teilweise die Form des Gesichts feststellen.




Mit 96-prozentiger Sicherheit kann man mit einer Erbgutanalyse feststellen, ob ein Mensch rote Haare hat oder nicht






"Alles liegt im Gesicht"
Hiermit sind die Forscher einem Geheimnis auf der Spur, das die Menschheit schon immer bewegte. Bereits vor über 2.000 Jahren philosophierten römische Gelehrte über die Beschaffenheit des menschlichen Gesichtes. Cicero beschrieb es so: "Alle Charaktereigenschaften eines Menschen erkennt man im Gesicht. Alles liegt im Gesicht." Für Sokrates ist das Gesicht die "letzte Wahrheit und Fata Morgana zugleich". Doch was macht das Gesicht so einzigartig? Warum gibt es auf der Welt kein Gesicht zweimal? Und wird man auf Grund eines Tropfen Blutes tatsächlich bald ein Gesicht rekonstruieren können? Oder gibt es zu viele Merkmale, die im Erbgut nicht festgeschrieben sind - Merkmale, die z.B. durch Umwelteinflüsse, durch persönliche Erlebnisse entstanden?


In Deutschland verboten
Wie dem auch sei, in Deutschland können die ersten Erfolge des so genannten DNA-Photofit sowieso nicht genutzt werden. Nach deutschem Gesetz dürfen - anders als in Amerika oder Großbritannien - nur der genetische Fingerabdruck, der keine Rückschlüsse auf Aussehen und andere Eigenschaften erlaubt, und das Geschlecht aus Erbgutproben vom Tatort bestimmt werden. Doch auch mit dieser Einschränkung konnten die Fahndungserfolge der deutschen Polizei sensationell verbessert werden.


Phantasien werden wahr
In elektronischen Spezialdateien können 6.000 Fingerabdrücke pro Sekunde abgeglichen werden, in der Abteilung Sprecheridentifizierung entwerfen Tonfrequenz-Spektografen Stimmprofile, Computer werden immer professioneller im Zeichnen von Phantombildern, die Ermittlungsmethoden immer raffinierter.


Verräterisches Haar
So konnte zum Beispiel zehn Jahre nach der Ermordung des Treuhand-Chefs Detlev Karsten Rohwedder nachgewiesen werden, dass sich Wolfgang Grams in der Nähe des Tatorts befand. Der Beweis: ein Haar. Die ganzen Jahre hatten die Beamten das Fundstück aus der Nähe des Tatorts aufbewahrt, bis die Herausfilterung des DNA-Musters aus dem Haar technisch möglich war. Und prompt konnte das verlorene Haar Wolfgang Grams zugeordnet werden.


Die Entwicklung des genetischen Fingerabdrucks ist also rasant, die kühnsten Träume diverser Thriller-Autoren scheinen wahr zu werden. Barbara Völkel hat sich für aspekte mit den neuesten Fahndungsmethoden der Polizei vor Ort in den USA in Florida (Sarasota) vertraut gemacht.


http://www.zdf.de/ZDFde/inhalt/0,1872,2021201,00.html

Roger

[js200]

11/07/2002 (15:21 ET) Family Tree DNA to Market and Distribute ANCESTRYbyDNA - Business Wire
10/29/2002 (10:30 ET) PR: DNAP Announces Development Site Agreement w/ NGEN - Knobias
10/29/2002 (10:15 ET) DNAPrint Enters Into Development Site Agreement With Nanogen to Develop DNA Chip Based Tests - Business Wire

JS200

[js200]

Von Gestern

DNAP
DNAPRINT GENOMICS INC
0.035
+0.002 +6.06%


Daily Commentary
WAIT

Our system recommends WAIT as of today. Previous SELL recommendation was made on 11/1/2002 (6) days ago, when the stock price was 0.035. Since then the stock gained 0.00% .

Today the stock closed higher, close to its high (sign of strength) with a lower high and a lower low. The volume is normal. The security price is trending sideways.

Candlestick Analysis

Today’s Candlestick Patterns:
Long White Candlestick

Today a Long White Candlestick formed. Buyers were aggressive and buying pressure was strong. Be careful, this may lead to excessive bullishness!

Stock Quote
Last 0.035
Previous Close 0.033
Change +0.002
% Change +6.06%
Volume 1,631,000
Stock Activity
Open 0.032
Day`s High 0.036
Day`s Low 0.031
52 Week High 0.080
52 Week Low 0.018

Stock Price History
3 Month % Change -12.50
6 Month % Change -35.78
12 Month % Change -50.00
Stock Statistics
50 Day Close MA 0.028
200 Day Close MA 0.049
65 Day Volume MA 1,666,448

JS200

[js200]

Von GESTERN

DNAP
DNAPRINT GENOMICS INC
0.037
+0.002 +5.71%


Daily Commentary
WAIT

Our system recommends WAIT as of today. Previous SELL recommendation was made on 11/1/2002 (7) days ago, when the stock price was 0.035. Since then the stock gained 5.71% .

Today the stock closed higher, at its high (sign of strength) with a higher high and a higher low. The volume is low. The security price is trending sideways.

Candlestick Analysis

Today’s Candlestick Patterns:
Hanging Man
Bearish Star

Today a Hanging Man formed. The bears drove the price down, but the bulls were able to mount a rally and the close was relatively strong. Be careful, this is a sign of potential weakness!

The last two candlesticks formed a Bearish Star. The buying pressure may be diminishing and the uptrend could be nearing an end. Even though the bulls are starting to lose control of the advance, further downside is required to confirm any reversal. Be on alert for a potential Evening Star!

Stock Quote
Last 0.037
Previous Close 0.035
Change +0.002
% Change +5.71%
Volume 1,172,100
Stock Activity
Open 0.036
Day`s High 0.037
Day`s Low 0.033
52 Week High 0.080
52 Week Low 0.018

Stock Price History
3 Month % Change -2.63
6 Month % Change -32.73
12 Month % Change -38.33
Stock Statistics
50 Day Close MA 0.028
200 Day Close MA 0.049
65 Day Volume MA 1,674,355

JS200

[cariocca]

Grüsse aus Zürich

http://www.chalberweid.ch/applet/snow.html


Roger
.

[wsperber]

Hallo Leute,

ich hab leider den Bericht, in dem DNAP in Aspekte
(Sendung im ZDF) am Wochenende nicht gesehen.
Im Raging-Bull-Board hat, der von mir wegen seiner
besonders kompetenten Postings (auch hier auf WO)
hoch geschätzte Gerd (SmpCpHunter), einen kleinen
Bericht darüber geschrieben, sowohl in englisch:

http://ragingbull.lycos.com/mboard/boards.cgi?board=DNAP&rea…

als auch in deutsch:

http://ragingbull.lycos.com/mboard/boards.cgi?board=DNAP&rea…

Ich weiß nicht, ob er dies auch hier schreiben will, da es
aber doch sehr interessant ist, habe ich die Links hier einfach
mal reingestellt.

Gruß

Wolfgang

[js200]

DNAPrint genomics to develop chip-based tests
Tampa Bay Business Journal, FL - 29 Oct 2002
DNAPrint genomics Inc. announced Tuesday that it would begin developing
DNA chip-based tests with San Diego-based Nanogen Inc. Under ...

Wires cross over genes
Financial Times (subscription), UK - 01 Nov 2002
... As chief executive of DNAPrint Genomics, which started selling kits in September,
Frudakis volunteered to submit a blood sample for an ancestral profile. ...



JS200

[morchel]

voll super geschrieben....

Ich bin echt beeindruckt!

In dieser kleinen Firma steckt enormes Potential!

überzeugter den je

und wenn ich noch 5 jahre Warten muß, meine DNAP geb ich nicht her!

morchel

[Morgagelchel]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[fonx]

@alle,Dnap würde mich auch reizen,schaue sie mir auch schon ziemlich lang an.Aber muss man nicht Sorge um einen Reservesplitt haben? Antwort? Würde mich freuen!!Fonx

[js200]

11/11/2002 (10:55 ET) Bully Bullies Covers POSO, GNNU, APMC, DNAP, RRUN - Knobias
11/11/2002 (10:36 ET) MOVER(-): DNAP Trading Lower - Knobias
11/07/2002 (15:21 ET) Family Tree DNA to Market and Distribute ANCESTRYbyDNA - Business Wire
10/29/2002 (10:30 ET) PR: DNAP Announces Development Site Agreement w/ NGEN - Knobias
10/29/2002 (10:15 ET) DNAPrint Enters Into Development Site Agreement With Nanogen to Develop DNA Chip Based Tests - Business Wire

JS200

[js200]

company news

--------------------------------------------------------------------------------

DNAP - DNAPrint Genomics Inc (OTCBB : DNAP)

--------------------------------------------------------------------------------
Bully Bullies Covers POSO, GNNU, APMC, DNAP, RRUN



MONDAY , NOVEMBER 11, 2002 10:55 AM

Prosoft Training.com (Nasdaq NM: POSO), Global Network Inc (OTCBB: GNNU), Applied Microsystems Corporation (Nasdaq NM: APMC), DNAPrint Genomics Inc (OTCBB: DNAP) and RRUN Ventures Network Inc (OTCBB: RRUN) are all on the Bully Bullies watch list.

POSO has a current price of $0.21000 per share.

GNNU has a current price of $0.75000 per share.

APMC has a current price of $0.19000 per share.

DNAP has a current price of $0.03300 per share.

RRUN has a current price of $0.02800 per share.

After going over their Disclosure/Disclaimer statement, Knobias was unable to determine whether or not Bully Bullies was compensated.

JS200

[js200]

Von Gestern

DNAP
DNAPRINT GENOMICS INC
0.033
+0.003 +10.00%


Daily Commentary
WAIT

Our system recommends WAIT as of today. Previous SELL recommendation was made on 11/1/2002 (12) days ago, when the stock price was 0.035. Since then the stock fell -5.71% .

Today the stock closed higher with an unchanged high and an unchanged low. The volume is normal. The security price is trending sideways.

Candlestick Analysis

Today’s Candlestick Patterns:
Spinning Top

Today a Spinning Top formed. Both the bulls and the bears were active during the session. Even though the session opened and closed with little change, prices moved significantly higher and lower in the mean time. Be careful, this indicates weakness among the bulls and a potential change or interruption in the current trend!

Stock Quote
Last 0.033
Previous Close 0.030
Change +0.003
% Change +10.00%
Volume 1,595,000
Stock Activity
Open 0.032
Day`s High 0.034
Day`s Low 0.029
52 Week High 0.080
52 Week Low 0.018

Stock Price History
3 Month % Change -13.16
6 Month % Change -41.07
12 Month % Change -45.00
Stock Statistics
50 Day Close MA 0.028
200 Day Close MA 0.049
65 Day Volume MA 1,709,335

JS200

[Neoe]

Q3-Zahlen , leider hat GMED wieder nicht viel abgedrückt und ANCESTRY ist ja erst dieses Quartal angelaufen , also nicht viel tolles zu sehen , dieses Quartal werden aber noch
vier neue Wissenschaftler eingestellt:


State the number of shares outstanding of each of the issuer`s classes of common
equity, as of October 3, 2002

451,366,213


Transitional Small Business Disclosure Format:

YES ( ) NO (X)



1






DNAPrint genomics, Inc.
(A Development Stage Enterprise)

INDEX TO FORM 10-QSB


PART I. FINANCIAL INFORMATION

Item 1. Consolidated Financial Statements (unaudited):

Consolidated Balance Sheets as of September 30, 2002
and December 31, 2001................................................. 4

Consolidated Statements of Operations for the three and
nine months ended September 30, 2002 and 2001, and the
period December 10, 1998 (date of inception) to September 30,
2002.................................................................. 5

Consolidated Statements of Cash Flows for the nine months
ended September 30, 2002 and 2001, and the period December 10, 1998
(date of inception) to September 30, 2002............................. 6

Notes to Consolidated Financial Statements............................ 8



Item 2. Management`s Discussion and Analysis of Financial Condition and
Results of Operations................................................ 12

Item 3. Controls and Procedures.............................................. 14



PART II. OTHER INFORMATION

Item 1. Legal Proceedings.................................................... 14
Item 2. Changes in Securities................................................ 14
Item 3. Defaults Upon Senior Securities...................................... 14
Item 4. Submission of Matters to a Vote of Securities Holders................ 14
Item 5. Other Information.................................................... 15
Item 6. Exhibits and Reports on Form 8-K..................................... 15

Signatures 15




2







PART I

FORWARD-LOOKING STATEMENTS

Certain statements contained in this filing are "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995, such as statements relating to financial results and plans for future
business development activities, and are thus prospective. These statements
appear in a number of places in this Form 10-QSB and include all statements that
are not statements of historical fact regarding intent, belief or our current
expectations, with respect to, among other things: (i) our financing plans; (ii)
trends affecting our financial condition or results of operations; (iii) our
growth strategy and operating strategy; and (iv) the declaration and payment of
dividends. The words "may," "would," "could," "will," "expect," "estimate,"
"anticipate," "believe," "intend," "plans," and similar expressions and
variations thereof are intended to identify forward-looking statements.

Investors are cautioned that any such forward-looking statements are not
guarantees of future performance and involve risks and uncertainties, many of
which are beyond our ability to control. Actual results may differ materially
from those projected in the forward-looking statements as a result of various
factors. Among the key risks, assumptions and factors that may affect operating
results, performance and financial condition are changes in technology,
fluctuations in our quarterly results, ability to continue and manage our
growth, liquidity and other capital resources issues, competition and the other
factors discussed in detail in our filings with the Securities and Exchange
Commission.





3





DNAPrint genomics, Inc.
(A Developmental Stage Enterprise)

CONSOLIDATED BALANCE SHEETS

_________________________________________________________________________________________



September 30,
2002 December 31,
(Unaudited) 2001
ASSETS

CURRENT ASSETS:
Cash and cash equivalents $ 131 $ 42,992
Receivables:
Accounts (net of allowance for doubtful accounts
of $2,250) 14,302 -
Subscriptions 25,000 -
Due from affiliate - 50,815
Prepaid expenses 19,647 23,577
Total current assets 59,080 117,384

PROPERTY AND EQUIPMENT (net of accumulated
depreciation and amortization of $306,380 and
$178,769, respectively) 678,695 814,852

OTHER ASSETS 5,000 5,000

TOTAL $ 742,775 $ 937,236
============= ==============

LIABILITIES AND STOCKHOLDERS` (DEFICIT) EQUITY

CURRENT LIABILITIES:
Accounts payable and other liabilities $ 608,110 $ 186,503
Accrued payroll and payroll taxes 104,884 54,775
Note payable to related party 292,737 -
Current portion of capital lease obligation 121,644 110,870
Total current liabilities 1,127,375 352,148

CAPITAL LEASE OBLIGATIONS, net of current portion - 100,541
Total liabilities 1,127,375 452,689

STOCKHOLDERS` (DEFICIT) EQUITY:
Preferred stock, $.01 par value, 10,000,000 shares
authorized; -0- shares issued and outstanding - -
Common stock, $.01 par value, 500,000,000 shares
authorized; 451,366,213 and 429,287,374 shares
issued and outstanding, respectively 4,513,662 4,292,874
Additional paid-in capital 11,083,062 9,877,369
Deferred stock compensation (503,550) (534,020)
Deficit incurred prior to development stage (7,427,422) (7,427,422)
Deficit accumulated during the development stage (8,050,352) (5,724,254)
Total stockholders` (deficit) equity (384,600) 484,547

TOTAL $ 742,775 $ 937,236
============= ==============

_________________________________________________________________________________________


See notes to consolidated financial statements.



4



DNAPrint genomics, Inc.
(A Development Stage Enterprise)

CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
____________________________________________________________________________________________________________________________



For the For the For the For the
Nine- For the Three- Three- Period
Months Nine- Months Months Months December 10,
Ended Ended Ended Ended 1998
September September September September to September
30, 2002 30, 2001 30, 2002 30, 2001 30, 2002

REVENUES $ 132,201 $ 12,370 $ 17,042 $ 320 $ 218,588

COST OF REVENUES 70,067 - 9,065 - 169,738

Gross Profit 62,134 12,370 7,977 320 48,850

OTHER OPERATING EXPENSES:
Research and development 1,726,945 1,149,284 557,046 575,338 3,961,793
General and administrative 215,071 308,421 32,826 45,896 1,676,566
Total operating expenses 1,942,016 1,457,705 589,872 621,234 5,638,359

LOSS FROM OPERATIONS (1,879,882) (1,445,335) (581,895) (620,914) (5,589,509)

OTHER INCOME (EXPENSE):
Other income - 248 31 248 353,121
Other expense (12,849) (6,294) (5,039) (6,266) (361,855)
Interest expense (433,366) - (12,207) - (463,880)

Total other income (expense) - net (446,215) (6,046) (17,215) (6,018) (472,614)


NET LOSS $(2,326,097) $(1,451,381) $ (599,110) $ (626,932) $(6,062,123)
============ ============ ============ ============ ============

NET LOSS PER SHARE - Basic and Diluted $ (0.01) $ (0.00) $ (0.00) $ (0.00)
============ ============ ============ ============

SHARES USED IN COMPUTING NET LOSS
PER SHARE - Basic and Diluted 439,707,600 393,035,200 449,927,300 404,282,900
============ ============ ============ ============

____________________________________________________________________________________________________________________________

See notes to consolidated financial statements.


5



DNAPrint genomics, Inc.
(A Development Stage Enterprise)

CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

_______________________________________________________________________________________________________________________




For the For the Nine- For the Period
Nine- Months Months December 10,
Ended Ended 1998
September September to September
30, 200230, 200130, 2002

CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss $(2,326,097) $(1,451,381) $(6,062,123)
Adjustments to reconcile net loss to net cash
used in operating activities:
Depreciation and amortization 137,472 111,721 321,603
Loss on disposal of investments - - 11,772
Loss on disposal of property and equipment 5,039 - 5,039
Provision for bad debts 2,250 - 2,250
Amortization of deferred stock compensation 202,270 - 421,800
Common stock issued for interest expense on related
party notes payable 407,323 - 407,323
Common stock issued for reorganization/court order - - 343,000
Common stock issued for services 8,000 163,040 589,415
Common stock issued for bankruptcy settlement - - 28,080
Changes in operating assets and liabilities:
(Increase) decrease in accounts receivable (16,552) 500 309,139
Decrease (increase) in prepaid expenses other
assets 3,930 (5,000) (24,647)
Increase in accounts payable and other current
liabilities 471,714 273,660 845,751
NET CASH USED IN OPERATING ACTIVITIES (1,104,651) (907,460) (2,801,598)

CASH FLOWS FROM INVESTING ACTIVITIES:
Decrease in investments - 5,997 -
Purchases of property and equipment (16,454) (189,927) (761,364)
Proceeds from disposal of property and equipment 10,100 - 10,100
Net bankruptcy adjustment - - 511,274
NET CASH USED IN INVESTING ACTIVITIES (6,354) (183,930) (239,990)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock 271,000 801,693 1,461,950
Collections from stock subscriptions - 297,460 836,960
Proceeds from settlement with Tampa Bay Financial 34,200 - 34,200
Advances from Tampa Bay Financial, net 50,815 26,545 384,581
Principal payments on capital lease obligation (89,766) (27,718) (127,067)
Proceeds from notes payable related party 801,895 - 801,895
Repayments of notes payable - - (350,800)
NET CASH PROVIDED BY FINANCING ACTIVITIES 1,068,144 1,097,980 3,041,719

NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS (42,861) 6,590 131

CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD 42,992 16,724 -

CASH AND CASH EQUIVALENTS, END OF PERIOD $ 131 $ 23,314 $ 131
============ ============ ============

_______________________________________________________________________________________________________________________


(continued on page 7)

6




DNAPrint genomics, Inc.
(A Development Stage Enterprise)

CONSOLIDATED STATEMENTS OF CASH FLOWS (continued)
(Unaudited)

_______________________________________________________________________________________________________________________



For the For the Nine- For the Period
Nine- Months Months December 10,
Ended Ended 1998
September September to September
30, 200230, 200130, 2002

SUPPLEMENTAL DISCLOSURE OF CASH FLOW
INFORMATION:

Income taxes paid $ - $ - $ -
============ ============ ============

Interest paid $ 22,782 $ - $ 53,265
============ ============ ============

SUPPLEMENTAL DISCLOSURE OF NON-CASH
INVESTING AND FINANCING ACTIVITIES:

Stock subscriptions receivable arising from acquisition
of DNAPrint genomics, Inc. (Florida) $ - $ - $ 1,000,000

Stock subscription receivable $ 25,000 $ - $ 25,000

Unrealized gain (loss) on long-term investments $ - $ (30,920) $ (222,443)

Common stock issued for land subsequently swapped for
investment in Heroes, Inc. $ - $ - $ 2,000,000

Common stock issued for related party notes payable $ 509,158 $ - $ 509,158

Dividends paid in stock of Heroes, Inc. $ - $ - $(1,988,228)

Common stock arising from reorganization/court order
arising from conversion of claim to stock $ - $ - $(2,905,500)

Conversion of Tampa Bay Financial advance to stock $ - $ 249,470 $ 453,331

Equipment leased under capital lease $ - $ 234,634 $ 248,712

Deferred compensation on grants of stock options $ 171,800 $ - $ 925,350

_______________________________________________________________________________________________________________________

See notes to consolidated financial statements


7




DNAPrint genomics, Inc.
(A Development Stage Enterprise)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

________________________________________________________________________________

NOTE A - ORGANIZATION AND DESCRIPTION OF BUSINESS

DNAPrint genomics, Inc., which was organized for the purpose of investing in all
forms of investments ("DNAP Utah") was initially incorporated under the laws of
the State of Utah on January 3, 1983 as Lexington Energy, Inc, and subsequently
changed its focus to human genome sciences. In connection with this change in
focus, on July 15, 2000, DNAP Utah acquired DNAPrint genomics, Inc. a Florida
corporation ("DNAP Florida") through the issuance of 192,000,000 shares of its
common stock. DNAP Florida specializes in the construction of electronic
facilities to assist scientists in researching and assembling data from the
human genome and other advances in genetics research. As a result of this
acquisition, the accompanying consolidated financial statements include the
accounts of DNAP Utah and its wholly owned subsidiary, DNAP Florida
(collectively referred to as "we", "us", "our"). All significant intercompany
accounts and balances have been eliminated in consolidation.

Because we have not yet generated significant revenues and/or commenced our
planned principal operations we are considered to be in the development stage as
defined in Financial Accounting Standards Board Statement No. 7. Accordingly,
some of our accounting policies and procedures have not yet been established.

Use of Estimates

The preparation of financial statements in conformity with accounting principles
generally accepted in the United States of America requires us to make certain
estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of
the financial statements. The reported amounts of revenues and expenses during
the reporting period may be affected by the estimates and assumptions we are
required to make. Actual results could differ from our estimates.

Basis of Presentation

Our accompanying unaudited consolidated financial statements have been prepared
in accordance with accounting principles generally accepted in the United States
of America for interim financial information and the instructions to Form 10-QSB
and Rule 10-1 of Regulation S-X of the Securities and Exchange Commission (the
"SEC"). Accordingly, these consolidated financial statements do not include all
of the footnotes required by accounting principles generally accepted in the
United States of America. In our opinion, all adjustments (consisting of normal
and recurring adjustments) considered necessary for a fair presentation have
been included. Operating results for the three and nine months ended September
30, 2002 are not necessarily indicative of the results that may be expected for
the year ended December 31, 2002. The accompanying consolidated financial
statements and the notes thereto should be read in conjunction with our audited
consolidated financial statements as of and for the year ended December 31, 2001
contained in our Form 10-KSB.


8



NOTE B - GOING CONCERN

Our consolidated financial statements are prepared using accounting principles
generally accepted in the United States of America applicable to a going
concern, which contemplates the realization of assets and liquidation of
liabilities in the normal course of business. We have incurred losses since our
inception, and have experienced and continue to experience negative cash flows
from operations. Because of this, we have working capital and stockholders`
deficiencies of approximately $1,068,300 and $384,600 at September 30, 2002.
In addition, we continue to have ongoing requirements for substantial additional
capital investment to accomplish our business plan over the next several years.
Over the past two years, our operations have been funded through private equity.
We expect to seek additional funding through private or public equity, as well
as continuing to pursue various licensing agreements. As discussed at Note E, in
connection with this matter, two of our shareholders have agreed to lend us up
to $1,000,000 in 2003 to assist with our cash flow needs. In addition, we have
recently completed laboratory facilities to run scientific tests that we believe
will begin to generate operating revenues. However, there can be no assurance as
to the ultimate success of our products and/or that we will have the cash flow
to meet our operating requirements. These factors, among others, indicate that
we may be unable to continue as a going concern for a reasonable period of time.

Our financial statements do not include any adjustments relating to the
recoverability and classification of recorded asset amounts or the amounts and
classification of liabilities that might be necessary should we be unable to
continue as a going concern.

NOTE C - EQUITY TRANSACTIONS

Common Stock

During the first nine months of 2002, we had the following common stock
issuances:

o 6,444,443 shares for $296,000
o 944,978 shares from the exercise of employee stock options
o 142,063 shares issued for consulting services
o 14,547,355 shares issued for the settlement of related party notes payable
(see Note E)

In June 2001, Tampa Bay Financial, Inc., a related party ("TBFI"), agreed to
purchase up to a maximum of 40,000,000 shares of our common stock (restricted)
during the period July 2001 - July 2002. This agreement was terminated in 2002,
at which time TBFI was relieved of its obligation to make advances to us under
this agreement, and simultaneously received the option to purchase the stock it
would have otherwise obtained under this agreement for a price of $.05 per
share. This option expires in February 2005. In accordance with the terms of
this agreement, we have placed 19,549,680 shares of our common stock in escrow
(which shares represent the maximum number of shares TBFI may purchase under
this option).

In February 2002, we entered into an agreement with one of our directors. As
consideration for agreeing to serve on our Board of Directors, we granted him
options to purchase 2,600,000 shares of our common stock at an exercise price of
$0.03 per share. The options vest ratably over a period of four years from the
date of the contract.

In February 2002, we entered into a Consulting Agreement and a Stock Purchase
Option with one of our directors. Under this agreement, the director has agreed
to provide us substantial management, business development and strategic
planning advice through at least May 31, 2003.




9



The parties may extend the agreement by mutual consent. As consideration for
such services, we have agreed to issue up to 28,000,000 shares of our stock to
this director at an exercise price of $0.01 per share. 1,680,000 of these shares
are earned by this director by providing services as required by the Consulting
Agreement, but without the achievement of any particular performance milestones.
The remaining options are earned by assisting us to achieve defined milestones,
such as the sale or license of one of our products to a purchaser introduced to
us by this director. In addition, the issuance of the stock underlying such
options will require the approval of our shareholders of an increase in our
authorized capitalization. While we may elect to do so in the future, the
Consulting Agreement acknowledges that we are under no obligation to propose
such an increase. To the extent that any of the options become vested, they are
exercisable until February 23, 2012.

During May 2002, we entered into an agreement with a company in which one of our
directors is an owner, to provide us with consulting services through December
31, 2005. We estimate these consulting services will have a value of
approximately $110,000. As consideration for these services, we have agreed to
pay $15,000 and issue approximately 2,800,000 options to purchase our common
stock at a price of $0.001 per share. In addition, if this company is successful
in helping us raise capital, we have agreed to compensate them by issuing
additional options to allow them to purchase shares of our common stock at a
price of $0.001 per share. The number of options issued will be based on the
amount of capital raised, as defined in the agreement.

During June 2002, we entered into a five-year agreement with an individual to
serve as a member of our Scientific Advisory Board (See Note E). We will
compensate this individual annually, with 50,000 shares of our common stock.

NOTE D - OTHER COMMITMENTS

We rent our operating facility from Pacific Atlantic Corporation, a related
entity controlled by one of our shareholders under a ten-year operating lease
agreement expiring in October 2010, requiring monthly rent of approximately
$5,300 (plus related taxes and adjusted for annual increases in the Consumer
Price Index). During the nine months ending September 30, 2002 and 2001, rent
expense was approximately $48,000 and $47,400, respectively. In addition, the
lease requires us to pay utilities and various other occupancy related expenses.

NOTE E - OTHER RELATED PARTY TRANSACTIONS

Funding Agreement

In February 2002, we entered into a funding agreement with 4 shareholders, one
of whom is our CEO. These shareholders initially agreed to loan us $2,000,000
between March 2002 and December 2002. These loans were to be repaid along with
all accrued interest at 8% on January 31, 2003. In spite of this provision, in
June 2002, we elected to satisfy $509,160 of these notes through the issuance of
14,547,355 shares of our common stock.

During October 2002 the terms of this agreement were modified, effectively
terminating the participation of two of the shareholders. Pursuant to the
amended agreement, the remaining two shareholders (one of whom is our CEO), have
agreed to loan us $1,000,000 between December 2002 and December 2003. These
loans are scheduled to mature, along with all accrued interest at 8%, on
December 31, 2003. In the event of our default, the lenders` only remedy is to
require us to issue shares of our stock as consideration for satisfaction of the
debt. The number of shares to be issued for satisfaction of the debt will be
based on a price of $.035 per share if the weighted average price of our stock
is $.05 per share or above; alternatively if the weighted average price or our
shares is less than $.05, the number of shares due will be calculated using a
40% discount to the market price. Notwithstanding this, in no event will the


10


shares to be issued under this arrangement be based on a price of less than $.01
per share. At September 30, 2002, our notes payable to these shareholders
approximated $292,700. From the period October 1, 2002 - November 1, 2002, we
borrowed approximately $321,000 in additional funds under this arrangement.

In the event that we are unable to secure at least $1,000,000 in funding under
this arrangement, TBFI has agreed to purchase an additional $1,000,000 of our
common stock at the lesser of $.05 per share, or one half of the market price of
our common shares as of the date of funding. At this time, we do not foresee
having to invoke this provision.

Consulting Agreement

During June 2002, we entered into an agreement with a member of our Scientific
Advisory Board, to collaborate with us to develop a kit product that could be
used to infer Ancestry Admixture Ratios in human beings. We have agreed to l
compensate the consultant with quarterly payments of $4,000 and 50,000 shares of
our common stock for the term of this contract. We have also agreed to provide
the consultant with a number of shares of our common stock equal to 2.5% of the
Net Revenues derived from a product developed with his help. The term of this
agreement is two years, and the parties may agree to renew it for consecutive
two-year terms.



11


ITEM 2.

MANAGEMENT`S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis should be read in conjunction with the
balance sheet as of September 30, 2002 and the financial statements as of and
for the nine months ended September 30, 2002 and 2001 included with this Form
10-QSB.

Critical Accounting Policies and Results of Operations

Our critical accounting policies, including the assumptions and judgments
underlying them, are disclosed in the notes to the financial statements, which
are contained in our December 31, 2001 form 10-KSB. We have consistently applied
these policies in all material respects. Although we have been in existence for
a number of years, our efforts to develop our business have not yet resulted in
generation of significant revenues. To date, our efforts have focused on
developing licensing relationships and promoting and conducting research and
development to demonstrate the feasibility and efficacy of our products. Until
potential customers are convinced of the viability of our technology, it is
unlikely that we will generate significant revenue. The following discussion of
our historical financial results should be read against that background. In
light of this, the small amount of revenue that we have earned at this stage
minimizes the impact of any judgments regarding revenue recognition. We do not
believe that our operations to date have involved uncertainty of accounting
treatment, subjective judgment, or estimates, to any significant degree.

Three months ended September 30, 2002 vs. three months ended September 30, 2001

For the three months ended September 30, 2002 and 2001, revenues were
approximately $17,000 and $300, respectively. This increase was a result of our
decision to supplement our cash flow by using our facilities to provide certain
commercial genotyping and contract sequencing services to select customers. This
also increased due to the recent marketing of our ancestry test product to the
general public, which began Sept. 19, 2002, 11 days prior to the end of the
quarter. For the same period, cost of sales increased from approximately $0 in
2001 to $9,100 in 2002. Because of the small sales volume and its dependence on
the type of testing conducted in a particular period, these results are not
indicative of the margins that we expect to attain if our long-term goals are
achieved.

For the three months ended September 30, 2002 and 2001, the largest component of
our operating expenses was research and development, which consists
substantially of laboratory supplies, equipment rental, facilities and personnel
related costs. During the three months ended September 30, 2002 and 2001, these
costs remained relatively constant - from approximately $575,300 in 2001 to
$557,000 in 2002.

The other component of our operating expenses is general and administrative
expenses. For the three months ended September 30,2002 and 2001, these expenses
were approximately $32,900 and $45,900, respectively. These expenses result from
(i) accounting and other fees associated with the completion of our quarterly
filings and other regulatory compliance activities, (ii) legal fees associated
with our patents, immigration activities and preparation of our securities law
filings and (iii) administrative and other salaries and expenses. The decrease
is primarily due to our adoption of a more streamlined administrative structure.

For the three months ended September 30, 2002 and 2001, interest expense
increased from approximately $0 in 2001, to $12,200 in 2002. This increase
arises from interest paid and/or accrued on capital leases and related party
notes which were not in existence during the quarter ended September 30, 2001.



12



Nine months ended September 30, 2002 vs. Nine months ended September 30, 2001

For the nine months ended September 30, 2002 and 2001, revenues were
approximately $132,200 and $12,400, respectively. This increase was a result of
our decision to supplement our cash flow by using our facilities to provide
certain commercial genotyping and contract sequencing services to select
customers, as well as the recent marketing of our ancestry test product to the
general public. For the same period, cost of sales increased from approximately
$0 in 2001 to $70,100 in 2002. Because of the small sales volume and its
dependence on the type of testing conducted in a particular period, these
results are not indicative of the margins that we expect to attain if our
long-term goals are achieved.

In 2002, the largest component of our operating expenses was research and
development, which consists substantially of laboratory supplies, equipment
rental, facilities and personnel related costs. For the nine months ended
September 30, 2002, these costs increased from approximately $1,149,300 in 2001
to $1,727,000 in 2002, an increase of $577,800, or 50 %. The substantial
increase in research and development results from the initiation of new research
projects.

The other component of our operating expenses are general and administrative
expenses. For the nine months ended September 30,2002 and 2001, these expenses
decreased from approximately $308,400 in 2001 to $215,100, in 2002. These
expenses result from (i) accounting and other fees associated with completion of
our audited financial statements, quarterly filings and other regulatory
compliance activities, (ii) legal fees associated with our patents, immigration
activities and preparation of our securities law filings, and (iii)
administrative and other salaries and expenses. The decrease is primarily due to
our adoption of a more streamlined administrative structure.

For the nine months ended September 30, 2002 and 2001, interest expense
increased from $0 in 2001 to approximately $433,400 in 2002. This increase is
primarily due to the issuance of our common stock for the settlement of related
party notes payable, at an agreed upon per share price which was less than the
market price of our stock. We accounted for the difference between the stock
issue price and the market price, as interest expense.

Future Periods

We expect that personnel costs will increase substantially in future years as we
expand our research efforts. We also expect most of our other operating expenses
to grow with time and expansion. We will also increase consumable expenses due
to a ramp-up in our data production capabilities. We believe that the level of
professional fees we pay will remain stable through 2002. We will also require
testing to establish the efficacy of our products as current research and
development matures and as our products are exposed to the marketplace through
our own efforts and those of our licensees. We expect to see the results of
these efforts beginning in 2003.

Liquidity

Our operating requirements generated a negative cash flow from operations as we
continue to engage in testing and development of our products. Our cash used by
operating activities for the nine months ended September 30, 2002 was
approximately $1,104,700. The resulting cash shortfall was financed primarily
through related party funding and sales of common stock.

Based upon our current plans, we anticipate that we will need to seek additional
financing. We are pursuing entering into license agreements with entities for
the distribution of our products. Pursuit of licensing relationships is in its
early stages, however, and it is difficult to predict what revenue stream, if
any, they will generate.

We do not expect our revenue stream to be sufficient to cover costs of
operations in the immediate future. We expect that we will continue to be
required to raise capital to fund operations at least through the remainder of
2002 and some part of 2003. We anticipate that we will be able to borrow the
necessary funds we need under a funding arrangement we have entered into with
two of our shareholders. However, we may still need to engage in one or more



13



private placements of common stock to fund our operating needs. We have engaged
in discussions with several parties who have expressed interest in assisting us
in such a private offering, and we are confident t that private equity financing
will be available to fund us until revenues from operations are sufficient to
fund operations.

Capital Expenditures

At this time, we do not anticipate a need to make significant capital expenditures
in the next twelve months.

Staffing

We plan to increase our work force. Currently, we have fourteen full-time
employees. We plan to add three research scientists to continue developing our
products. Upon development of the products, our marketing plan does not call for
building a sales force to sell to end-users. Rather, we intend to license the
technology to market segment leaders with existing sales forces. We will train
our partners` sales forces to sell our products and to provide technical
assistance. We also intend to add personnel in the accounting, administrative
and investor relations areas. Management expects to add at least four more
employees during 2002. We expect the cost of these additional employees to be in
excess of $200,000 in 2002.

ITEM 3.

Controls and Procedures

Within 90 days prior to the filing of this report, we carried out an evaluation,
under the supervision and with the participation of our management, including
the Chief Executive Officer (who also effectively serves as our Principal
Financial Officer), of the design and operation of our disclosure controls and
procedures. Based on this evaluation, or Chief Executive Officer concluded that
our disclosure controls and procedures are effective for the gathering,
analyzing and disclosing the information we are required to disclose in the
reports we file under the Securities Exchange Act of 1934, within the time
periods specified I the SEC`s rules and forms. There have been no significant
changes in our internal controls or in other factors that could significantly
affect internal controls subsequent to the date of this evaluation.

PART II



Item 1.Legal Proceedings.

NONE



Item 2. Changes in Securities.

Sales of Unregistered Securities

In the third quarter of 2002, we issued (1) 1,388,888 shares of our
common stock for $25,000 and (2) 50,000 shares of our common stock in
exchange for consulting services valued at $2,000. These shares
were consummated with two "sophisticated investors" in transactions
that we believe were exempt from registration under Rule 506
promulgated under the Securities Act of 1933. The offerings were not
underwritten.



Item 3.Defaults upon Senior Securities.

NONE



Item 4.Submission of Matters to a Vote of Security Holders.

NONE




14






Item 5.Other Information.

NONE



Item 6.Exhibits and Reports on Form 8-K.

(a) Exhibits

10.29 Funding Agreement between Tony Frudakis, George Frudakis and the Company


99.1 Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002


(b) Reports on Form 8-K.

NONE


SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

DNAPrint genomics, Inc.


By:/s/ Tony Frudakis, CEO
Tony Frudakis, CEO, Principal Financial
Officer
Date: November 14, 2002

CERTIFICATION

I, Tony Frudakis, certify that:

1. I have reviewed this quarterly report on Form 10-QSB of DNAPrint genomics, Inc.

2. Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;

3. Based on my knowledge, the consolidated financial statements, and other
financial information included in this quarterly report, fairly present in all
material respects the consolidated financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this
quarterly report.

4. I am responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the issuer
and have:

(i) Designed such disclosure controls and procedures to ensure that
material information relating to the issuer is made known to me,
particularly during the period in which the periodic reports are
being prepared;

(ii) Evaluated the effectiveness of the issuer`s disclosure controls
and procedures as of September 30, 2002; and



15



(iii)Presented in the report my conclusions about the effectiveness
of the disclosure controls and procedures based on my evaluation
as of the Evaluation Date;

5. I have disclosed, based on my most recent evaluation, to the issuer`s
auditors and the audit committee of the board of directors (or persons
fulfilling the equivalent function):

a. All significant deficiencies in the design or operation of
internal controls which could adversely affect the issuer`s
ability to record, process, summarize and report financial data
and have identified for the issuer`s auditors any material
weaknesses in internal controls; and

b. Any fraud, whether or not material, that involves management or
other employees who have a significant role in the issuer`s
internal controls; and

6. I have indicated in the report whether or not there were significant changes
in internal controls or in other factors that could significantly affect
internal controls subsequent to the date of our most recent evaluation,
including any corrective actions with regard to significant deficiencies and
material weaknesses.


Date: November 14, 2002

/S/Tony Frudakis
Tony Frudakis
Chief Executive Officer and Principal Financial Officer





16





--------------------------------------------------------------------------------


FUNDING AGREEMENT


THIS FUNDING AGREEMENT made this 25th day of October, 2002 by and among
DNAPRINT GENOMICS, INC., a corporation organized under the laws of the state of
Utah (the "Company"),TONY FRUDAKIS, a citizen of the state of Florida ("T.
Frudakis"),GEORGE FRUDAKIS, a citizen of the state of Florida ("G. Frudakis"),
(collectively with T. Frudakis, G. Frudakis or each individually an "Investor").

RECITALS

WHEREAS, the Company desires to complete its procurement of funding at a
level of Two Million Dollars ($2,000,000) which commenced March 1, 2002 (the
"Term") pursuant to a Funding Agreement dated February 25, 2002, and extended
for a ten (10) month period; and,

WHEREAS, the Investors desire to modify the terms of the previous funding
agreement.

NOW THEREFORE, the parties hereby revise the previous funding agreement to
read as follows:

1.Funding. Beginning August 29, 2002, each Investor agrees to provide a
loan of not less than Five Hundred Thousand Dollars ($500,000) to the Company in
equal quarterly installments of $125,000, each on Dec 31, 2002, April 30, 2003,
August 30, 2003 and Dec 31, 2003 (each a "Funding Date").

2.Consideration. In consideration for the payments set forth above, and on
December 30, 2003, the Company shall repay the principal together with simple
interest at a rate of 8% per annum. If for any reason the Company shall fail to
repay the loan at maturity, the sole remedy of the Investors shall be the
issuance by the Company of shares of its restricted common stock. The number of
shares to be issued will be calculated using the then-current principal balance,
together with accrued but unpaid interest, and a share price based on the
trailing 30 trading-day volume weighted average price ("VWAP") at the time each
funding installment is made, such that if the VWAP is $0.05 per share or above,
the number of shares due will be calculated using a $0.035 per share rate, and
if the VWAP is below $0.05 per share, the number of shares due will be
calculated using a 40% discount to the VWAP, however, under this agreement under
no circumstances will shares be issued to Investors for less than $.01 per
share.

3.Joint and Several Liability. The liability of the Investors to the
Company to make the required payments shall be joint and several. Thus, if in
any quarter during the Term one or more of the Investors defaults in his
obligation to make his required payment, the remaining non-defaulting Investors,
within five (5) business days of receipt of written notice from the Company of
such default, shall each pay to the Company his pro rata share of the payment
amounts in default.



1


4.Indemnification. Each Investor who defaults in his obligations hereunder
agrees to protect, indemnify and hold each of the other Investors harmless from
and against all damages, losses, claims, cost, expenses or actions arising from
said Investor`s default.

5.Miscellaneous.

a.Notices. All notices and other communications given or made
pursuant hereto shall be in writing and shall be deemed to have been duly
given or made as of the date delivered, mailed or transmitted, and shall be
effective upon actual receipt, if delivered personally or by courier,
mailed by registered or certified mail (postage prepaid, return receipt
requested) to the parties at the following addresses (or at such other
address for a party as shall be specified by like changes of address) or
sent by electronic transmission to the facsimile number specified below:

If to Company:

DNAPrint genomics, Inc.
900 Cocoanut Avenue
Sarasota, Florida 34236
Attention: Tony Frudakis

If to T. Frudakis:

900 Cocoanut Avenue
Sarasota, Florida 34236

If to G. Frudakis:

900 Cocoanut Avenue
Sarasota, Florida 34236

or to such other address as any party may have furnished in writing the other
parties in the manner provided above.

b.Parties Bound. The provisions of this Agreement shall apply to,
inure to the benefit of, and be binding upon the parties hereto and their
respective heirs, successors, assigns, administrators, executors. In no
event may any party assign any of its rights, privileges, duties, or
obligations hereunder. Any assignment in violation of the foregoing shall
be null and void.

c.Multiple Counterparts. This Agreement may be executed in multiple
counterparts, each of which shall be deemed an original and all of which
shall be deemed collectively one agreement, but, in making proof hereof, it
shall never be necessary to exhibit more than one such counterpart.

d.Entire Agreement: Modifications. This Agreement constitutes the
final, exclusive, and complete understanding of the parties with respect to


2



the subject matter hereof and supersedes any and all prior agreements,
understandings and discussions with respect thereto.

e.Captions. The captions in this Agreement are for convenience only
and shall not be considered a part of or affect the construction or
interpretation of any provision of this Agreement.

f.Governing Law. This Agreement shall be governed by and enforceable
under, and construed in accordance with, the laws of Florida, regardless of
the laws that might otherwise govern under applicable principles of
conflicts of law.

g.Third Party Beneficiaries. No individual, firm, corporation,
partnership, or other entity shall be a third-party beneficiary of this
Agreement.

h.Remedies Cumulative. The remedies of the parties under this
Agreement are cumulative and will not exclude any other remedies to which
any party may be lawfully entitled.

i.Severability. If any provision of this Agreement is held to be
illegal, invalid, or unenforceable under present or future laws effective
during the term hereof, such provision shall be fully severable and this
Agreement shall be construed and enforced as if such illegal, invalid, or
unenforceable provision never comprised a part hereof; and the remaining
provisions hereof shall remain in full force and effect and shall not be
affected by such illegal, invalid, or unenforceable provision or by its
severance herefrom. Furthermore, in lieu of such illegal, invalid, or an
enforceable provision, there shall be added automatically as part of this
Agreement a provision as similar in its terms to such illegal, invalid, or
unenforceable provision as may be possible and be legal, valid, and
enforceable.


[Signatures on following page.]



3



IN WITNESS WHEREOF, the parties have executed this Funding and Subscription
Agreement on the date set forth above.

DNAPRINT GENOMICS, INC.


By:/s/Tony Frudakis
Tony Frudakis
As its President


INVESTORS


/s/Tony Frudakis
Tony Frudakis


/s/George Frudakis
George Frudakis


Agreed to and Ratified by the DNAPrint Board of Directors:

/s/Jack Luchese
Jack Luchese

/s/Hector Gomez
Hector Gomez


4






Exhibit 99.1


CERTIFICATION PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
(18 U.S.C. SECTION 1350)

In connection with this quarterly filing of DNAPrint genomics, Inc., a Utah
corporation (the "Company"), on Form 10QSB for the quarter ending September 30,
2002 as filed with the Securities and Exchange Commission (the "Report"), I,
Tony Frudakis, Chief Executive Officer and Principal Financial Officer of the
Company, certify, pursuant toss.906 of the Sarbanes-Oxley Act of 2002 (18
U.S.C.ss.1350), that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of
the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material
respects, the financial condition and result of operations of the Company.


/S/Tony Frudakis
Tony Frudakis
Chief Financial Officer and Principal Financial Officer
November 14, 2002







--------------------------------------------------------------------------------
End of Filing

[cariocca]

November 14, 2002 DNAPRINT GENOMICS INC (DNAP.OB)

Quarterly Report (SEC form 10QSB)

MANAGEMENT`S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis should be read in conjunction with the balance sheet as of September 30, 2002 and the
financial statements as of and for the nine months ended September 30, 2002 and 2001 included with this Form
10-QSB.

Critical Accounting Policies and Results of Operations

Our critical accounting policies, including the assumptions and judgments underlying them, are disclosed in the notes to the
financial statements, which are contained in our December 31, 2001 form 10-KSB. We have consistently applied these policies in all material respects. Although
we have been in existence for a number of years, our efforts to develop our business have not yet resulted in generation of significant revenues. To date,
our efforts have focused on developing licensing relationships and promoting and conducting research and development to demonstrate the feasibility and
efficacy of our products. Until potential customers are convinced of the viability of our technology, it is unlikely that we will generate significant revenue. The
following discussion of our historical financial results should be read against that background. In light of this, the small amount of revenue that we have
earned at this stage minimizes the impact of any judgments regarding revenue recognition. We do not believe that our operations to date have involved
uncertainty of accounting treatment, subjective judgment, or estimates, to any significant degree.

Three months ended September 30, 2002 vs. three months ended September 30, 2001

For the three months ended September 30, 2002 and 2001, revenues were approximately $17,000 and $300, respectively. This
increase was a result of our decision to supplement our cash flow by using our facilities to provide certain commercial genotyping and contract sequencing
services to select customers. This also increased due to the recent marketing of our ancestry test product to the general public, which began Sept. 19, 2002,
11 days prior to the end of the quarter. For the same period, cost of sales increased from approximately $0 in 2001 to $9,100 in 2002. Because of the small
sales volume and its dependence on the type of testing conducted in a particular period, these results are not indicative of the margins that we
expect to attain if our long-term goals are achieved.

For the three months ended September 30, 2002 and 2001, the largest component of our operating expenses was research
and development, which consists substantially of laboratory supplies, equipment rental, facilities and personnel related costs. During the three months
ended September 30, 2002 and 2001, these costs remained relatively constant - from approximately $575,300 in 2001 to $557,000 in 2002.

The other component of our operating expenses is general and administrative expenses. For the three months ended
September 30,2002 and 2001, these expenses were approximately $32,900 and $45,900, respectively. These expenses result from (i) accounting and other fees
associated with the completion of our quarterly filings and other regulatory compliance activities, (ii) legal fees associated with our patents, immigration
activities and preparation of our securities law filings and (iii) administrative and other salaries and expenses. The decrease is primarily due to our adoption of a
more streamlined administrative structure.

For the three months ended September 30, 2002 and 2001, interest expense increased from approximately $0 in 2001, to
$12,200 in 2002. This increase arises from interest paid and/or accrued on capital leases and related party notes which were not in existence during the
quarter ended September 30, 2001.

Nine months ended September 30, 2002 vs. Nine months ended September 30, 2001

For the nine months ended September 30, 2002 and 2001, revenues were approximately $132,200 and $12,400, respectively.
This increase was a result of our decision to supplement our cash flow by using our facilities to provide certain commercial genotyping and contract
sequencing services to select customers, as well as the recent marketing of our ancestry test product to the general public. For the same period, cost of sales
increased from approximately $0 in 2001 to $70,100 in 2002. Because of the small sales volume and its dependence on the type of testing
conducted in a particular period, these results are not indicative of the margins that we expect to attain if our long-term goals are achieved.

In 2002, the largest component of our operating expenses was research and development, which consists substantially of
laboratory supplies, equipment rental, facilities and personnel related costs. For the nine months ended September 30, 2002, these costs increased from
approximately $1,149,300 in 2001 to $1,727,000 in 2002, an increase of $577,800, or 50 %. The substantial increase in research and development results from
the initiation of new research projects.

The other component of our operating expenses are general and administrative expenses. For the nine months ended
September 30,2002 and 2001, these expenses decreased from approximately $308,400 in 2001 to $215,100, in 2002. These expenses result from (i) accounting and
other fees associated with completion of our audited financial statements, quarterly filings and other regulatory compliance activities, (ii) legal fees
associated with our patents, immigration activities and preparation of our securities law filings, and (iii) administrative and other salaries and expenses. The
decrease is primarily due to our adoption of a more streamlined administrative structure.

For the nine months ended September 30, 2002 and 2001, interest expense increased from $0 in 2001 to approximately
$433,400 in 2002. This increase is primarily due to the issuance of our common stock for the settlement of related party notes payable, at an agreed upon per
share price which was less than the market price of our stock. We accounted for the difference between the stock issue price and the market price, as interest
expense.

Future Periods

We expect that personnel costs will increase substantially in future years as we expand our research efforts. We also expect
most of our other operating expenses to grow with time and expansion. We will also increase consumable expenses due to a ramp-up in our data
production capabilities. We believe that the level of professional fees we pay will remain stable through 2002. We will also require testing to establish the efficacy of our
products as current research and development matures and as our products are exposed to the marketplace through our own efforts and those of our
licensees. We expect to see the results of these efforts beginning in 2003.

Liquidity

Our operating requirements generated a negative cash flow from operations as we continue to engage in testing and
development of our products. Our cash used by operating activities for the nine months ended September 30, 2002 was approximately $1,104,700. The resulting cash
shortfall was financed primarily through related party funding and sales of common stock.

Based upon our current plans, we anticipate that we will need to seek additional financing. We are pursuing entering into
license agreements with entities for the distribution of our products. Pursuit of licensing relationships is in its early stages, however, and it is difficult to predict what
revenue stream, if any, they will generate.

We do not expect our revenue stream to be sufficient to cover costs of operations in the immediate future. We expect that we
will continue to be required to raise capital to fund operations at least through the remainder of 2002 and some part of 2003. We anticipate that we will be
able to borrow the necessary funds we need under a funding arrangement we have entered into with two of our shareholders. However, we may still need to
engage in one or more private placements of common stock to fund our operating needs. We have engaged in discussions with several parties who
have expressed interest in assisting us in such a private offering, and we are confident t that private equity financing will be available to fund us until
revenues from operations are sufficient to fund operations.

Capital Expenditures

At this time, we do not anticipate a need to make significant capital expenditures in the next twelve months.

Staffing

We plan to increase our work force. Currently, we have fourteen full-time employees. We plan to add three research scientists
to continue developing our products. Upon development of the products, our marketing plan does not call for building a sales force to sell to end-users.
Rather, we intend to license the technology to market segment leaders with existing sales forces. We will train our partners` sales forces to sell our products
and to provide technical assistance. We also intend to add personnel in the accounting, administrative and investor relations areas. Management
expects to add at least four more employees during 2002. We expect the cost of these additional employees to be in excess of $200,000 in 2002.

[wsperber]

T. Frudakis im australischem Fernsehen:

http://www.abc.net.au/catalyst/stories/s720292.htm

Dank an stockholder101 (RB) für den Link.

[cariocca]

Das DNAP Ancestry-Kit:



http://www.chalberweid.ch/DNAPrint/dnaprint_ancestry.html

roger

[ge4teilter]

Nüscht mehr los hier, wa?! Wo sin´se denn alle?

[wsperber]

hallo g4,

das ist die Ruhe vor dem Sturm (vielmehr Orkan)

[ge4teilter]

Wolfgang,

was läßt Dich das glauben?

Und ....... wird es ein Orkan der Freude oder doch eher einer der Entrüstung sein?

[wsperber]

g4,

obwohl mir dieses ganz Abstammungszeug nicht sonderlich
gefällt, glaub ich, dass dnap sich damit fürs Nächste
über Wasser halten kann. Meine Hoffnung ist im Moment,
dass die Polizei nicht mehr lange auf die Erkenntnisse
von Dr. T verzichten kann. Der große Durchbruch werden
aber sicherlich die Cholesterinsenker sein, die ja
eventuell auch für viele andere Dinge nützlich sein können,
wenn bei einigen Menschen diese tückische Nebenwirkungen
nicht wären. Aber diese sind ja gerade die große Chance
für DNAP.

Ich hatte mir übrigens einen Termin bis Ende des Jahres
gesetzt, ob ich weiterhin in dnap investiert bleibe.
Im Moment denke ich aber mehr an nachkaufen und wenn
ich ehrlich bin, hoffe ich auf einen Kurs um die 2 Cent
zum nachkaufen. Das Weihnachtsgeld möchte ja, trotz
der neuen Aktien-Besteuerung, der Finanzwelt in den Rachen
geschmissen werden.

Die Hoffnung stirbt übrigens zum Schluss

Gruß

Wolfgang

[wsperber]

cari ist jetzt 42.

Ich hoffe du machst dir einen schönen Tag.

Herzlichen Glückwunsch

Wolfgang

[ge4teilter]

Watt, so alt is der Sack schon?

Glückwunsch!!!!

g4

P.S. Jetzt nachkaufen - pro und contra - was meint Ihr?

[cariocca]

Vielen Dank für Eure Glückwünsche.




Roger Der alte Sack

[wsperber]

Hallo Roger,

tröste dich, ich bin noch älter als du (auch 1960 geboren).

[hvs1]

Hallo meine "Kleinen",

was soll ich denn sagen.Geburtsjahr 1947 (55)und ich will
mit DNAP in Rente gehen.
Habe mich lange nicht gemeldet,verfolge aber alles genau
auch im RB.

Gruß an alle DNAPèrs
hvs1

[js200]

Hier ist noch ein 1960ziger

JS200

[cariocca]

DNAP-DD-PAGE, für die
"tollen sechziger"
und alle anderen.

http://www.chalberweid.ch/DNAPrint/dnaprint.html

Roger

[CR0K0]

Hoppla,da bin ich ja mit BJ 1971 ein richtiges Küken hier

DNAP beobachte ich tagtäglich,nur ist z.Z. die Kasse leer...

Zu den Webseiten:

spatializer.org ist soweit fertig,dnap.info gekündigt und dnaprint.org ist bei sedo "geparkt"...

Ich will Anfang nächstes Jahr oder evtl.noch im Dezember wieder aufspringen,auf jeden Fall wünsche ich Euch alles Gute mit DNAP !

Grüße aus Köln - Croko

[Blackjack2000]

@ Croko
Was soll ich da erst sagen,bin BJ 1978.
Sehe(mit DNAP)sehr gelassen in die Zukunft!

Wünsche euch allen noch ein schönes Wochenende!

Blackjack

[cariocca]

Heute Morgen erreichte mich eine sehr traurige EMail.

Unser geschätzter Freund und Bord-Mitglied "Martin" aka "sauvignon99" ist leider vor wenigen Tagen verstorben.

Wir hatten eine schöne und interessante Zeit miteinander. Seine Weine welche ich probieren durfte, sein Wissen um die Südsteiermark und die Einladung an mich ihn zu besuchen. Leider ist nun alles vorbei, unwiederruflich.

Doch die Erinnerung an einen wertvollen, selbstlosen und gutherzigen Freund wird in meinem Herzen zurückbleiben und mich mahnend daran erinnern wie schnell und unbarmherzig sich das Leben von uns verabschieden kann.


Ich werde Dich sehr vermissen, Martin.
Doch meine Gedanken und Gebete werden bei Dir und Deiner Familie sein.


Roger und Familie aus Adliswil / Schweiz


Hier ist die Mail von Eva Benesch:


Hallo Roger,

durch Zufall habe ich Ihre Mailadresse gefunden und da Martin immer viel von Ihnen gesprochen hat - wie von einem lieben Freund - möchte ich Ihnen heute mitteilen, dass er am
13.09.2002 sehr überraschend innerhalb von nur 10 Tagen an einem bösartigen Gehirntumor verstorben ist.

Langsam beginne ich, seine Unterlagen aufzuarbeiten, es fällt mir allerdings noch sehr sehr schwer.

Liebe Grüße aus der Steiermark
Eva Benesch

[CR0K0]

[wsperber]

Hallo Roger,

was soll man sagen außer herzliches Beileid
allen Angehörigen. Letztes Jahr traf es
den Bruder meiner Freundin, er starb auch an
einem Gehirntumor. Ich weiß deswegen, wie schnell
einem, gestern noch kerngesunden Menschen, durch eine
so heimtückische Krankheit schnell alle Kraft
genommen werden kann.

[ge4teilter]

Es scheint den anderen so zu gehen wie mir auch: Man weiß einfach nicht, was man zu sowas sagen soll! Es ist einfach schade und traurig, wenn jemand, der noch viele Wünsche, Hoffungen und Träume hatte, so plötzlich abberufen wird.

Bye bye Martin!

g4

[cariocca]

IN MEMORIAM



Martin aka Sauvignon99

[fonx]

habe fertig oder watt? Allen viel glück!!!!!!!!!!!!!!! Hätte mich auch gereizt, Fonx

[meisterspieler]

roger

bin auch erschüttert...habe vor einiger zeit noch sein bild auf deiner homepage gesehen und im rb eine message von ihm gelesen (worin er sich mit einem alten jahrgang wein verglich...)
schade, nun wird er gar nicht mehr am erfolg von dnap (für mich irgendwie sicher...) patizipieren können.

mail doch seiner frau herzliches beileid von einem unbekannten board teilnnehmer und vielleicht einen hinweis auf seine dnap aktien - und das du sie am laufenden hälst, was sie gerade wert sind (vor allem wenn sie endlich mal steigen sollten...)

ciao in die schweiz...

[morchel]

...........mir fehlen die Worte angesichts so einer Tragödie!

morchel

[CR0K0]

@Martin aka Sauvignon99

See you @ da moon,rest in peace...



@carrioca
Auch mein herzliches Beileid weiterleiten...
Irgendwo hatest Du Recht,ist alles nur Geld...

Shit...

Croko - und jetzt erst recht

[cariocca]

Der ultra neue NEWSTETTER

http://www.chalberweid.ch/DNAPrint/dnaprint.html

Lesen und geniessen!


Roger

[js200]

DNAPrint Launches Revolutionary Pan-Genome Screening Platform Based on Ancestral Admixture Mapping
via COMTEX

December 9, 2002

SARASOTA, Fla., Dec 9, 2002 /PRNewswire via COMTEX/ --

DNAPrint genomics, Inc. (OTC Bulletin Board: DNAP) (the `Company`), unveiled a new whole-genome screening platform (ADMIXMAP) that promises to rapidly change the landscape of disease and drug response gene hunting. The new platform is revolutionary because it represents the first yet developed for cost-effective whole-genome scanning in large, heterogeneous populations. It taps into sequence differences among the world`s various continental population groups to increase the power and efficiency of pan-genome disease gene screening.

ADMIXMAP will allow DNAPrint to identify new disease and drug response genes 10 times faster and 1,000-times less expensively than others who use existing methods. Dr. Tony Frudakis, CEO, informally announced the introduction of ADMIXMAP to attendees at the invitation-only IBM Life Science Solution Developer Conference in Boca Raton, FL, and proclaimed the Company`s intent to partner collaborative services based on the platform to pharma, biotech and academia.

The development of ADMIXMAP was a culmination of years of research into population genomics structure and human ancestry conducted with Dr. Mark Shriver of the Pennsylvania State University. The primary focus of the work was to create an original type of human genome map based on validated and characterized Ancestry Informative Markers. snAIMs are Single Nucleotide Polymorphsims (SNPs) of significant allele frequency differences between the world`s various continental population groups; prior to DNAPrint`s work, such a map had not existed. This map is combined with other compositions and new, highly specialized analytical algorithms to constitute the ADMIXMAP platform. The platform functions by allowing a fine appreciation of population genomics structure relevant for solving complex human conditions, and it is based on a process called Mapping by Admixture Linkage Disequilibrium (MALD) or Admixture Mapping (AM).

DNA exists in a block like state, and hypothesis-free genome screens aim to inspect each of several hundred thousand of these blocks for sequence correlation with disease or drug response. A genome-wide study usually queries hundreds of genomes. Because each genotype costs about $0.50 and hundreds of thousands of genotypes need be created per genome, a typical genome study costs several tens of millions of dollars.

On the other hand, Mapping by Admixture Linkage Disequilibrium (MALD) or Admixture Mapping (AM) takes advantage of the fact that in recently admixed populations (i.e. Hispanics or African Americans, among many others), the block-like structure of DNA extends for MegaBases rather than kilobases (Chakraborty and Weiss, 1988; Stephens et al., 1994, McKeigue 1998, McKeigue et al., 2000). Because the DNA is made of a relatively small number of very large blocks, pan-genome coverage can be obtained with as few as 1,500 markers at a cost of only $1-2K per sample or a couple hundred thousand dollars per study.

MALD and AM can only be accomplished using Ancestry Informative Markers (AIMs) and to its knowledge, the Company is the only to yet mine the human genome to produce a pan-genome map of validated snAIMs. In addition to a validated AIM map, the MALD/AM methods also require the determination of individual ancestry admixture proportions and DNAPrint was the first to reduce the determination of individual admixture proportions using AIMs to commercial practice (see www.ancestrybydna.com). As a result, DNAPrint believes it is the only company in the world capable of practicing the MALD and AM methods.

`The single largest problem drug and diagnostics developers currently face is the cost associated with genotyping,`said Dr. Matt Thomas, DNAPrint`s Chief Molecular Biologist. `Due to this cost, most whole-genome research today is restricted to isolated, homogeneous populations, which can limit the general applicability of the results obtained.`

`In part, the human genome was sequenced to help us get away from a restrictive focus on homogeneous, isolated populations for drug and diagnostics design,`said Zack Gaskin, DNAPrint`s Chief Technician. `Because ADMIXMAP is the first platform to enable cost-effective whole genome scans in heterogeneous populations, we expect it to have a profound impact on genomics- based drug and diagnostics design and we consider its development to represent an important milestone in human genome research.`

DNAPrint intends to partner this new platform with biotech, pharma and academia seeking to identify new drug targets and diagnostic tests. Using this model, partners would fund the work and the Company would retain a share of the intellectual property produced. DNAPrint hopes to use the method with partners to discover hundreds or even thousands of disease genes and to acquire a significant stake in the future of genomics-based medicine. Given the magnitude of drug and diagnostics royalties, relatively few of the discovered genes need be developed as drug targets or diagnostic tests to render the endeavor a success.

About DNAPrint genomics, Inc.

DNAPrint genomics Inc. is a personalized medicine company founded by a team of scientists with research and commercial experience in high-level mathematical modeling, programming and molecular genetics. The Company is traded on the Nasdaq OTC Bulletin Board under the ticker symbol: DNAP. For more information about the company, please visit www.dnaprint.com.

References contained herein: 1. Chakraborty, R. and K. Weiss. 1988. PNAS 85: 9119-9123. 2. Stephens J.C. Briscoe, D., and O`Brien, S.J. 1994. AJHG 55: 908-924. 3. McKeigue, P.M. 1998. AJHG 63:241-251. 4. McKeigue, P.M., et al., 2000. Ann. Hum. Genet. 64:171-186.
All statements in this press release that are not historical are forward- looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint`s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Media and Press Contacts Carrie Castillo DNAPrint genomics, Inc. Director, Marketing Communications [phone] [e-mail] MAKE YOUR OPINION COUNT - Click Here http://tbutton.prnewswire.com/prn/11690X75671382
SOURCE DNAPrint genomics, Inc.

Carrie Castillo, Director, Marketing Communications of DNAPrint genomics, Inc., [phone], or [e-mail]

http://www.dnaprint.com

Copyright (C) 2002 PR Newswire. All rights reserved.


JS200

[js200]

12/09/2002 (11:18 ET) DNAPrint Launches Revolutionary Pan-Genome Screening Platform Based on Ancestral Admixture Mapping - PR Newswire
11/14/2002 (15:08 ET) New 10QSB just released for DNAP - Edgar
11/11/2002 (10:55 ET) Bully Bullies Covers POSO, GNNU, APMC, DNAP, RRUN - Knobias
11/11/2002 (10:36 ET) MOVER(-): DNAP Trading Lower - Knobias


JS200

[smiling]

Hallo Freunde!

Wollte nur die aktuellen News reinstellen,

Alles Gute

GO LONG

[js200]

DNAP - DNAPrint Genomics Inc (OTCBB : DNAP)

--------------------------------------------------------------------------------
MOVER(+): DNAPrint Genomics Trading Higher



MONDAY , DECEMBER 09, 2002 11:39 AM

DNAPrint Genomics Inc (OTCBB: DNAP)
- Last Trade: $0.03
- Up: $0.004
- % Change: 15.38%
- Volume at publication: 1,548,200
- 20-day average volume: 1,387,855

RECENT NEWS:

12/09: Unveiled a new whole-genome screening platform (ADMIXMAP) that promises to rapidly change the landscape of disease and drug response gene hunting.

RECENT SEC FILINGS:

10QSB filed on 11/14 for the third quarter 2002.

For the three months ended 9/30/02; 9/30/01
Revenues: $17,042; $320
Net Loss: $(599,110); $(626,932)

KNOBIAS TECHNICAL ANALYSIS:
- Above 2 of 4 moving averages
- Near-term support price: $0.023
- 5-day resistance price: $0.026
- 20-day resistance price: $0.036

JS200

[fonx]

herzlichen Glückwunsch der dabei war!!!!!!!!! Fonx

[cariocca]

Heute Abend in Adliswil...

Schnee fällt - DNAP steigt...



Roger

[cariocca]

Ich hoffte Martin "sauvignon99" wäre noch bei uns
und könnte sich mit uns freuen...

Roger

[ge4teilter]

Ist ja auch mal nett, so ein Tagesschluß von +50%!

[wsperber]

Interessant zu lesen:

http://www.heraldtribune.com/apps/pbcs.dll/article?Site=SH&D…

und

alles wird gut!

[ge4teilter]

Ja, Nina, alles wird gut!

[ge4teilter]

...... in ein, zwei Jahren!

[wsperber]

früher

[cariocca]

Viel früher...

Roger

[ge4teilter]

Wolfgang, Roger,

je eher, desto besser!

ge4teilters überflüssige Luxuswünsche sind teuer!



Go, Tony, go!



g4

[ge4teilter]

Und damit´s schneller geht bin ich nach 3 Monaten Kaufabstinenz heute mal wieder mit einer Order drin!

[cariocca]

Get4eite Freude ist doppelte Freude...

Ich nehm den...



Roger

[cariocca]

Tschuddligung, Ge4teilte sollte`s heissen.

[cariocca]

13. Kriminalistik der Zukunft: Phantombild aus DNA?
Quelle: bdw, 29.08.2002

Wie bdw berichtet, können britische Ermittler sich in Zukunft aus Erbgutspuren am Tatort ein grobes Bild vom Täter machen. In Deutschland dagegen ist ein so genanntes DNA-Photofit verboten.

Häufig findet die Polizei nach einem Mord keine Spur außer einem Blutspritzer vom Täter. Die Ermittler bestimmen anhand der Blutspuren den genetischen Fingerabdruck und geben das Profil in die Datenbank ein. Fehlanzeige. Bislang blieb in solchen Fällen der Polizei nichts anderes übrig, als von Verdächtigen in der Gegend und den Bekannten des Ermordeten ebenfalls einen DNA-Fingerabdruck zu nehmen. Aber wenn der Täter ein vollkommen Fremder ist? In Zukunft könnten die Ermittler dann möglicherweise aus einer Analyse des Blut-Erbgutes ungefähr das Aussehen des Täters bestimmen – schwarze Haare, blaue Augen, Boxerkinn, leicht dunkle Haut – und ein grobes Fahndungsbild erstellen. Erste Erfolge hin zu einem solchen "DNA-Photofit" vermeldete kürzlich der Britische Forensische Wissenschaftsdienst (FSS).

Aus wenigen Tropfen von Speichel, Samenflüssigkeit oder Blut konnte bisher schon die Haarfarbe und die Ethnie des Täters abgeschätzt werden, am sichersten bei Rothaarigen: Schon 1995 fanden britische Forscher, dass die meisten Rothaarigen einen bestimmten Gendefekt tragen, der ihre Pigmentzellen schädigt. Die Wissenschaftler des FSS spürten daraufhin weitere Erbgutveränderungen auf und können nun aus einer Erbgutanalyse mit 96-prozentiger Sicherheit sagen, ob ein Täter rote Haare hat oder nicht. Der Test wird der Polizei jedoch nur in wenigen Fällen helfen – selbst unter den Briten sind nur sechs Prozent rothaarig. Ein Test für schwarze, braune oder blonde Haare wäre deshalb nützlicher. Bislang scheiterten Forscher jedoch an der enormen Komplexität, da sehr viele Gene die Haarfarbe bestimmen.

Unmöglich ist jedoch ein solcher Test nicht. Bei der Augenfarbe, deren Tönung ein ähnlich verwirrendes Zusammenspiel von Genen ausmacht, hat die amerikanische Biotech-Firma "DNAPrint Genomics" bereits die Grundlagen für einen DNA-Test geschaffen. Deren Forscher entdeckten, dass die Augenfarbe im wesentlichen durch Variationen von vier Genen bestimmt wird. In Erbgut-Tests konnten die Wissenschaftler Freiwillige mit 97-prozentiger Sicherheit drei Klassen zuordnen: Dunkeläugige, Helläugige und solche mit hellbrauner Iris. Zur Zeit würden sie mit ersten Erfolgen an einem Test für die Haarfarbe arbeiten, sagte Forschungsleiter Tony Frudakis dem Wissenschaftsmagazin "New Scientist".

Der Leiter des Fachbereiches Serologie beim Bundeskriminalamt in Wiesbaden, Hermann Schmitter, ist jedoch skeptisch. Er hält die Ansätze eher für "Fiction" als "Science" und ein wahres DNA-Photofit, also das Erstellen eines Phantombildes aus einer Erbgutanalyse, werde es wohl überhaupt nie geben. Denn viele Merkmale seien im Erbgut nicht definitiv festgeschrieben. So würden auch Umwelteinflüsse und das zeitliche Muster, in dem Gene an- und abgeschaltet werden, eine Rolle spielen. Selbst bei eineiigen Zwillingen sei der Fingerabdruck auch nicht identisch, obwohl sie die gleichen Gene hätten. Dennoch vermutet der Forscher, dass sich irgendwann bestimmte äußere Merkmale aus Erbgutanalysen tatsächlich abschätzen lassen. So untersuchten britische Forscher neben Haar- und Augenfarbe etwa die Erblichkeit des Kinngrübchens, und amerikanische Wissenschaftler spürten dem Zusammenspiel von Genen und Glatze nach.

Deutschen Ermittlern würden aber auch zuverlässige Tests nichts bringen, da deren Anwendung nach Angaben des Bundeskriminalamtes in Deutschland verboten ist. Nach Gesetz dürfen nur der genetische Fingerabdruck, der keine Rückschlüsse auf Aussehen und andere Eigenschaften erlaubt, und das Geschlecht aus Erbgutproben vom Tatort bestimmt werden. Schon beim Geschlecht aber werde zur Zeit diskutiert, ob das nicht eine so genannte Überschussinformation sei, die nicht für die Ermittlungen genutzt werden darf, sagt Schmitter.

Roger

[cariocca]

Erbgut soll Phantombilder von Straftätern liefern
DNA-Analyse verrät Augen- und Haarfarbe
Birmingham - Nach einem grausigen Mord hat die Polizei nur eine einzige Spur: einen winzigen Spritzer Blut des Täters. Die Fahnder schicken die Probe zur DNA-Analyse und erhalten wenig später ein Phantombild des Verbrechers. Das klingt wie in einem Science-Fiction-Film, ist aber vielleicht in Zukunft möglich.

In Großbritannien ist der Forensische Wissenschaftsdienst (FSS) bereits dabei, ein so genanntes DNA-Photofit zu entwickeln - ein Phantombild des Täters auf der Basis seiner Gensequenz. Mit 96-prozentiger Sicherheit lässt sich bereits feststellen, ob der Täter rothaarig ist oder nicht. Dies ist relativ einfach, da die Wissenschaftler dazu nur ein einzelnes Gen betrachten müssen. Komplexer ist die Zuordnung der DNA zu einer bestimmten ethnischen Bevölkerungsgruppe. Diese kann bislang nur grob geschätzt werden durch den Vergleich von mehreren DNA-Sequenzen.

Die amerikanische Biotech-Firma "DNAPrint Genomics" bietet ein weiteres Puzzlestück für das Phantombild: Sie hat ein Nachweisverfahren entwickelt, mit dem sie die Augenfarbe anhand der DNA bestimmen kann - mit 99-prozentiger Sicherheit, wie sie auf ihren Internetseiten verkündet. An einem Test, der jede mögliche Haarfarbe auf Basis von DNA-Daten liefert, arbeitet das Unternehmen zurzeit. Auch andere äußere Merkmale könnte das Erbgut möglicherweise bald liefern, schätzen Wissenschaftler, etwa ob jemand ein Kinngrübchen hat oder ob die Ohrläppchen angewachsen sind.

In Deutschland verbietet die Strafprozessordnung Untersuchungen der DNA hinsichtlich des Aussehens eines Täters. Solange diese gesetzliche Grundlage besteht, sieht das Bundeskriminalamt (BKA) auch keine Veranlassung, auf diesem Gebiet zu forschen. "Wir werden uns auf dem Laufenden halten, wie es sich entwickelt," so ein Sprecher des BKA. "Unsere Wissenschaftler halten das Thema jedoch im Moment für mehr fiction als science." BSW

[wsperber]

Hallo Leute,

ich weiss nicht, ob jeder von euch das Raging-Bull-Board vollständig liest.
Ich jedenfalls nicht, schaue aber doch häufig mal hinein. Heute ist dort
eine interessante Sache zu finden. Vor einigen Tagen gab es eine wissenschaftliche
Publikation:

"Race Not Reflected in Genes, Study Finds"

siehe z.B. den Artikel in:

http://ragingbull.lycos.com/mboard/boards.cgi?board=CLB01189…

Gandolf3 aus dem Raging-Bull-Board hat bei DNAP nachgefragt:

Carrie

As a DNAP shareholder and someone not very bright but quite interested in the developing science that DNAprint Genomics is
involved in, I am curious as to the companies? (DNAP) response to the research sited in the article below. Thanks in advance
for your reply and hopefully you?ll all get some time to slow down and enjoy the holidays???..

Die Antwort von Herrn Frudakis kann man hier nachlesen:

http://ragingbull.lycos.com/mboard/boards.cgi?board=CLB01189…

oder nachfolgend der Text:

Response from Carrie/Dr Frudakis........



Andy,

I have conferred with Dr. Frudakis about this article and this is his response to shareholders:

Yesterday, an article that was recently published in PNAS was disseminated by a variety of news services. The theme of the
article is that ?race? as defined by the group does not exist. This is not an unusual assertion by geneticists, because race implies
more than just the heritable differences between people - such as eye shape, skin color, height etc. but sociological and cultural
differences as well - and defining the genetic basis for these latter features has so far proven impossible.

However, those that claim that there is no such thing as race are wrong!



Specifically, they are wrong to not distinguish between the heritable and socio-cultural aspects of race. By not making the
distinction and denying the existence of ?race? in general, the group that published this recent paper, like many who have
come before them denies the existence of something that your own two eyes tells you exists. BioGeographical ancestry is the
scientifically acceptable way to speak of the heritable component of ?race? (meaning it is passed from parents to offspring
through the genes). Not only can we easily tell by looking at a person of relatively pure BioGeographical ancestry whether they
are of East Asian, African or European heritage, but we can see that noble features characteristic of the worlds various
continental population groups are passed from parents to offspring. We know that a fraction of the 0.1% of the genome that
is different between individuals contains information about BioGeographical Ancesry, first referred to as ?private? SNPs, and
later as Ancestry Informative Markers or AIMs. Geneticists have established the mechanism by which these differences arise in
man and in all other animal species. Even the most basic population genetics textbooks teach college students that this natural
variation, shaped by genetic drift and in some cases, natural selection have given rise to measurable and real molecular distance
between the worlds various peoples.



The conclusions of the Brazilian group would seem to refute these basic genetic concepts, concepts present in all genetic
textbooks and first introduced by great scientists like Alan Wilson, Ranajit Chakraborty, Sewell Wright and R. Fischer.



The problem is that reading ancestry from genome sequence is not easy. The fact that we do this with our ancestrybydna 2.0
test and not just measuring the major ancestry, but reading the actual proportions of ancestry, is a testimony to the advanced
level on which we work. However, others seem to have more trouble emulating our work.



What the Brazilian group is saying in their paper is that because they cannot measure a something; that something must not
exist. Obviously this logic is unsound. It is clear that they and others before them that claim the same thing are either
intentionally obfuscating the issue for sociological reasons, but in other cases it is because they do not know how to measure
ancestry or ancestral admixture. In fact, the Brazilian group does know how to measure crude ancestry - they described 10
markers that can be used to determine the degree of African ancestry (how could such markers exist if the heritable component
of race does not, as they imply?). They next attempted to draw a correlation between African ancestry and skin color. The
problem with their work is that:

a) They did not measure skin color objectively with a machine - and given their sample size, such a correlation would not be
observable with subjectively measured color.

b) They only used 10 markers - which is probably too simple a test for what they were trying to do.

c) They attempted to find their correlation in a highly complex, admixed group without measuring African ancestry in terms of
admixture proportions, presumably because they didn?t know how.

d) They did not know what markers in the genome they needed to look at in order to find the correlation they sought. It so
happens that there are few precious polymorphisms in the genome linked to skin color, and though most of these are AIMs,
not all AIMs are good pigmentation markers because not all of them are linked to the genes that are involved in pigmentation.



Notwithstanding these defects in their work, producing negative results like they did is not a crime. However, overstating them
to promote a political objective, in my mind, is. What is the most difficult to understand is they equate the ability to predict skin
color with ?race? without measuring the proportion of African ancestry. It so happens that there is a correlation between skin
color and proportionality of African ancestry, (as with Native Americnan ancestry as well), so not only are the conclusions
overstated and wrong, but the negative results they obtained are relatively meaningless.



In my opinion, if it were any other topic, less politically charged, they would be far more responsible in their claims - admitting
that just because they do not know how to measure something does not mean it does not exist. However, lamentably, they
take the extremely arrogant tack of attempting to convince us all that something that we can all see with our eyes does not
exist simply because they do not know how to measure it. Look at it this way, if CNN reported tomorrow that a group of
scientists reported that there is no moon, would you go out that evening and see a big round thing in the sky and conclude ?it
is not the moon because scientists reported today in CNN that there is no moon?? Think how foolish it would make you feel to
even read that article - almost as if the scientist and the media believe you are that gullible. Unfortunately, by not distinguishing
between the heritable and socio-cultural aspects of race, and claiming that race in general does not exist, this article attempts
to accomplish the same exact thing.



Not only is there such as thing as BioGeographical Ancestry, or the heritable aspect of race, but it is useful as an extremely
powerful tool by which to map the genes for many common human traits, as many other esteemed scientists other than us
have described over the years (see our website for a list of references - www.ancestrybydna.com). Your own two eyes and
common sense tell you there is a heritable component to race, so hopefully I do not have to convince you of this. There is
nothing wrong with admitting that the human population is diverse, and that much of this diversity is heritable. In fact,
diversity is the strength of any population. Genetic diversity is Natures way of hedging its bets, and it serves as the engine by
which we evolved to exist in the first place. It exists in every population of every species of animal on this planet, and it should
be celebrated and recognized rather than obfuscated. I think these ?scientists? and journalists do us all a disfavor by
deliberately attempting to confuse the issue. Their hearts are in the right place- but I, and other geneticists believe that many of
the worlds problems would be better served through a recognition and celebration of the truth rather than through deception
and obfuscation. People are not stupid, and treating them this way causes more problems than it fixes.



Though it may be disconcerting to read such pablum in the scientific literature, especially since it seems to challenge work we do,
it actually has a silver lining. First, it shows that in order to conduct the type of science the Brazilian group tried to conduct,
one needs to be able to measure proportional ancestry in admixed individuals more exquisitely. They would have benefited from
using our AncestrybyDNA test. Second, it suggests that if this is representative of the level of our competition out there, I
think the future of DNAP looks bright. While other scientists are stumbling over their own inabilities and attempting to mold
public opinion from their negative results, functioning more like politicians than scientists, we will be the measuring the heritable
component of ?race? to map disease and drug response genes?



Don?t forget that we have successfully performed over 1,700 validations of AncestrybyDNA 2.0 so far. Many of these were
for journalists and law enforcement, and each has observed sound performance in terms of majority ancestry (which is the only
aspect of the test they can evaluate it for - in terms of actual percentage numbers, pedigrees must be used and these results are
also sound as can be seen on our website www.ancestrybydna.com). We have sold hundreds of kits so far, and we have yet to
deliver a result claiming majority European ancestry to an dark skinned individual who describes themselves as African American,
or vice versa, or any similarly egregious result involving other ancestries. If there were no heritable component to race, as
implied by these and other politically motivated ?scientists?, then how is it that we can so accurately measure it?

Carrie Castillo
Corporate Communications
DNAPrint genomics
www.dnaprint.com
941-366-3400


Ich finde die Antwort sehr interessant und auch sehr schlüssig. Scheint ein kluger Mann zu sein,
der Chef von unserem Investment.

Gruß

Wolfgang

[js200]

Von Gestern

DNAP
DNAPRINT GENOMICS INC
0.029
+0.001 +3.57%


Daily Commentary
HOLD

Our system recommends HOLD as of today. Previous BUY recommendation was made on 12/10/2002 (8) days ago, when the stock price was 0.033. Since then the stock fell -10.77% .

Today the stock closed higher, at its high (sign of strength) with an unchanged high and an unchanged low. The volume is high. The security price is trending sideways.

Candlestick Analysis

Today’s Candlestick Patterns:
White Candlestick

Today a White Candlestick formed. Buyers were in control but the buying pressure was not very strong.

Stock Quote
Last 0.029
Previous Close 0.028
Change +0.001
% Change +3.57%
Volume 2,640,200
Stock Activity
Open 0.027
Day`s High 0.029
Day`s Low 0.027
52 Week High 0.080
52 Week Low 0.018

Stock Price History
3 Month % Change 3.57
6 Month % Change -51.67
12 Month % Change -42.00
Stock Statistics
50 Day Close MA 0.030
200 Day Close MA 0.045
65 Day Volume MA 1,871,274

JS200

[HelmutPollinger]

Bin ab morgen 14 tage Snowboarden auf meinem WO-Board...da kann ich richtig posten und die post abgehen lassen...denn ich hab alles verkauft wenn ihr kauft...und ich sauf wenn ihr lauft


gruesse
Helmut der Schluchtenscheisser

[CR0K0]

Moin,DNAPer

Ende Dezember bin ich auch wieder dabei

Es ist Zeit,die Segel zu setzen,auch im Hinblick auf die neue Speku-Steuer...

Für Käufe vor dem 1.Januar 2003 gilt doch noch die alte Regelung,oder irre ich mich da ?



Croko

[cariocca]

Allen meinen Freunden wünsche ich
schöne und besinnliche Festtage und
ein erfolgreiches 2003

http://www.chalberweid.ch/Fireworks/merry_christmas.html

Roger

[cariocca]

Noch was lustiges zum runterholen....
ähhh runterladen...

http://www.chalberweid.ch/DNAPrint/to_da_moon.html


Roger

[cariocca]

Aus dem Raging-Bull

BBabe - Re: Patent information - It downloaded as a PDF "save file" for me. Here`s the summary - looks like one more rock solid piece of the DNA Identa-puzzle for DNAP and us investors...!

International Publication Date - 5 December 2002 (05.12.2002)

International Publication Number
WO 02/097047 A2

Applicant: DNAPrint Genomics- 900 Cocoanut Ave, Sarasota, FL 34210
Inventor/Applicant: Frudakis, Tony (US)

Title: COMPOSITIONS AND METHODS FOR THE INFERENCE OF PIGMENTATION TRAITS

Abstract: The invention relates to the method for inferring a genetic pigmentation trait of a human subject from a nucleic acid sample or a polypeptide sample of the subject, and compositions for practicing such methods. The methods of the invention are based, in part, on the identification of single nucleotide polymorphisms (SNPs) that, alone or in combination, allow an inference to be drawn as to the genetic pigmentation trait such as hair shade, hair color, eye shade, or eye color, and further allow an inference to be drawn as to race. A method of the invention can be performed, for example, by identifying in a nucleic acid sample at least one pigmentation-related haplotype allele of at least one pigmentation gene, and preferably a combination of pigmentation related haplotypes alleles.

* While the most immediate use is of course for DNA identification, it also has tremendous potential applications in skin disease and other pigmentation related research.

BBabe - thanks for your warm hearted poetry over the past year and for your wishes and dreams of harmony and peace on Planet Earth. I add my blessings and prayers along with the many fine people on this board...!

May you and your family be filled with unbounded health and happiness and the wonders of Life...!

Happy Holidays and Best Wishes for A Joyful and Prosperous New Year to EVERYONE....!

God Bless and Good Luck To All Of Us!

Robert

[ge4teilter]

Heißt?

[ge4teilter]

Werden wir jetzt reich?

[ge4teilter]

Werden jetzt Wünsche erfüllt? Thread: Ich hab´ mich verknallt und kann seitdem nicht mehr ruhig schlafen!

[morchel]

nur eine Frage der Zeit!

morchel

[robby.r]

nicht das Geld ist böse oder gut ,
es liegt an dem , der es brauchen tut


http://www.superlaugh.com/1/cheese.swf


schöne Feiertage

[JS222]

DNAP
DNAPRINT GENOMICS INC
0.029
0.000 0.00%


Daily Commentary
WAIT

Our system recommends WAIT as of today. Previous SELL recommendation was made on 12/24/2002 (2) days ago, when the stock price was 0.029. Since then the stock gained 0.00% .

Today the stock closed unchanged with an unchanged high and an unchanged low. The volume is extremely low. The security price is trending sideways.



Click here to get a full trend analysis of this stock Candlestick Analysis


Today’s Candlestick Patterns:
Short White Candlestick


Today a Short White Candlestick formed. There was a limited price change that may represent consolidation.





Stock Quote
Last 0.029
Previous Close 0.029
Change 0.000
% Change 0.00%
Volume 604,000
Stock Activity
Open 0.028
Day`s High 0.030
Day`s Low 0.028
52 Week High 0.080
52 Week Low 0.018


Stock Price History
3 Month % Change 16.00
6 Month % Change -50.00
12 Month % Change -42.00
Stock Statistics
50 Day Close MA 0.030
200 Day Close MA 0.044
65 Day Volume MA 1,785,326

[wsperber]

Hallo allen die immer noch an DNAP interessiert sind,

ich habe letzten Freitag meine letzten DNAP-Aktien gekauft. Jetzt kann DNAP
anfangen zu steigen.

Übrigens ob Herr Frudakis sein Versprechen aus dem zweiten Newsletter erfüllt:


RETINOME - We have announced our intention to have either a beta trial or a partnership with a large company in place by the
end of the year. This is an important part of our business strategy you should understand. We would prefer to partner our
products with capable partners so we can devote ourselves to discovery and grow our revenue base more rapidly. However, if
we cannot obtain satisfactory terms from a prospective partner, we will market a given test ourselves. This would provide us
more profit from each test, but would increase product development costs and reduce the number of tests we could develop.
We are currently in discussions with four large corporations to help us commercialize this test.

wird sich heute oder morgen zeigen.

Ich würde nicht darauf bauen, wär zwar schön, aber da kann sich immer etwas verschieben.
Denkt daran, DNAP ist in einem Bereich der die Zukunft stark mit beeinflussen kann.
Mein Verständnis reicht leider nicht aus, um zu beurteilen, ob diese Firma weiter als
die Konkurrenz ist, oder nicht. Ich hoffe es nur.

Ich würde übrigens vorschlagen, dass Roger (der mit den größten europäischen
Verdiensten in DNAP (http://www.chalberweid.ch/DNAPrint/dnaprint.html)
einen neuen Thread im nächsten Jahr aufmacht, mein Vorschlag für den Namen des
Threads "DNAP 2003: Das Jahr der Entscheidung".

Sonst wünsche ich allen Mitinvestierten (aber nicht denen, die in Nachbarthreads
immer wieder einen mir nicht verständlichen Ton finden)

einen guten Rutsch und vor allem ein gesundes Jahr 2003

Wolfgang

[JS222]

3:55pm ET
0.033
0.00 (10.73%)
Day`s Range: 0.028 - 0.033
Day`s Volume: 1,920,400
Avg. Volume: 1,714,420


JS200

[JS222]

Von Gestern

DNAP
DNAPRINT GENOMICS INC
0.033
+0.003 +10.74%


Daily Commentary
HOLD

Our system recommends HOLD as of today. Previous BUY recommendation was made on 12/30/2002 (0) days ago, when the stock price was 0.033. Since then the stock gained 0.00% .

Today the stock closed higher, at its high (sign of strength) with a higher high and an unchanged low. The volume is normal. The security price is trending up.

Candlestick Analysis

Today’s Candlestick Patterns:
Long White Candlestick

Today a Long White Candlestick formed. Buyers were aggressive and buying pressure was strong. Be careful, this may lead to excessive bullishness!

Stock Quote
Last 0.033
Previous Close 0.030
Change +0.003
% Change +10.74%
Volume 2,030,400
Stock Activity
Open 0.030
Day`s High 0.033
Day`s Low 0.028
52 Week High 0.080
52 Week Low 0.018

Stock Price History
3 Month % Change 37.50
6 Month % Change -37.14
12 Month % Change -34.00
Stock Statistics
50 Day Close MA 0.031
200 Day Close MA 0.044
65 Day Volume MA 1,756,937

JS200

[cariocca]

Vielen Dank Wolfgang

Gerne werde ich den neuen Thread eröffnen.

Allen treuen DNAPstern wünsche ich ein tolles und spannendes 2003.

Bleibt gesund und denkt auch mal an jene Menschen welche zur falschen Zeit am falschen Ort ihr Leben fristen müssen.


In diesem Sinne: Happy New Year


http://www.chalberweid.ch/Fireworks/merry_christmas.html

Bitte habt 2-3 Minuten Geduld bis die Seite geladen hat.


Roger und Familie

[morchel]

Hallo DNAP Longs!

Am Anfang dieser Story dachten wir alle das alles ein wenig schneller funktionieren würde!

Doch gut Ding braucht Weile....

2003 das DNAP Jahr? Möglich ist es.

Stehe immer Gewehr bei Fuß um meinen DNAP Bestand kräftig aufzustocken!

Happy New Year

morchel

[Loserman]

Hallo Morchel,

DNAP ist genauso eine Träumerbude wie die SPAZEN.....
Ich denke außer Spesen nichts gewesen, schon heute ist diese Kiste überbewertet und noch keinen Dollar hat diese Unternehmen verdient !!!
Luft nach unten gibts noch genug (Ground Zero), nach oben keine !!!

Gruß Loserman

[JS222]

Von Gestern

DNAP
DNAPRINT GENOMICS INC
0.030
-0.003 -9.09%


Daily Commentary
HOLD

Our system recommends HOLD as of today. Previous BUY recommendation was made on 12/30/2002 (1) days ago, when the stock price was 0.033. Since then the stock fell -9.09% .

Today the stock closed lower, at its low (sign of weakness) with a lower high and a higher low (sign of decrease in volatility). The volume is low. The security price is trending up.

Candlestick Analysis

Today’s Candlestick Patterns:
Black Candlestick

Today a Black Candlestick formed. Sellers were in control but the selling pressure was not very strong.

Stock Quote
Last 0.030
Previous Close 0.033
Change -0.003
% Change -9.09%
Volume 945,900
Stock Activity
Open 0.032
Day`s High 0.032
Day`s Low 0.030
52 Week High 0.080
52 Week Low 0.018

Stock Price History
3 Month % Change 25.00
6 Month % Change -42.86
12 Month % Change -40.00
Stock Statistics
50 Day Close MA 0.031
200 Day Close MA 0.043
65 Day Volume MA 1,764,018

JS200

[JS222]

Von Gestern

DNAP
DNAPRINT GENOMICS INC
0.032
0.000 0.00%


Daily Commentary
HOLD

Our system recommends HOLD as of today. Previous BUY recommendation was made on 12/30/2002 (4) days ago, when the stock price was 0.033. Since then the stock fell -3.03% .

Today the stock closed unchanged, at its high (sign of strength) with a lower high and an unchanged low. The volume is extremely low. The security price is trending up.

Candlestick Analysis

Today’s Candlestick Patterns:
Dragon-Fly Doji

Today a Dragon-Fly Doji formed. Sellers dominated trading and drove prices lower during the session. However, by the end of the session, buyers resurfaced and pushed prices back to the opening level and the session high. Be careful, this may be a sign of a potential bearish reversal or top!

Stock Quote
Last 0.032
Previous Close 0.032
Change 0.000
% Change 0.00%
Volume 802,700
Stock Activity
Open 0.032
Day`s High 0.032
Day`s Low 0.030
52 Week High 0.080
52 Week Low 0.018

Stock Price History
3 Month % Change 60.00
6 Month % Change -34.69
12 Month % Change -54.29
Stock Statistics
50 Day Close MA 0.031
200 Day Close MA 0.043
65 Day Volume MA 1,725,877

JS200

[js200]

01/28/2003 (16:27 ET) New DEF 14A just released for DNAP - Edgar
01/21/2003 (15:54 ET) MOVER(-): DNAP Forensics Tests Pass Blind Validation - Knobias
01/21/2003 (11:20 ET) Law Enforcement Independently Validate DNAPrint`s Forensics Tests - PR Newswire
01/21/2003 (09:35 ET) GAP-DN: Opening Lower SBLU, DNAP, ETPI - Knobias
01/17/2003 (15:11 ET) PRE 14A: DNAP Seeks 200% Auth Shares Increase - Knobias


JS200

[CR0K0]

Up > nur wegen der Überschrift...

www.dnaprint.org ist under construction

Happy WE - Croko

[BlackAngel]

Wahnsinn, ewig hats gedauert, aber seit heute wird DNAP auch in Frankfurt notiert !!!

[Raucherschweinchen]

nun kann ich endlich die stücker auch in frankfurt verkaufen...hab noch 3000000

[was]

warum tust du`s dann nicht ????

(Lumpige 2000.- € Umsatz in Frankfurt!)

Willst wohl ein bischen angeben,- äh ???

[TheWorld]

Nur so als kleiner Aufsteller nach dem heutigen herben Rückschlag

19:33 16.06.2003
Nationalrat bewilligt DNA-Analysen bei polizeilicher Ermittlung

DNA-Analyse bei polizeilicher Ermittlung

Künftig können bei Ermittlungen "genetische Fingerabdrücke" verwendet werden. Der Nationalrat hat die letzte Differenz beim DNA-Profil-Gesetz oppositionslos ausgeräumt.
[sda] - Das Gesetz ermöglicht es, mittels DNA-Analyse Verbrechen und Straftaten aufzuklären sowie unbekannte, vermisste oder tote Personen zu identifizieren. Ebenfalls sollen zu Unrecht Verdächtigte entlastet werden können.

Massenuntersuchungen werden auf Personen beschränkt, die bestimmte Merkmale in Bezug auf die "Tatbegehung" aufweisen.

Ein DNA-Profil wird erstellt, wenn jemand wegen eines vorsätzlichen Deliktes zu einer Freiheitsstrafe von mehr als einem Jahr verurteilt wurde, das Urteil wegen Delikten gegen Leib, Leben und sexuelle Integrität erfolgte oder wenn eine Verwahrung verhängt wurde.

DNA-Analysen zur Informationsgewinnung über die Vererbung und den Gesundheitszustand einer Person werden verboten. Zudem gelten Auflagen zum Persönlichkeitsschutz: Die DNA-Profile werden anonymisiert und separat von anderen Personendaten behandelt.

Die Daten werden gelöscht, sobald eine Person nicht mehr verdächtigt oder freigesprochen wird oder stirbt. Entsprechend der Schwere einer Straftat werden die Daten automatisch nach einer bestimmten Anzahl Jahren gelöscht.

Gruss aus der schönen Schweiz

TheWorld